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ABSTRACT

ALEXIS M TEMKIN. Identification and Characterization of Dioctyl Sodium
Sulfosuccinate (DOSS) as an Obesogen and Metabolic Disruptor
(Under the direction of DEMETRI D. SPYROPOULOS)

The National obesity epidemic has reached a point where 36.5% of the adults are
obese. While diet, exercise and genetics are major factors driving obesity, recent studies
also implicate environmental chemical agents known as ‘Obesogens’. Research efforts
have begun to identify obesogens, which promote obesity and metabolic syndrome and
are especially potent during fetal and childhood development. The research presented
herein provides a logical framework for the identification, characterization and validation
of obesogens in environmental samples.
This framework was developed based on potential obesogens present in crude oil
(MC252 oil) and dispersant (Corexit) from the Deepwater Horizon oil spill given the
magnitude of the spill and cleanup efforts and that components of oil have been
previously implicated as obesogens. Receptor transactivation assays for nuclear receptors
that regulate metabolic pathways previously implicated were used to identify obesogenic
activities. Corexit components were identified to have obesogenic activities, including
dioctyl sodium sulfosuccinate (DOSS), Span 80 and Tween 80. These candidate
obesogens were then validated in vitro using adipogenic differentiation assays. DOSS
increased adipogenesis in both mouse and human pre-adipocytes and stem cells. DOSS is
a ubiquitous chemical used as a food additive and stool softener often prescribed to
pregnant women. As such, DOSS was evaluated in vivo using mice in a scenario

xv

imitating human pregnancy-associated exposure. Significantly, DOSS exposure to
pregnant dams produced increased weight gain and adiposity, glucose intolerance,
decreased bone area, altered adipokine production, a proinflammatory state and
dyslipidemia in the male F1 population. Together, these studies provide a framework for
investigation of obesogens. Furthermore, the data suggest that DOSS can act as an
obesogen in vivo at physiologically relevant doses and prompt further research into the
safe use of DOSS during pregnancy.

xvi

CHAPTER 1: GENERAL INTRODUCTION
1.1 Obesity, Diabetes and Metabolic Syndrome
The number of overweight and obese children, adolescents and adults in the
United States has been growing at an alarming rate since the 1980s. The most recent data
collected indicates that in the United States, 37.7% of adults are obese and 7.7% are
extremely obese, based on data from 2013-2014 [1]. Strikingly, this epidemic affects
children and adolescents as well with 17% of children ages 2-19 obese and 5.8%
extremely obese [2]. Rates of diabetes, particularly non-genetic type-two diabetes (T2D)
characterized by extreme insulin resistance, follow similar trends to those observed for
obesity. Data indicates that in the United States, diabetes incidence doubled between
1990 and 2008 for data analyzed from 1980-2012 [3]. A recent study identified nearly
half of the US population as diabetic or prediabetic [4].
Obesity and being overweight has been established as major risk factors for T2D
with 80% of individuals diagnosed with T2D clinically over weight at time of diagnosis
[5]. Obesity is also often associated with other metabolic symptoms including abdominal
obesity specifically, dyslipidemia, hypertension, glucose intolerance, and
proinflammatory state [6]. Together, this combination of metabolic risk factors stemming
from obesity has become classified as metabolic syndrome and can increase one’s risk
for development of T2D and cardiovascular disease. The prevalence of metabolic
syndrome in adults in the United States is similar to that of the obesity epidemic, with
34.7% of US adults diagnosed with metabolic syndrome between 2011 and 2012 [7].
Given that over 30% of the adult population suffers from such a chronic disorder has
enormous public health and economic impacts. The economic burden of such a public
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health disorder is estimated to increase by $48-66 billion/year in the United States by
2030 with an estimated 65 million more obese adults by this time [8]. For an individual
with metabolic syndrome, individual health care costs are generally $2000 more per year
when compared to individuals without metabolic syndrome [9].
Obesity in adults is characterized as having a body mass index (BMI) greater than
30 and overweight as being in the BMI range of 25-29.9. BMI is a measurement of
weight to height ratio. While BMI is still used as a clinical measurement for obesity,
some data suggests it is not the most accurate or the best predictor of obesity associated
symptoms and that certain types of fat are more pathological than others such as visceral
fat compared to subcutaneous fat [10]. Data from the National Health and Nutrition
Examination Survey of roughly 15,000 adults indicates that waist circumference better
explains obesity related health risks, like metabolic syndrome, better than BMI [11].
For several decades, the general public and the medical community has thought of
obesity as a simple issue that could be solved and regulated by the number of calories an
individual consumes and burns, suggesting that obesity is ultimately a result of
behavioral choices [12]. The negative attitude of our society associated with obesity can
lead to severe psychological issues in those afflicted. Obese individuals are often
considered lazy, uneducated, and suffer discrimination making this a significant and
complicated public health issue [13].
However, great strides have been made in understanding the physiological roles
of adipose tissue, pathophysiology of obesity associated adipose tissue and the molecular
mechanisms by which obesity and metabolic syndrome develop in an effort to effectively
treat and prevent obesity and are discussed as follows.
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Additionally, new findings are suggesting that obesity risk might be influenced
by factors beyond behavioral choices, including genetic and environmental factors
discussed in Sections 1.2 and 1.3.
1.1.1 It’s about communication: Action of Adipokines
Obesity research has shed light onto the intricate mechanisms of the disease. For
instance, the discovery of fat specific hormones, shifted the field and medical perspective
for treatment dramatically. As the biological roles of fat as an organ (adipose tissue) were
elucidated, so was the complex nature of treating a disease like obesity as well as
understanding the root causes of the disorder. Since the classification of adipose tissue as
an endocrine organ and discovery of adipokines, signaling molecules secreted from
adipose tissue, their functional role in normal physiology as well as how they are altered
in disease states has been an active area of investigation [14].
Along the lines of genetics, the first spontaneous mouse model of obesity was
discovered in 1949, when an unknown mutation, deemed ob, for obese, caused extreme
weight gain, hyperglycemia and hyperlipidemia in the mutant mice [15]. Ten years later
another obese mouse model was observed and classified as db/db due to the onset of
insulin resistance and diabetes in this mouse strain [16]. It wasn’t until roughly 50 years
later in the mid 1990’s that the genes responsible for the mutations, Lep and Lepr, were
discovered. Lep encodes for the protein Leptin and Lepr encodes for the receptor in
which leptin binds [17, 18]. Leptin binds to the leptin receptor primarily expressed in the
brain and results in satiety signaling. While some researchers may have hypothesized that
similar mutations would be observed in the obese human population, one study describes
only two individuals with a mutation in the leptin gene leading to early-onset morbid
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obesity [19]. Similarly, recent investigation into polymorphisms in the LEP and LEPR
genes are inconclusive with half of the studies showing association and half showing no
correlation [20]. However, there is consistent observation that circulating levels of leptin
are positively correlated with obesity in humans [21]. This observation indicates perhaps
a resistance to leptin in obesity and ultimately a more complicated regulatory system
driving disease development and progression.
Adiponectin is a signaling molecule exclusively secreted by adipocytes and was
discovered as a prevalent plasma protein in an adipose tissue cDNA screening effort to
identify novel drug and pathological targets in obesity [22]. The murine homologue was
discovered in 1995 as a novel protein secreted by 3T3-L1 mouse adipocytes, a common
cell culture model for adipogenesis [23, 24]. Adiponectin can bind to the adiponectin
receptor, which upon complex formation activates AMP kinase signaling, an important
step in regulating energy metabolism signaling cascades. A reduction in both adiponectin
and adiponectin receptor has been observed in both diet induced and genetically induced
models of obesity in mice. While mice homozygous for adiponectin deletions do not
develop obesity like ob/ob mice do, they do develop diet induce obesity and
hyperglycemia more rapidly and severely than wild type mice [25]. When supplemented
with adiponectin, this phenotype is reversed. Similarly, mice that over express
adiponectin display increased insulin sensitivity, resistance to high fat diet-induced
hyperinsulinemia, and impaired glucose tolerance [26].
In summary, these observations indicate that adiponectin plays an important
protective role in preventing obesity development and associated insulin resistance.
Further supporting the plausible protective role of adiponectin in human incidence of
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obesity and T2D is the negative correlation often observed between circulating
adiponectin levels and incidence of diabetes, insulin resistance and obesity in human
disease [27-30]. This relationship is generally reproduced in animal models of T2D and
obesity. However, some animal studies report no change in circulating adiponectin levels
despite increased adiposity and reduced adiponectin gene expression in white adipose
tissue deposits [31] indicating a possible need to interpret circulating adiponectin levels
as relative to adiposity in animal models. Similarly, higher circulating levels are observed
in lean individuals and patients with anorexia nervosa and extremely low levels of body
fat [32]. Furthermore, treatment of diabetic individuals with agonists of PPARg, a lipid
sensing nuclear receptor that promotes insulin sensitization, such as Rosiglitazone,
increase adiponectin levels and improves insulin sensitization suggesting a direct role for
adiponectin in glucose intolerance and insulin resistance present in T2D [33].
Importantly, some clinical data suggestions that circulating adiponectin levels can predict
T2D disease trajectory, indicating that individuals with the lowest levels of adiponectin
are more likely to develop diabetes than those with higher levels [34-36]. In summary,
these data indicate that reduced production of adiponectin can promote the development
of obesity and subsequent T2D and determining the mechanism contributing to reduced
adiponectin expression can identify treatment and prevention targets. One such
mechanism may be by epigenetic regulation.
Given that diet and lifestyle are fundamental to weight gain and metabolism, the
study of environmental and epigenetic regulation of adipokines signaling are likely to
further our understanding of the molecular mechanisms associated with metabolic
syndrome. DNA methylation occurring at CpG sequences within a regulatory region of a
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gene can influence recruitment of transcription factors thereby influencing gene
expression of a given gene. Generally, hypermethylation of a promoter region results in
reduced gene expression for a given loci [37]. However, CpG methylation can also serve
to recruit certain methylation dependent transcription factors at cis regulatory elements
promoting gene expression [38]. DNA methylation can also be directly influenced
through diet since folate, a common dietary supplement especially in the diets of
pregnant women, is a key source for the carbon group required to methylate DNA. In
fact, dietary supplementation with folate results in hypermethylation of DNA and can
ameliorate gastrointestinal pathologies associated with DNA hypomethylation [39-41].
Additionally, maternal supplementation with folate can also rescue bisphenol-A (BPA)
induced hypomethylation [42]. Specifically relating DNA methylation to obesity,
changes in DNA methylation as a result of exercise or weight loss surgery have been
observed [43, 44] and adipose tissue DNA methylation profiles differ in identical twins
discordant for obesity and BMI [45]. Together these observations not only implicate
DNA methylation as a potential mechanism of gene regulation and disease development
in metabolic syndrome and metabolic disruption but also simultaneously a target for
treatment and prevention of such disease development.
Investigation of the adiponectin promoter region reveals hypermethylation of four
CpG sites in high fat diet-induced obesity animal models however, two other CpG sites
nearby (within 50 base pairs) seem to be unaltered [46]. This promoter site-specific
hypermethylation correlated with reduced expression of the AdipoQ gene [46]. In human
samples, ADIPOQ methylation of one CpG site is associated with BMI while another is
associated with waist circumference. These data indicate DNA methylation as a plausible
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gene regulatory mechanism by which adiponectin expression and regulation are
augmented in obesity [47]. For leptin, a diet-induced obesity animal model revealed a
curious positive correlation between average promoter methylation and leptin gene
expression in adipose tissue [48]. The same study identified other types of epigenetic
modifications such as histone modifications that may play a more dominant regulatory
role in leptin expression than that of DNA methylation. In human adipose tissue samples,
negative associations between specific CpG sites and leptin expression have been
observed but are dependent on leptin SNP genotypes of individuals [49] highlighting the
importance of gene by environment interactions in metabolic phenotypes. So, while
preliminary investigation has been done to establish a role for DNA methylation in
regulation of adipokine expression and function, the evidence does not articulate a
common mechanism in terms of CpG site, gene or phenotype. This subject warrants
further investigation especially in the context of how changes in DNA methylation due to
environmental contributors can lead to aberrant signaling and metabolic syndrome
development.
1.1.2 Obesity and Inflammation
The role of inflammation in chronic diseases like obesity and diabetes is an active
area of investigation. In both mouse and human studies, it has been observed that disease
states of these disorders coincide with markers of chronic inflammation. Understanding if
inflammation in fact can cause obesity or occurs after the fact is still relatively
unanswered although obesity is associated with an infiltration of macrophages into white
adipose tissue, which in turn secrete proinflammatory cytokines [50]. Several
inflammatory cytokines, such as IL-6, TNF-a IL-1B and MCP-1, have been documented
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to be upregulated in obesity, classifying the disease as associated with systemic
inflammation or a proinflammaory state [51] . It is hypothesized that the action of these
cytokines contribute to insulin resistance and other symptoms observed in metabolic
syndrome. The majority of research has focused on IL-6 and TNF-a since they are the
most prevalent and pathological associated.
IL-6 can be secreted by adipose-associated macrophages and by adipocytes
themselves, although adipocytes contribute only a small percentage of overall tissue IL-6
levels [52]. Interestingly, different adipose tissue deposits can secrete different levels of
IL-6 [52]. Increases in IL-6 levels have been shown to predict the development of T2D,
suggesting a pathogenic role for the cytokine, although a combination of inflammatory
cytokines is likely a better predictor [53, 54]. Conversely, IL-6 knockout mice develop
obesity and have impaired glucose metabolism which would suggest a protective role for
the cytokine [55]. It will be important to determine the factors influencing whether IL-6
has a pro- or anti-inflammatory action in obesity and T2D development although the
majority of studies point to its role as a pathological pro-inflammatory cytokine. For
example, a positive correlation between serum IL-6 levels and presence of obesity and
diabetes is consistently observed in human cohort studies [56, 57]. Additionally, weight
loss can reduce circulating IL-6 levels and improve insulin sensitivity [58]. When used in
in vitro studies, IL-6 treatment promotes insulin resistance in cultured adipocyte cell
lines, with reduced adiponectin and insulin receptor substrate-1 as possible mechanisms
of action [59, 60]. Regulation of IL-6 in adipose tissue by DNA methylation has not been
evaluated in rodent or human studies and could be an unidentified but important
mechanism by which IL-6 pathogenicity in adipose tissue occurs during obesity.
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Like IL-6, TNF-a is similarly upregulated in proinflammatory-dependent obesity,
often concomitantly with IL-6 [61]. Adipose derived TNF-a is produced exclusively by
adipose associated macrophages and can play a direct role in mediating obesity-linked
insulin resistance [50]. Seminal work from Spiegelman, et al., showed that neutralization
of circulating TNF-a in obese rats resulted in improved insulin response as measured by
uptake of glucose [62]. TNF-a has also been the target of therapeutics to treat obesity and
insulin resistance with some successful results, and similarly, circulating TNF-a can be
reduced after weight loss [63, 64]. Taken together, our current view is that cytokine
signaling is an important contributor to metabolic syndrome but that more research into
the mechanisms (epigenetic) controlling cytokine production in adipose tissue is needed.
In summary, as depicted in Figure 1, adipocyte dysfunction in obesity is marked
by hypertrophy and/or hyperplasia of adipose tissue, infiltration of macrophages that
increase adipose tissue associated proinflammatory cytokines (IL-6 and TNF-a), which
in turn promotes insulin resistance (hyperinsulinemia), reduced adiponectin and increased
leptin secretion, impaired glucose tolerance, and dyslipidemia [65]. Together these
measureable observations signify metabolic syndrome.
While the symptoms classifying metabolic syndrome and the associated health
risks are well established, the causes of obesity and metabolic syndrome are still under
investigation. A recent notable observation indicates a direct correlation between the
rising rate of chemical production in the US and the increase in rates of obesity in the US
(Figure 2A) [66]. Beginning in the,1940s there have been dramatic increases in chemical
production, with approximate 20 billion kg/year produced by the 1960s and climbing to
about 250 billion kg/year by 2010. Obesity incidence began its dramatic increase in the
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1980s, beginning with approximately 15% percent of the adult population being obese in
1980, and climbing to over 35% by 2010. As described by Sargis et al., a steady increase
in diabetes rates turned to dramatic increases from the late 1990s onward. (Figure 2B)
[67]. It is not clearly defined why the dramatic increases in obesity began in the 1980s
and in diabetes in the late 1990s, but it may be related to the total chemical burden
mixture, synthesis of specific types of chemicals or because obesity often precedes the
development of diabetes [68, 69]. Domesticated animals and animals living within close
proximity to industrialized cities and humans have also experienced unprecedented
increases in weight gain and obesity [70]. Identification of this correlation helped in the
development of the obesogen hypothesis, which suggests a causal link between
exogenous chemical exposure and obesity development. This general hypothesis is
explored in section 1.2 and foundational to the work performed and discussed in the
following chapters
1.2 The Developmental Origins of Adult Health and Disease, Endocrine Disrupting
Chemicals and Obesogens
The developmental origins of adult health and disease (DOHAD) hypothesis was
first proposed by Barker in the 1980s [71]. Barker linked the incidence of cardiovascular
disease in adults who experienced poor fetal nutrition in the Netherlands as a result of
Nazi occupation during WWII [72]. Research later documented incidence of obesity and
diabetes in offspring of mothers who experienced malnutrition during pregnancy as a
direct result of the Irish potato famine [73]. Together, this research provides evidence to
support the hypothesis that the maternal environment during fetal development might
result in fetal epigenetic reprogramming that influences disease susceptibility and
development later in life. Development being exquisitely sensitive is likely related to the
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prevalence of stem cells who’s patterning is not hard-wired but highly amenable to
epigenetic reprogramming [74].
Similar observations connecting conditions experienced during early life to later
onset phenotypes were being made in wildlife and environmental studies. Rachel
Carson’s publication of Silent Spring in 1962 enlightened the public to the harsh –level
effects caused by the widespread use of the pesticide dichlorodiphenyltrichloroethane
(DDT) on the ecosystem. Similarly, the foundational work of the Guillette lab on the
alligator population of the heavily polluted Lake Apopka in Florida clearly demonstrated
reproductive abnormalities in the field could be reproduced under chemical exposure in
the lab [75-77]. The terms endocrine disruptor, environmental endocrine disruptor and
endocrine disrupting chemicals (EDCs) became commonly used and an active area of
study in the 1970s. Environmental endocrine disruptors have long been studied for their
interactions and effects primarily within the reproductive system. A pharmaceutical
example of endocrine disruption on reproduction is diethylstilbestrol (DES), a potent
pharmaceutical estrogen prescribed to pregnant women to help prevent preterm birth. It
was only later learned, that daughters exposed to DES in the womb experienced severe
reproductive disorders including a rare vaginal cancer [78]. Virtually all of the adverse
reproductive phenotypes described in the DES-exposed mouse model have now been
identified in daughters of DES exposed women [79-81]. This work was foundational
evidence supporting the presence of endocrine disruption and validated the use of mouse
models as strong models for study of potential EDCs with translatable human results.
Once a clear link was established between contaminant exposure and disease
outcomes, investigators began to tease apart the multiple mechanisms whereby endocrine
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disrupting chemicals act. The most commonly studied mechanism of endocrine system
regulation is via hormone/endogenous ligand interaction with target nuclear hormone
receptors (either in the binding pocket or allosterically). Upon ligand binding, the
receptor is translocated to the nucleus where it regulates targeted gene expression via
specific response element binding and recruitment of transcription machinery and coregulatory proteins [82]. Through a variety of interactions with the receptor, exogenous
EDCs can act as agonists, antagonists or simply block endogenous ligands from binding.
(i.e., acting as competitive inhibitors) [83]. EDCs could also sequester the ligand
preventing action on its receptor, block receptor nuclear translocation, and alter co-factor
(activators and repressors) recruitment to target response elements resulting in gene
expression of select genes [84-86]. Additionally, synthesis of endogenous steroid
hormones involves the activity of several enzymes including but not limited to aromatase
for conversion of testosterone to estrogen and estrogen sulfotransferases, both of which
can be inhibited by EDCs [87]. Lastly EDCs can alter epigenetic patterning of genes
committing cells towards specific disease lineages [88].
Historically, reproductive effects have been the primary focus of research on
EDCs, and more recently, metabolic disorders have emerged as likely targets of chemical
exposures in combination with diet, exercise and lifestyle [88]. More research has been
devoted to identifying novel metabolic disrupting chemicals, as well as identifying
additional effects of legacy chemicals, as they relate to metabolic systems. For example,
canonically estrogenic compounds including DES, BPA and polychlorinated biphenyls
(PCBs), known for their adverse reproductive effects, also exhibit weight gain and
impaired glucose tolerance and thus result in metabolic disorder phenotypes [89-91].
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These novel compounds have been termed “obesogens” and more recently
classified as a subset of EDCs known as metabolic disruptors [92]. The most well studied
obesogen to date is tributyltin (TBT). Exposure of pregnant mice to TBT, whether
throughout or at a single time point in pregnancy, produce obesogenic effects in offspring
[93, 94]. Alternatively, daily TBT exposure over several weeks promotes weight gain and
increased adiposity in adult mice [95]. The proposed mechanism by which TBT elicits its
obesogenic effects is through the PPARg/RXRa signaling pathway, whereby it acts as a
ligand that activates both PPARg and RXRa in receptor transactivation assays and
promotes adipogenesis in vitro through either a PPARg-dependent mechanism [96] or
through a PPARg-independent mechanism (e.g. RXRa) [97].
PPARg is a member of the nuclear receptor super family functioning as a ligand
activated transcription factor. In order to elicit a transcriptional response, PPARg first
forms a heterodimeric complex with RXRa, a common partner for orphan nuclear
receptors, then binds to a PPAR response element (PPRE) [98-100]. PPRE sequences are
found in the promoter of several genes that are integral in lipid metabolism and
homeostasis [101, 102] and PPARg, along with other transcription factors including the
Ccaat-enhancer-binding protein (C/EBP) family, is known as the master regulator of
adipogenesis [103]. Endogenous ligands for PPARg include fatty acids, such as
arachidonic acid, and their fatty acid derivatives, specifically eicosanoids [104]. There
are two alternatively spliced isoforms of PPARg, PPARg1 and PPARg2. While PPARg2
is primarily expressed in mesenchymal stem cells and preadipocytes during adipogenesis,
PPARg1 is more highly expressed in adipose tissue and also involved in lipid
homeostasis [105-107].
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In addition to adipogenesis, activation of PPARg results in several metabolic
outcomes including insulin sensitization, lipid metabolism, hepatic lipid storage, and
glucose-stimulated insulin secretion [108]. Due to the role of PPARg in insulin
sensitization, it has been the target of a class of drugs, termed the thiazolidinediones
(TZD), that are aimed at ameliorating the symptoms and pathologies of T2D and
metabolic syndrome [109]. The multiple pathways downstream of PPARg are particularly
vulnerable to disruption due to activation or inhibition of the receptor by exogenous
ligands [110].
The approach used to identify TBT as a PPARg agonist and its further
classification as an obesogen primarily focused on receptor activity and has been used to
identify other potential obesogens [111]. A list of publications that provide evidence for
metabolic disruption in mouse models by exogenous chemicals is summarized in Table 1.
Such compounds include air pollutants like PAHs, the antifouling agent TBT, the stain
and water repellent perfluorooctanoic acid (PFOA), the plasticizer diethylhexyl phthalate
(DEHP) and its metabolite mono (2-ethylhexyl) phthalate (MEHP), the pesticides
triflumazole and tolyfluanid, and the estrogenic compounds DES and BPA. Despite their
diversity in utility, structure and function, many obesogens appear to act through a
common mechanism, that is, binding and/or activating the PPARg receptor, although this
observation could be due to an imbalance in research efforts focusing primarily on
PPARγ mediated obesogen mechanisms of actions. In fact, EPA obesogen screening
efforts (ToxCast) have primarily focused on chemicals that activate PPARγ while a less
characterized and emerging mechanisms of action for obesogens is through interaction
with the glucocorticoid receptor [112, 113]. An appreciation for which
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obesogenic/metabolism-disrupting chemical compounds came into production at
different times may help shed light on the dramatic increases in obesity and diabetes
shown in Figure 2.
Also shown in Table 1, is the variability in timing of dose on outcomes. Broadly,
studies fall into two categories, gestational/perinatal exposure and adult exposure. Even
within those studies treating during times of development, there is extreme variability for
dose timing and mode of delivery. Several studies provide a single dose during gestation,
while others provide daily injections delivering a desired dose from gestation through
weaning. Understanding the environmental relevance of dose, time, and mode of delivery
when considering experimental design is paramount in order to provide research with
results that better inform exposure and health effects observed in human populations.
While there may be diversity among type of EDC and timing of dose, the obesogenic end
points of analysis generally remain consistent. Based on this literature (Table 1), end
points that should be included in a study evaluating obesogens and metabolic disruptors
include, glucose tolerance tests, body weight, adiposity as a function of adipose tissue
weight specifically, general body composition, adipokine, cytokine and hormone analysis
in serum or plasma, and gene expression of obesity associated genes in adipose tissue.
Importantly, these are the same parameters that help define metabolic syndrome in
human patients.
One significant weakness amongst the animal data presented in Table 1 is the
inadequate presentation of sex-specific differences in outcomes resulting from EDC
exposure. Often studies analyze one sex with unclear reasoning for the omission of the
other sex. In these cases it is unclear if the other sex was tested or if this omission
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represents inconclusive or negative results and likely an overgeneralization because
multiple different phenotypes could be assayed for and identified. Previous publications
that utilize one sex, such as high-fat diet induced obesity studies that use males [114],
may be driving choices to use one sex over the other. For those studies reporting results
in both sexes, there is often clear sexual dimorphism in regard to exposure effects, as is
the case with the metabolic disruptor tolyfluanid [115]. If results are not clearly and fully
reported in the context of different sexes, it is possible for the results to be interpreted
incorrectly. Additionally, female mice have traditionally been underrepresented in studies
and a call to research was made the NIH to begin examination of both sexes for their
outcomes in order to gain a more complete understanding of biological variables that
contribute to disease [116]. This may be particularly relevant for the role of endocrine
disruptors in the promotion of obesity, diabetes and metabolic syndrome.
While there is strong evidence for metabolic disruption induced by exogenous
chemicals in animal models, epidemiological studies in humans are not conclusive. Many
of the data for the effects of obesogens in humans is based on cross sectional studies,
particularly for studies on phthalate plasticizers. Using urinary phthalates levels from the
National Health and Nutrition Examination Survey (NHANES) data, multiple groups
have identified correlations between certain phthalate metabolite levels and markers of
obesity like BMI and waist circumference in adult men and women [117, 118]. Other
studies examine single time point analyses during pregnancy and single time point
analyses in offspring. For example, child adiposity at 8 years of age was the single time
point used and found to be associated with higher maternal serum levels of PFOA during
pregnancy [119]. Interestingly, while cross sectional studies for BPA levels have been
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observed to be associated with markers of obesity [120], maternal BPA levels negatively
correlate with BMI in children [121, 122]. Well-designed longitudinal studies are
necessary in order to determine how results from animal models studying metabolic
disruptors can be translated into human health. The “Obesogenic Endocrine disrupting
chemicals: Linking prenatal exposure to the development of obesity later in life”
(OBELIX) project was funded with this intention in mind and will provide data to fill a
knowledge gap in this field [123]. The objective of this project is to use four mother-child
cohorts to evaluate the link between contaminant exposure to pregnancy and obesity end
points in children. Data from the OBELIX project has already identified a link between
prenatal dichlorodiphenyldichloroethylene (DDE) exposure and increases in infant
growth [124].
1.3 The Deepwater Horizon Oil Spill, Surfactants and Dioctyl Sodium Sulfosuccinate
The Deepwater Horizon Oil Spill breach occurred in April 20, 2010. It was a
massive industrial disaster in which 200 million gallons of oil was released into the Gulf
of Mexico due to an oil rig explosion, the largest oil spill in US history [125]. In order to
remediate the effects of the spill, 1.8 million gallons of Corexit® dispersant was applied
to the spill both at the surface and in an unprecedented event via injection underwater
near the well head. Dispersants are used as detergents to remove oil from surface slicks,
break it into droplets and disperse it throughout the water column to prevent oiling of
fragile shoreline habitats and ecosystems. This is done through the combined use of
surfactants and solvents that contain both hydrophobic and hydrophilic moieties. The
majority of dispersants used was Corexit 9500,® (from here on referred to as Corexit)
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which contains approximately 10-30% ,dioctyl sodium sulfosuccinate (DOSS), an active
surfactant (MSDS for Corexit® EC9500A, Nalco Environmental Solutions).
The massive nature of the spill and contamination of the surrounding environment
has persisted well past the capping of the well head on July 25, 2010. The staggering
geographic coverage of the oil spill and aerial dispersant coverage depicted in Figure 3,
emphasize the broad impacts of such a natural disaster on multiple marine habitats
(pelagic, benthic, coastal), organismal life stages, and several species, including humans,
highlighting the need for research across all levels involving multiple disciplines.
Toxicological effects of oil and dispersant have been the primary area of research
to understand the immediate impacts of the DWH oil spill with some focus on sub lethal
effects. Many studies indicate that dispersed oil is more toxic than either crude oil or
dispersant on its own, with one argument being that dispersant makes toxic compounds
(e.g. polycyclic aromatic hydrocarbons; PAHS), in crude oil more bioavailable to marine
organisms [126, 127]. Other studies indicate that exposure to oil and dispersant during
the vulnerable life stages of development and embryogenesis, can cause teratogenic
effects in zebrafish animal models [128] and impact cardiovascular development of
several commercially and ecologically important Gulf of Mexico large, pelagic,
predatory fish species [129]. Marine mammals were also impacted from the spill; one
study observed higher prevalence of disease and worse health prognosis in dolphins from
a population that resides in a heavily oiled area when compared to a population from an
unoiled site [130]. With regard to human health, acute exposure to Corexit caused
respiratory distress in oil spill remediation workers as Corexit can be harmful to human
airway epithelial cells via surfactant perturbation [131-133]. Moreover, exposed workers
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experienced significantly altered blood profiles and liver function and enzyme levels
[131, 132]. Together these data indicate overall adverse health effects across a multitude
of species impacted by the oil spill and use of Corexit, potentially implicating both
immediate and long-term effects on Gulf of Mexico human and marine species
populations.
Despite large amounts of research efforts assessing the effect of MC252 oil and
Corexit on several species, few studies have focused on potential endocrine disrupting
effects of such a large environmental exposure, including the identification of EDCs
present in the complex mixtures of oil, dispersant and dispersed oil specific to the DWH
spill. However, some evidence for endocrine disrupting effects in other types of oils and
dispersants/surfactants exists for both terrestrial mammals and marine organisms, as
follows. One week of dietary exposure to Nigerian bonny light crude oil reduced
testicular steroidogenesis in male rats as measured by enzyme function and circulating
hormone levels [134]. Work by Skinner et al., reported jet fuel exposure via
intraperitoneal injection of pregnant dams during development resulted in
transgenerational inheritance of obesity (F3 only), polycystic ovarian diseases and
changes in sperm epigenetic marks observed in subsequent generations [135]. In both of
the above examples, the exposure routes are unlikely real word scenarios making the
implications and translatability of observed results difficult to interpret.
Environmentally relevant exposure to ambient PAH’s, compounds known for
their prevalence in oil and associated toxicity and carcinogenicity, resulted in increased
adiposity in mice and associated changes in adipose tissue gene expression and DNA
methylation in offspring and grand offspring of exposed dams [136]. Similarly, Kim et al.
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(2005) reported several PAHs to activate PPAR signaling providing a potential
mechanism by which PAHs can influence lipid metabolism and homeostasis [137]. These
two studies together provide a plausible mechanism by which crude oil may be a
metabolic disruptor but replication and consideration for different types of crude oil and
exposure routes is necessary.
Water accommodated fractions prepared from crude oil bunkers in South Africa
display multiple endocrine disrupting properties including thyroid, estrogen, androgen,
and PPAR activities when screened in vitro with some translatable effects to in vivo
studies in amphibian and freshwater fish animal models [138]. With regard to
mammalian responses to crude oil, investigators observed potent estrogenic effects of
several types of oil in vitro measured by receptor transactivation assays and increased
proliferation of a human breast carcinoma cell line [139].
With regard to dispersant, one group did perform receptor transactivation
screening assays in eight dispersants, including Corexit [140]. Like most EDC screening
efforts, priority was put on screening for estrogens and androgens using receptor
transactivation assays. Investigators observed no androgenic activity for any of the
dispersant analyzed while weak estrogenic activity was detected for two dispersants (not
Corexit). This group also performed a multiplexed reporter assay screen and identified
PPAR activity for many dispersants, particularly Corexit. Validation of this activity
required more detailed experimentation, which was pursued in research efforts described
in subsequent chapters.
Other surfactants that are widely used in cleaning products, pesticides and
cosmetics and have been evaluated for the endocrine disrupting properties are
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alkylphenolic (AP) compounds and alkylphenol polyethoxylates (APEs). While APEs
have been used in other oil dispersants, they were not part of the Corexit® composition.
In the environment AP and APEs can break down into multiple nonylphenol (NP) and
octylphenol (OP) compounds, which are more persistent, bioactive and toxic molecules
and can be detected in surface waters and sewage sludge [141, 142]. In in vitro receptor
transactivation assays, breast cancer cell line growth assays and vitellogenin assays,
multiple investigators have reported weak estrogenic activity for NP- and OP-like
biodegradation products [140, 143, 144]. In vivo studies also indicate that these
compounds and mixtures of these surfactants with other pesticides behave as estrogenic
endocrine disruptors, functioning to increase vitellogenin expression in fish [142, 145]
although secondary sex characteristics seem to be unaffected [146]. However, these
studies describe effects observed in laboratory experiments using concentrations higher
than those observed in the field and documenting population-based effects is difficult.
Because NPs can also be found in several commercial food products, including infant
formula [147], determining physiologically relevant exposure doses for humans is
feasible and could inform the experimental design of animals studies to determine if
these concentrations of NPs have endocrine disrupting effects in mammalian species.
Similar to NPs, several components of Corexit have broad commercial use as
many serve multiple purposes including acting as food additives, pharmaceutical stool
softeners, and house hold cleaning products. While DOSS is a prevalent component of
Corexit (10-30%) it is also a food additive particularly in dried beverages (75 ppm) [148]
and prescribed as a stool softener (Colace/docusate sodium) at recommended doses of
200-300 mg/day with a maximum dose of 500 mg/day. Toxicity data for DOSS does not
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indicate it as carcinogenic, teratogenic or to have an effect on reproductive function in
rodents exposed to 1% DOSS in their food [149, 150]. Similarly, use of DOSS as a stool
softener during pregnancy and breast feeding were not previously found to produce any
apparent adverse health effects in the children [151-154]. However, DOSS can alter
absorption of other compounds (Danthron; a stimulant laxative) and a caution is advised
when taking docusate in combination with certain medications [155]. To the best of my
knowledge, DOSS has not been evaluated as a metabolic disruptor at environmentally
relevant concentrations.
In summary, evaluation of Corexit and its components for their endocrine
disrupting potential at physiologically relevant doses and primary routes of exposure are
particularly necessary given that human exposure to these compounds is likely
widespread and can occur through multiple routes. For example, exposure to Corexit and
oil components could occur through consumption of contaminated seafood. And while
direct human exposure to Corexit via oil spill remediation is likely acute and would have
immediate effects such as respiratory distress and alterations to hepatic function,
exposure to the Corexit component DOSS via Colace use during pregnancy or long-term
dietary intake could result in sub lethal endocrine/metabolic disrupting effects.
1.4 Hypothesis and Specific Aims
Due to the massive nature of the DWH oil spill, and given the lack of research on
EDCs specific to MC252 oil and Corexit dispersant, I sought to identify and characterize
potential EDCs present in these mixtures. The overarching hypothesis of this
Dissertation is that DOSS, a major functional component of Corexit, is a metabolic
disruptor. Particular emphasis was put on identifying potential novel obesogens given the
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rise in obesity and diabetes epidemics. Furthermore, in vitro and in vivo validation and
characterization of obesogens was performed and designed in a context relevant for
human health. The specific aims testing the above hypothesis are summarized as follows
and in Figure 4:
Specific Aim 1: Identify potential obesogens present in MC252 oil and/or
Corexit® 9500 dispersant via effects based screening (Chapter 2).
Hypothesis:

Components of oil, primarily PAHs would be potential obesogens.
These experiments included screening several types of oil and
dispersant mixtures for PPARγ, RXRα and estrogen receptor
activation using receptor transactivation assays to determine if the
oil itself, components of oil and/or DOSS, exhibited obesogenic
activity.

Specific Aim 2: Validate candidate obesogen/s in vitro (Chapter 3).
Hypothesis:

Potential obesogens identified in Aim 1 (ie. DOSS) will act as an
obesogen in vitro via PPARγ agonist activity promoting
adipogenesis and gene expression of PPARγ regulated
proadipogenic genes. This hypothesis was tested using adipogenic
differentiation assays of three adipocyte progenitor cells in the
presence of DOSS or a vehicle control.

Specific Aim 3: Characterize validated obesogen in vivo in an environmentally
relevant manner (Chapter 4).
Hypothesis:

DOSS can act as a metabolic disruptor in vivo promoting a unique
phenotype associated with developmental DOSS exposure. To
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test this hypothesis the F1 population of dams treated with DOSS
from mid gestation through weaning was analyzed for markers of
metabolic syndrome including glucose tolerance tests, circulating
adipokines and cytokines, dyslipidemia, adipose tissue gene
expression and DNA methylation.
The work presented herein strives to build evidence for the overall metabolic
disruptor hypothesis, that is exposure to exogenous chemicals during development can
predispose an individual to develop metabolic syndrome in their adult life. Given the
potential for human exposure to MC252 oil and Corexit via consumption of contaminated
seafood, ambient exposure due to proximity to the spill or exposure to a specific Corexit
component (DOSS) via stool softener/Colace use during pregnancy (critical windows of
development), there is a need to fully evaluate the potentially adverse effects associated
with exposure to these compounds, including their potential role as endocrine/metabolic
disruptors.
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Figure 1. Molecular signaling in the development of obesity mediated metabolic
syndrome.
Metabolic syndrome is characterized as increased adiposity particularly in the abdomen,
impaired glucose tolerance and insulin resistance, dyslipidemia and a proinflammatory
state. Together these symptoms increase an individual’s risk for development of T2D and
cardiovascular disease. Figure adapted from [65].
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A

B

Figure 2. Prevalence of obesity and diabetes in the US correlates with chemical
production.
Annual chemical production data was collected from US Tariff Commission reports and
Chemical and Engineering News and data for obesity (A) and diabetes (B) incidence
were provided by the CDC. Figures were adapted from [66] and [67] for A and B
respectively.
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Table 1. Literature Review of In Vivo Obesogen Experiments
Chemical and
Reference
PAH mixture
[136]

Mouse
Strain
BALB/
cByj –
9wk

TBTa
[94]

[Dose]

Dose Time

Mechanism

End Points

Results

-Body weight –PND21 – PND 60
-Body lean and fat mass – MRS
-histological and morphometric
analysis of adipose tissue (number and
size)
-qPCR of inguinal WAT and BAT –
PND 60, PPARg, Cox2, CEBPa, FAS,
adiponectin
-DNA methylation
-F2 cohort – same endpoints as F1
-stem cell differentiation of mADSCs
-methylation of Fabp4 promoter

- inc. PAH à inc. F1 weights
- inc. PAH à inc. WAT
- inc. PAH à inc. adipocyte size
- inc. PAH à dec. PPARγ promoter
methylation in fat

Every day
from GD 1/3
– 19-21

?

C57BL/6J

0.1 mg/kg
with 0.5%
CMC
vehicle
Prenatal

Gavage at
E16.5

PPARg/RXRa

TBTb
[93]

C57BL/6J

5.42, 54.2,
542 nM in
0.5% CMC

7 days before
pregnancy and
throughout
pregnancy

PPARg/RXRa

-Adipose Tissue Histology
-Adiposity
-Liver Histology and gene expression
-BM-MSC differentiation and gene
expression

-male and female have same
response
-TBT à inc. adipocyte size and
number
-TBT à inc. expression of
proadipogenic genes in BM-MSCs
-TBT à inc. liver lipid accumulation

PFOA
[156]

CD1

0.01, 0.1,
0.3, 1, 3 or
5 mg/kg
BW

oral gavage
once daily
from GD 1-17

PPAR

-glucose tolerance test –young (15-16
wk) and old (70-74 wk)
-body mass composition (42 wks)
-serum adipokine – leptin and insulin
(21-33 wk)

-only female analyzed
-low PFOA à inc. body weight
-low PFOA à inc. leptin and insuln
-low PFOA à no change in
adiposity

DEHP
[157]

129S6 –
obesity
resistant

0.05 mg/kg
Adult

Daily in chow
from 10wk-20
wk

PPAR
Oxidative
stress

-insulin tolerance test – 6wks
- glucose tolerance test – 8 wks female
- body composition – 10 wks
- adipokine and hormone ELISA
- metabalomics

- DEHP à increased body weight
- DEHP à alters insulin tolerance
- DEHP à reduced adiponectin and
PPARγ protein levels
- DEHP à inc. PCs 38:X
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7.38-40
ng/m3
Prenatal

-no indication of sex differences
-TBT à promotes adipogenic
differentiation mASDCs
- TBT à reduces osteogenic
capacity of mASDCs
TBT à reduces Fabp4 promoter
methylation

- qPCR – adiponectin, PI3K, Igfr1r,
Vamp4
-8 wks
-body weight
-adipose and liver tissue weight
-blood glucose level
-serum cholesterol and TAGs

C57BL/6J

0.5, 0.25,
0.05
mg/kg/day

Oral gavage
E12 to PND 7

PPARg

Triflumazole
[159]

CD1

0.1, 1.0, 10
uM in 0.5%
CMC

PPARg

-Adipose Tissue Weight
-Adipose MSC qPCR – PPARg,
ZFP423, Pref-1, FABP4

Tolyfluonid
[115]

C57BL/6

100ppm in
diet
Adult

During
breeding and
throughout
pregnancy
12 wk
adult

GR

-ITT – 5 wk and 10 wk
-Body composition
-Adipokine and metabolites
-Adipose qPCR

DES – summarized
in [160]

CD1

0.001
mg/kg/day

GD 9-16 via
subcutaneous
injections

ER

-body weight gain
-adipose tissue weight

BPA
[161]

CD1

5, 50, 500,
5000,
50000
ug/kg.day

GD 9-18 daily
via
micropipetter

ER

-GTT and ITT – 18 wks
-adipose tissue number and volume
-serum hormones

-only males effected
high MEHP à inc. body weight,
adiposity
- high MEHP à inc. cholesterol,
TAGs, glucose
- MEHP à PPARγ adipose gene
expression
-only males analyzed
- 0.1 TFZ à inc. adiposity
- TFZ à inc. PPARγ, ZFP423,
FABP4 aMSC gene expression
- effects males only
- TF àinc. weight gain and adiposity
- TF à glucose intolerance and
insulin resistance
- TF à impairs adiponectin and
leptin signaling
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MEHP
[158]

-DES à inc. body weight over time
(6-14 wks
-DES à inc. adipose weight and
body fat percentage
-only males analyzed
- non-monotonic dose response
-BPA à body weight at certain time
points
-BPA à fat pad weight
-BPA à impaired glucose tolerance
-BPA à inc. insulin, leptin and dec.
adiponectin

Figure 3. Geographic coverage of oil and dispersant from the Deepwater Horizon
Oil Spill.
Data and figure were obtained from the NOAA Emergency Response Management
Application. Total oil coverage is represented in grey with overlaid aerial dispersant
release in yellow. Oiled shorelines range from no oil observed (blue) to heavily oiled
(red). https://erma.noaa.gov/gulfofmexico/erma.html
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Figure 4. Summary of specific aims and broad approach for dissertation research.
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CHAPTER 2: SCREENING MC252 OIL AND COREXIT 9500A DISPERSANT
FOR EDCS USING RECEPTOR TRANSACTIVATION ASSAYS
2.1 Introduction
The Deepwater Horizon (DWH) oil spill, which began April 20, 2010, resulted in the
release of approximately 205 million gallons of MC252 (Mississippi Canyon block 252) crude oil
into the Gulf of Mexico, exceeding the Exxon Valdez spill by an order of magnitude [125].
Approximately 2.1 million gallons of dispersant was used to dissolve the oil into the water
column, presumably aiding in oil biodegradation and preventing the oil from reaching fragile near
shore habitats [162]. The dispersant applied by aerial spray and at the wellhead oil source was
primarily Corexit 9500 (EC9500, EC9500A and EC9500B) and secondarily Corexit 9527 (Nalco
Environmental Solutions, Sugar Land, TX). Since the spill, many studies have focused on the
toxicity of crude oil, dispersed oil or dispersant alone in a variety of species and animal models,
many of which concluded that dispersed oil to be the most toxic mixture [126, 163, 164].
Contributing to this toxicity, dispersant has been shown to increase the bioavailability of oil
components, such as polycyclic aromatic hydrocarbons (PAHs) to fishes [127].

Given the unprecedented use of dispersant during the DWH oil spill and large
scale of the spill itself, it was crucial to go beyond acute toxicity testing to carefully
evaluate sublethal and potential long-term health effects of oil and dispersant to improve
oil remediation safety. Both oil and dispersant, or their components have been implicated
as potential endocrine/metabolic disruptors but only a few studies have been performed
addressing this question [134, 140, 145, 165]. Similarly, to our knowledge, no studies
have looked at the combination of MC252 oil and Corexit 9500 specifically for endocrine
disruption.
Endocrine disrupting chemicals (EDCs) have multiple types of mechanism of
action. They can prevent or alter synthesis of hormones through interaction with enzymes
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in tightly regulated pathways, affect clearance of hormones from the body, and alter
epigenetic marks and signaling, such as DNA methylation [166-169]. Arguably, the most
well studied mechanism of action is through direct binding and interaction of EDCs with
nuclear receptors, the class of receptors that endogenous hormones bind to as ligands.
Nuclear receptors are ligand activated receptors that translocate to the nucleus and
regulate gene expression once activated, resulting in downstream signaling cascades
[170]. EDCs can mimic endogenous ligands leading to unintended activation of receptors
or they can block endogenous hormones from binding to receptors causing antagonistic
effects [171]. For example, legacy EDCs like DES [172] and PCBs [173, 174] and more
recently BPA [175], elicit their adverse reproductive effects via direct interaction with
and binding to the estrogen receptor. Additionally, these types of exposures can be more
harmful when they occur during vulnerable life stages including developmental and
larval stages, which are more sensitive to very low doses (many EDCs have nonmonotonic dose response curves) [176].
The objective of this study was to screen MC252 oil, Corexit® 9500A (from here
on referred to as Corexit), and water accommodated fractions of dispersed oil for
different endocrine disrupting activities using receptor transactivation assays for human
estrogen receptor alpha (ERα) and beta (ERβ), human progesterone receptor beta (PRβ),
human retinoid x receptor alpha (RXRα), and mouse peroxisome proliferated receptor
gamma (PPARγ). It was hypothesized that components of MC252 oil in particular, would
contain obesogenic EDCs given previous studies that identified PAHs as PPARγ/ERα
agonists and others that found correlations between human and animal prenatal PAH
exposure and offspring obesity [136, 137, 177, 178]. Identifying these obesogenic EDCs
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and understanding their potential sublethal effects should help predict outcomes of
exposures and provide more context for their appropriate use and regulation. Particular
emphasis was put on identifying novel obesogenic compounds given the rise of the
obesity epidemic and considering that some Corexit components are commonly used as
food additives, and in personal care products (multiple exposure sources and routes
relevant for human health).
2.2 Materials and Methods
2.2.1 Preparation of Corexit® water accommodated fraction of MC252 crude oil
To distinguish between activity originating from dispersant versus MC252 oil, a
suite of water accommodated fractions was prepared using alternative oils, solvents and
dispersants. All water accommodated fraction (WAF) mixtures were prepared the same
way by vigorously stirring the components at specified ratios overnight followed by 12
hrs of gravity-based separation and aqueous phase collection. All solutions were stored at
4°C in glass vials. Lecithin/Tween 80® (LT) dispersant was prepared as described in
Athas et al. (2014) [179]. Briefly, Lecithin, L-a-phosphatidylcholine, (Avanti Polar
Lipids) was mixed with Tween 80® (Sigma Aldrich and here on referred to without ®) at
a weight ratio of 60/40, respectively and dissolved in ethanol with the total surfactant
concentration at 60 wt %. CWAF (Corexit Water Accommodated Fraction) is Corexit
9500 (Nalco Environmental Solutions, LLC), MC252 oil (Louisiana sweet crude oil
collected from the Macondo wellhead 08/15/2010 by AECOM) and DMEM/F12 cell
culture media mixed 1:20:200 (v/v/v; ratios by volume). LT WAF is LT dispersant,
MC252 oil and DMEM/F12 culture media mixed at 1:20:200 (v/v/v). WAF is MC252 oil
and DMEM/F12 mixed 1:10. CMWAF (Corexit Mazola corn oil Water Accommodated
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Fraction) is Corexit, Mazola® corn oil and DMEM/F12 mixed 1:20:200 (v/v/v). Corexit
only or LT only mixtures are Corexit or Lecithin/Tween 80 dispersant and cell culture
media at a ratio of 1:200. DWAF (dimethyl sulfoxide water accommodated fraction) is
DMSO, MC252 oil and cell culture media mixed 2:20:200 (v/v/v).
2.2.2 Receptor transactivation and ligand induced activation assays
Estrogen-receptor alpha and beta (ERa and ERb) and progesterone-receptor beta
(PRb) plasmids were kindly provided by Dr. Satomi Kohno and Dr. Louis Guillette Jr at
the Medical University of South Carolina. PPARg and RXRa plasmids were kindly
provided by Dr. Bruce Blumberg of UC Irvine. Estrogen receptor and progesterone
receptor assays were performed in collaboration with Merry Anderson and Caitlin Sojka
respectively, both students in the MUSC Summer Undergraduate Research Program
(SURP). For estrogen and progesterone receptor assays, full-length human receptors and
their corresponding response element-luciferase reporters were used. For PPARg and
RXRa assays, a GAL4 (yeast transcription activator protein) DNA binding domain with
the receptor ligand binding domain fusion protein and upstream activation sequence
(UAS)-luciferase reporter system derived from yeast was used and referred to as ligand
induced activation assays.
For all receptor activity based assays, HEK293T/17 cells (ATCC CRL-11268)
were maintained in DMEM/F12 (Gibco by Life Technologies; Grand Island, NY)
containing 10% fetal bovine serum (ThermoScientific; Waltham, MA), 2 mM glutamax,
100 mM nonessential amino acids and antibiotic/antimycotic. Cells were transfected with
Lipofectamine® 2000 according to the manufacturer’s protocol (Invitrogen by Life
Technologies; Grand Island, NY) and plated in 96-well dishes at a density of 20,000 cells
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per well. Each well of cells was transfected with full length receptor (human ERa, ERb,
PGRb) or LBD-GAL4 fusion protein vectors (mouse PPARg ligand-binding domain [a.a.
163-475] or human RXRa LBD [Glu203-Thr462] with GAL4 DNA-binding domain
[amino acids 1-147] [180]), receptor response element luciferase reporter plasmids
(4xERE-luc [181], MMTV-luc [182]) or UASx4 TK-luc (contains four copies of the
GAL4 Upstream Activating Sequence and the herpes virus thymidine kinase promoter [105/+51] driving firefly luciferase) and pRL vector (encoding Renilla luciferase to
control for transfection efficiency) at a ratio of 1:5:0.1 respectively. During transfection,
media containing charcoal stripped FBS (ThermoScientific) was used to prevent
activation of receptors from serum components. The next morning, media was replaced
with fresh charcoal stripped media to remove excess Lipofectamine® reagent that could
potentially react with test ligands. In the afternoon, triplicate wells of cells were treated
as described in serum free or 0.10% FBS conditions, as this was shown to increase assay
sensitivity using the RXRa and PPARg assays (Figure 2). Cell lysates were harvested
after 18 hours (based on assay time optimization shown in Figure 2) of treatment and the
Dual-Luciferase® Reporter Assay System (Promega; Madison, WI) and a BioTek
luminometer were used to measure firefly and Renilla luminescence according to the
recommendations of the manufacturers. Data are represented as normalized firefly:renilla
ratios expressed as fold change over the non-treated control (NTC). For EC50 curves,
data are expressed as percent activation normalized to 100% activation for a given
receptor by its positive control or endogenous ligand. For positive control hormone
ligands, DMSO was used as the vehicle/NTC. For oil/dispersant mixtures, cell culture
media was used as the vehicle/NTC.
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2.2.3 Solid-Phase Extraction
Solid phase extraction (SPE) protocols and fraction testing in transactivation
assays was performed in collaboration with Margaret Magaletta, a student in the MUSC
SURP. Fractionation of CWAF was performed to determine that compounds from
Corexit and not oil were responsible for the observed PPARg activity. Bond Elut® 3 mL
silica SPE columns (Agilent Technologies; Santa Clara, CA) and vacuum manifold
chambers were employed to fractionate CWAF. Before fractionation, the silica
chromatography columns were prewashed with 2 mL of water. Four fractions bearing
differential polarities and hydrophobicities were collected using 2 mL of: 50:50
water:ethanol v/v, methanol, dichloromethane, followed by hexanes. For every 75 µL of
CWAF loaded into the column, an additional 100 µL of water was used to pull the
sample through the column, and 2 mL of solvent was used to collect each fraction.
Before further testing of fractions the solvents were removed from the fractions by
centrifugal vacuum evaporation using a Savant ISS110 SpeedVac Concentrator (Thermo
Scientific; Waltham, MA) and resuspended in 10 µl DMSO per 500 µL of fraction
evaporated.
2.2.4 Chemical analysis of CWAF Sub-fractions using LC-MS/MS
Composition of the CWAF ethanol:water extractable SPE fraction was
determined using liquid chromatography (LC) for compound separation followed by
detection and identification of compounds using tandem mass spectrometry (MS/MS).
For separation of compounds in each SPE fraction, samples were injected onto a heated
(50°C) Kinetex C-18 LC column (100 mm x 2.1 mm, 1.7 µm; Phenomenex, Torrance,
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CA) on an Agilent 1100 LC with autosampler. The mobile phases used for separation by
LC were (A) milli-Q water with 1.0 M ammonium acetate (pH 6.5, Fisher Scientific) and
0.1% formic acid:water (volume fraction, 98%, ACS grade, EMD Millipore) and (B) 1:1
(v/v) isopropanol:acetonitrile (IPA:ACN; ACS plus, Fisher Scientific; Optima LC/MS
grade, Fisher Scientific, respectively) with 1.0 M ammonium acetate (pH 6.5) and 0.1%
formic acid:IPA/ACN (volume fraction). After sample injection (5 µL), the components
of CWAF were separated using a flow rate of 200 µL/min that started at 40 % solvent A
(for 5 min) and changed to 20 % A (0 min to 5 min), to 0 % A (5 min to 19 min), back to
40 % A (19 min to 20 min), and equilibrated at 40 % A for 5 min. Chromatographically
separated components were detected using an AB Sciex API 4000 triple quadrupole mass
spectrometer (equipped with a TurboV electrospray ionization source) operating with
Analyst software (v. 1.5.2). Full scan mass spectrometric experiments (scanning m/z 200
to 1200) were performed in both positive and negative polarity mode to identify potential
target masses in the ethanol/water fraction. The scan parameters (positive/negative) were:
a) scan rate (2 s), b) entrance potential (10/-10 V), c) declustering potential (75/-75 V), d)
curtain gas (20 psi), gas 1 (nebulizer gas; 20 psi), gas 2 (heater gas; 20 psi), ion spray
voltage (5000/-4500 V), source temperature (500 °C) and ihe on. To further characterize
the target masses, product ion scans (MS/MS) were collected (collisionally activated
dissociation (4), collision energy (30 eV), cell exit potential (15 V). Upon identification
of commonalities in the fragmentation of the target masses, precursor ion scans (PIS) of
m/z 307.3, 309.3 and 311.3 (corresponding to fragments of ethyl linoleate, ethyl oleate
and ethyl stearate, respectively) were employed to highlight analyte classes that exhibited
specific in-source fatty acid fragments commonly associated with Polysorbate (Tween®)
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materials [183]. Noting the recently reported ingredients of Corexit (EPA), tentative
identification of two dominant components of the CWAF ethanol/water extract,
Polysorbate 80 (Tween 80®) and dioctyl sodium sulfosuccinate (DOSS), was made by
comparing the acquired mass spectrometric data to previously published reports [183187].
2.2.5 Molecular modeling of Corexit components binding to the PPARg ligand binding
domain
Molecular modeling was assessed using MOE Software (Molecular Operating
Environment; Chemical Computing Group; Inc. Montreal, Canada). Two crystal
structures from the Protein Data Bank [188] comprising the human PPARg ligand
binding domain bound to different ligands (4EMA; human PPARγ in complex with
rosiglitazone [189] and 2HFP; crystal structure of PPARγ with N-sulfonyl-2-indole
carboxamide ligands [190]) were compared,. Using MOE’s superposition function, no
significant differences were observed in the active site of PPARg (RMSD < 2Å). Because
4EMA contained our positive control Rosiglitazone (Rosi) it was chosen as the model.
Ten compounds (Span 80 full and cleaved, DOSS full and cleaved, Tween 80 full and
cleaved, rosiglitazone, propylene glycol, 2-butoxyethanol, and 17β-estradiol), including
some metabolites, were docked to PPARg. Molecular parameters were set for maximum
energy minimization and Amber12 liquid state. Five compounds that comprise Corexit, a
negative control (17β-estradiol) and a positive control (Rosi) were assessed and virtually
synthesized based on liquid state parameters at pH 7.4. The run was set to 30 different
poses, with an area for 30 refinements if necessary. After parameters were set, a
continuous run of all compounds were docked, and descriptors of binding data were
given in ascending order related to E score. The E score gives binding efficiency in terms
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of energy state, with lower E scores indicating higher affinity. Compounds that had the
capability to be cleaved by esterases were assessed with and without the fatty acid chains.
2.2.6 Statistical analysis
All data analyses were performed using GraphPad Prism software (GraphPad v7
Software Inc.; La Jolla, CA). Prior to statistical analysis, data represented as fold change
or percentages were log transformed to meet Gaussian distribution and equal variance
conditions for ANOVA analysis. Normality and equal variance was assessed via
graphical display and confirmed using the Kolmogorov-Smirnov test and BrownForsythe test, respectively. Significantly different values were identified as having Pvalues < 0.05 using one-way ANOVA with Dunnett’s Multiple Comparison post hoc test.
Two-way ANOVA was used for multiple comparison analysis with Sidak’s or Tukey’s
test and significant p-value < 0.05. GraphPad Prism software was used to calculate EC50
data using sigmoidal, 4PL curves.
2.3 Results
2.3.1 MC252 oil demonstrates estrogenic activity
Estrogen receptor transactivation assays were optimized and validated using 17-bestradiol (E2) as a positive control (Figure 1 A and B). EC50s of E2 for ERa and ERb
were calculated to be 170pM and 7.6pM, respectively (Figure 1 A and B). The assays
were determined to be specific given that the non-estrogenic compound rosiglitazone did
not activate the receptor (data not shown).
MC252 oil-Corexit water accommodated fractions (CWAF), Corexit only, LT
WAF and LT only mixtures were tested for estrogenic activity using human ERa and
ERb receptor transactivation assays (Figure 3). CWAF significantly activated both
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receptors at all concentrations tested (6.25, 12.5 and 25 ppm), however ERb showed
significantly higher fold induction than ERa at all concentrations (Figure 3A). In fact,
ERb activation by 25ppm CWAF reached 100% activity (normalized to 100nM E2)
whereas ERa activation by CWAF only reached 13% maximal induction (Figure 3A). To
determine if estrogenic activity detected in CWAF was from oil or Corexit, Corexit alone
was tested as well as WAF from LT dispersed MC252 oil. Corexit only treatments
weakly activated both ERa and ERb approximately 2 fold, suggesting activity observed
in CWAF was primarily MC252 oil derived. Additionally, WAFs prepared with Corexit
and Mazola corn oil showed no significant estrogenic activity (Figure 3A). LT WAF
fractions also significantly activated both ERa and ERb in a dose dependent manner with
significant activation at all treatments (Figure 3B). While comparable activation was
observed for ERb between CWAF and LT WAF, LT WAF increased ERa activation
relative to WAF, suggesting that LT may be contributing estrogenic activity. In fact,
when LT alone was interrogated for estrogenic activity, activity was observed for ERa
but not ERb. Together these data indicate that MC252 oil has estrogenic activity, with oil
components having higher transactivation potential for ERb than ERa and LT
components lecithin and/or Tween 80 having higher transactivation potential for ERa.
2.3.2 Corexit may contain progesterone receptor beta antagonist(s)
Progesterone receptor beta transactivation assays were optimized using the
endogenous ligand progesterone (P4) (Figure 1C). The EC50 for P4 was determined to be
0.75nM. Additionally, non-progestin compounds like E2 were used in validation as
negative controls (data not shown). Antagonist assays were optimized using the known
progesterone antagonist RU486 (Figure 4D).
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We observed significant decreases in progesterone activation by CWAF and
Corexit relative to the non-treated control (Figure 4A). In LT WAF treatments we
observed no differences from the NTC and a slight increase in transactivation activity of
LT (Figure 4B). These data indicate that Corexit may contain a progesterone antagonist.
We tested the most abundant component of Corexit, dioctyl sodium sulfosuccinate
(DOSS), and found antagonist activity at 1, 2 and 4 ppm DOSS (Figure 4E). Whether this
activity is due to direct antagonism of ligand binding or another mechanism requires
further investigation. However, the fact that DOSS at a relatively high concentration of 4
ppm (9µM) reduced the activity of 5nM P4 by ~90% (similar to 10nM of the wellcharacterized and specific antagonist RU486), suggests DOSS has low affinity binding
(9uM vs 10nM) or causes interference through receptor interaction at a different site.
2.3.3 CWAF and Corexit exhibit RXRα activity.
To set up and validate this system (GAL4/UAS ligand induced activity assay),
RXRα reporter transfected HEK293 cells were first treated with negative control ligands
estrogen (17-β-estradiol; E2) or the PPARγ agonist rosiglitazone (Rosi), which did not
activate luciferase reporter expression, whereas treatment with the positive control RXRα
agonists all-trans-retinoic acid (RA) or tributyltin (TBT) resulted in robust, dose-dependent
increases in luciferase levels (Figure 5A).
RXRα reporter transfected HEK293 cells were then treated with CWAF and
Corexit, which exhibited dose- dependent RXRα activation (Figure 5B). The
demonstration that the RXRα activity of Corexit alone is comparable to or even slightly
elevated relative to CWAF suggested that one or more components of Corexit, not crude
oil, was primarily responsible for the RXRα activity observed in the CWAF. Similarly,
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CMWAF (that uses Mazola corn oil in place of crude oil) exhibited RXRa activation
comparable to that of CWAF or Corexit-only treatments. Additionally, when LT WAF
was tested for RXRa activity, significantly reduced activation was observed compared to
CWAF (Figure 5C). However, LT WAF did activate RXRa significantly above the NTC
at 25 ppm suggesting components of oil do, albeit weakly, activate RXRa. Perhaps LT
dispersant makes these compounds more bioavailable to cells than Corexit (Figure 5C).
LT dispersant alone showed no significant differences compared to NTC. Collectively,
these data suggest that Corexit contains one or more compounds that activate RXRa.
2.3.4 CWAF and Corexit exhibit PPARγ activity
PPARγ GAL4/UAS ligand induced activity assays were first validated and
optimized with E2 or RA treatment as negative controls, which as anticipated did not
increase luciferase activity, and Rosi treatment as a positive control, which did induce
marked luciferase activity (Figure 6A). The EC50 for Rosi was calculated to be 5nM
(Figure 1E).
To distinguish between PPARg activity originating from dispersant versus
MC252 crude oil several mixtures of MC252 crude oil, with and without Corexit, were
prepared and analyzed for PPARg activation including: CWAF, WAF, CMWAF and
Corexit only. Dose-dependent PPARg activation was detected in CWAF, CMWAF, and
Corexit dilutions but not in WAF (Figure 6B). The CWAF and CMWAF fractions
comprise an emulsified aqueous-oil fraction of the original mixtures of oil and dispersant
and a portion of the amphipathic compounds present in the original mixtures are expected
to partition to the organic phase. As the dose-dependent PPARg activation by Corexit
alone substantially outstripped those of CWAF and CMWAF, these results suggest that
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components of Corexit were responsible for the activity detected. To further rule out oil
as a primary contributor to the PPARg activity in the fractions, two alternate solvents
were used to prepare water-accommodated fractions, which lack Corexit, DMSO and LT
dispersant. Although twice the amount of DMSO was used to prepare DWAF than
Corexit used in preparing CWAF and CMWAF, no PPARg activity was observed in any
DWAF dilutions tested (data not shown) further implicating a Corexit ingredient and not
a component of oil. Similarly, we observed significantly reduced PPARg activation of LT
WAF compared to CWAF and no differences between LT only and NTC (Figure 6C).
Albeit, we did observe weak but significant activation of PPARg by 12.5 ppm and 25
ppm LT WAF (Figure 6C).
2.3.5 CWAF fractionation and analysis
To further investigate CWAF activation of PPARg, SPE was employed to
fractionate CWAF based on polarity and hydrophobicity; CWAF was fractionated into
50:50 water:ethanol, methanol, DCM and hexane soluble fractions. Substantial PPARg
activation was detected in the 50:50 water:ethanol fraction, whereas no activity was
detected in the other fractions (Figure 7).
Initial mass spectrometric experiments using LC-MS and LC-MS/MS were
performed to identify major components in the CWAF ethanol/water sub-fraction. The
approach first focused on analyzing the sub-fraction in positive full scan mode, which
resulted in the selection of over 200 unique target masses. A representative total ion
chromatogram is shown in Figure 8A. Manual inspection of the chromatogram revealed
several unique mass profiles with mass differences (between adjacent ions) of 22 and 44
amu, reported to be [M+NH4]+ and [M+2NH4]2+ ions of polysorbate species [187].
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Product ion scans (PISs) showed that the m/z 309.3 ion was the most frequent top
fragment for the target masses (present in almost 50% of the product ion spectra).
Previous reports attributed the m/z 309 fragment ion to an in-source loss of specific fatty
acid esters (ethyl oleate, for m/z 309.3) characteristic of polysorbate species [183], or
more recently to a strong presence of oleate-related species in Tween 80® [187]. PIS
scan of m/z 309.3 demonstrated several mass spectral profiles relating to sorbitan
monooleates (specifically 16 – 27 polyoxyethylene units, as shown in inset B; Figure 8),
isosorbide monooleates, and sorbitan dioleates, indicating the presence of Tween 80. The
PIS approach was also able to identify other fatty acid esters, including trace ethyl
stearate (PIS m/z 311.3) and ethyl linoleate (PIS m/z 307.3) species. Thus, this highly
abundant component is likely Tween 80.
Analyzing the sub-fraction in negative full scan mode produced the other highly
abundant component of the CWAF ethanol/water sub-fraction, namely DOSS. Initial
investigation revealed an intense ion at m/z 421. A total ion chromatogram performed in
negative FS mode is shown in Figure 8C with the peak at 2.45 min largely representing
the [M-H]- ion of DOSS. To confirm the presence of DOSS, a PIS of m/z 421.1 was
performed and the resultant fragmentation profile is shown in inset D of Figure 8. Based
on previous reports, which indicate the presence of fragment ions m/z 81 and m/z 227
[185, 186], it was confirmed that DOSS was abundantly present in the ethanol/water subfraction
Collectively, these transactivation assays and mass spectrometry analyses of the
active fraction of CWAF argued that relatively hydrophilic components of Corexit and
not MC252 oil were responsible for the observed PPARγ activity.
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2.3.6 Modeling of Corexit components: PPARg binding prediction
Since Corexit is a complex mixture of solvents and surfactants, molecular
modeling was employed, in conjunction with the LC MS/MS results described in Section
2.3.5, to aid in predicting which components could function as ligands for PPARg. Span
80, Tween 80 and DOSS were predicted to bind to the PPARg ligand-binding domain as
shown by their low E scores whereas propylene glycol and 2-butoxyethanol were not
(Figure 9A). Span 80 and Tween 80 have an ester bond that could be cleaved by cellular
esterases and, once cleaved, neither cleavage product is predicted to bind tightly (Figure
9A). For DOSS docking, the basic lysine 367 residue has a strong hydrogen bond with
the sulfonyl oxygen (Figure 9B). The α-carbon adjacent to the sulfonyl group of DOSS
shows potential for strong donation to a hydrogen of Methionine 364, which is slightly
exposed. PPARg has multiple basic residues that allow a great pairing with the acidic
sulfhydryl group of DOSS, thus increasing the efficacy of H-bonding between the ligand
and receptor. Tween-80 along with other compounds that exhibit low E scores, either
have too large a fatty acid group to effectively fit and bind into the binding site of PPARg
or have a charge that is too basic, and reject acid-base chemistry; therefore, they have
higher binding scores (Figure 8B).
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Figure 1. Receptor transactivation assay validation by positive control dose
response curves.
HEK293/T17 cells were transfected with receptor and reporter ligands as indicated in
methods and treated with positive control ligands for 18 hours in serum free media. EC50
values were calculated for positive control ligands for each receptor transactivation assay
used including A) ERa by 17-b-estradiol, B) ERb by 17-b-estradiol, C) PRb by
progesterone (P4), D) RXRa by tributyltin (TBT), and E) PPARγ by Rosi).
EC50 values were calculated using GraphPad Prism using Sigmoidal, 4PL non-linear
regression curves.
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Figure 2. PPARγ and RXRα activity in a GAL4-UAS system using serum-free
conditions.
HEK293T/17 cells were transfected and exposed to the PPARγ agonist Rosi or RXRα
agonist TBT under serum-containing (10% FBS and 0.1% FBS) and serum-free (SF)
conditions in triplicate and luciferase activities were measured following exposure for:
A) and D) 4 h, B) and E) 8 hr and C) and F) 18 h. Data are normalized to the serum free
control in each time point. As shown, assay sensitivity is greatly enhanced under SF or
0.1% FBS conditions. Data are expressed as Mean ± SD; n = 1-3 per group (* p < 0.05
versus serum free for each treatment group).

47

B

Estrogen Receptors
#

#

10

*

*
*

ERα
ERβ

#
#

5

Estrogen Receptors
Fold Change (to NTC)

Fold Change (to NTC)

A

*

*

* *
*

*
* **

0

#

ERα

*

10

#

*

* *
*

#

#

5

*

*

**

#

ERβ

#

*
#

*

*

*

N
T
6. .1n C
25 M
E
12 LT 2
.5 WA
LT F
25 W
LT AF
50 W
LT AF
W
A
6. F
25
12 LT
.5
LT
25
LT
50
LT

N
.1 T
6. nM C
25 E
12 CW 2
.5 A
C F
6. 25 WA
25 C F
12 CO WA
.5 R F
C EX
25 OR IT
C E
6. OR XIT
25 E
12 Cm XIT
.5 W
C A
25 mW F
C AF
m
W
A
F

0

Treatment (ppm)

Treatment (ppm)

Figure 3. Activation of estrogen receptors alpha and beta by components of MC252
oil, Corexit and lecithin/tween 80 dispersant.
HEK293T/17 cells were transfected with full length human estrogen receptor alpha or
beta, estrogen response element luciferase reporter and Renilla luciferase transfection
control. Cell were exposed A) CWAF, Corexit and CmWAF and B) LT WAF and LT.
Data are expressed as fold changed normalized to the non treated/vehicle control. Data
were analyzed using two-way ANOVA analysis *p<0.05 compared to NTC, #p<0.05
between receptors for a given treatment.

48

*

*

O
SS
4

D

O
SS
D

D
1

6.

25

2

P4
5n
M

N

O
SS

0.0

Treatment (ppm)

PGRβ

50
45
40
35
30

PGRβ

50

+ 5nM P4
*

4

Concentration (ppm)

E
Fold Induction

*

2

*

0

40

+ 5nM P4
* *

30
20

*

10

O
SS
D
4

O
SS

O
SS
D
2

D

O
SS
D

10

0

1

U
R

U
nM

R

U
10

nM

R

O
SS

6
48

6
48

6
48

48
U
nM
1

0

R

N

TC

6

0

0.
5

Fold Induction

*

0.5

Concentration (ppm)

D

PGRβ

*

1.0

N
T
5n C
M
P4
L
12 T W
.5
A
LT F
25 WA
LT F
W
A
6. F
25
L
12 T
.5
LT
25
LT

N
T
5n C
M
6.
25 P4
C
12 WA
F
.5
C
W
A
2
F
6. 5 C
25
W
A
C
F
12 OR
EX
.5
C
O IT
25 RE
X
C
O IT
R
EX
IT

0.0

*

* *

50
45
40
35
30
1.5

TC

*

Fold Induction

* * * *

TC

*

D

0.5

*

C

PGRβ

50
45
40
35
30
25
2.5
2.0
1.5
1.0
0.5
0.0

N

1.0

B

PGRβ

0

50
45
40
35
30
1.5

Fold Change (to NTC)

Fold Induction

A

Concentration (ppm)

Concentration (ppm)

Figure 4. Potential antagonist activity of progesterone receptor beta by components
of Corexit.
HEK293T/17 cells were transfected with full length human progesterone receptor beta,
MMTV promoter luciferase reporter and Renilla luciferase transfection control. Cell
were exposed A) CWAF and Corexit, B) LT WAF and LT, C) DOSS, D) 5nM P4 with 0,
1, 10, or 100nM of the antagonist RU486, and E) 5nM P4 with 0, 0.5, 1, 2, 4, ppm
DOSS. Data are expressed as fold changed normalized to the non-treated/vehicle control.
Data were analyzed using one-way ANOVA analysis *=p<0.05 compared to NTC (A-C)
or 5nM P4 (D-E).
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Figure 5. RXRα transactivation activity of the Corexit water accommodated
fraction of MC252 crude oil (CWAF), Corexit, the Lecithin/Tween 80 water
accommodated fraction of MC252 Oil (LT WAF) and Lecithin/Tween80 (LT).
HEK293T/17 cells were transfected with vectors encoding the RXRα ligand binding
domain – GAL4 DNA binding domain fusion protein and luciferase reporter constructs
and exposed to A) positive and negative control ligands, B)6.25, 12.5 or 25 ppm (vol/vol)
CWAF, Corexit and C) LT WAF or LT and luciferase activity was quantified as
described in Methods. Data are expressed in Firefly luminescence normalized to Renilla
luminescence as fold change over NTC: (* p < 0.05 versus control; error bars represent
Mean ± SD).
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Figure 6. PPARγ transactivation activity of the Corexit water accommodated
fraction of MC252 crude oil (CWAF), Corexit, the Lecithin/Tween80 water
accommodated fraction of MC252 Oil (LT WAF) and Lecithin/Tween80 (LT).
HEK293T/17 cells were transfected with vectors encoding the PPARγ ligand binding
domain – GAL4 DNA binding domain fusion protein and luciferase reporter constructs
and exposed to A) positive and negative control ligands, B) WAF, CWAF, CmWAF,
Corexit and C) LT WAF or LT and luciferase activity was quantified as described in
Methods. Data are expressed in Firefly luminescence normalized to Renilla
luminescence as fold change over NTC: (* p < 0.05 versus control; error bars represent
Mean ± SD).
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fraction.
CWAF mixtures were fractionated using solid phase extraction methods and four solvent
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A
B

C
D

Figure 8. Tween 80 and DOSS are present in the 50/50 ethanol:water fraction.
A) Total ion chromatogram in full scan positive mode of the CWAF ethanol/water SPE
extractable fraction. B) corresponding to peak at 5.33 min, displays a positive mode
precursor ion scan of m/z 309.3 that produces a mass spectral pattern (sorbitan
monooleates with 16 – 27 polyoxyethylene units) present in Tween 80. C) Total ion
chromatogram in full scan negative mode of the CWAF ethanol/water SPE extractable
fraction. D) Corresponding to peak at 2.45 min, displays a product ion scan for m/z 421.0.
Examining the fragmentation profile, noting the fragment ion m/z 81.0, indicates the
presence of DOSS.
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Figure 9. Molecular modeling suggests that Span 80, Tween 80 and dioctyl sodium
sulfosuccinate (DOSS) components of Corexit have predicted PPARγ ligand binding
activity.
A) Average E Score for COREXIT components analyzed for PPARγ ligand binding
using MOE as in Materials and Methods. B) DOSS modeled in the PPARγ ligand
binding pocket.
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2.4. Discussion
The work described in this chapter utilized mixtures of MC252 oil and Corexit
dispersant to test the hypothesis that components of MC252 oil would contain endocrine
disrupting activities as measured by PPARγ receptor and other nuclear receptor
transactivation assays. Here we provide evidence that the complex mixture of MC252 oil
(derived from the DWH source) and Corexit 9500 dispersant can activate several nuclear
receptors. Contrary to our hypothesis, the data indicate that components of Corexit, not
MC252 oil, primarily activate PPARγ and RXRa, and thereby identify Corexit
components as potentially obesogenic. This was accomplished using a series of
dispersant-solvent-oil mixtures to determine where the origin of specific activities was
derived. This type of effects-based method can be used in the future when screening oil
and dispersant mixtures and other matrices for endocrine disruption activities.
Additionally, this can help inform the safety of dispersant used during oil spill
remediation through consideration of multiple endpoints together with available toxicity
data.
Our results for estrogen receptor transactivation assays are consistent with
published studies on the estrogenic activity of oil discussed as follows. Collectively, it
appears that the components of oil are primarily estrogenic, and that they transactivate
ERb more strongly than ERa (Figure 2 and ref [165]). The implications of this result are
less well understood than results on ERa agonists, and warrant further investigation.
Rodent models suggest exposure to petroleum products and PAHs can induce
reproductive toxicity and disease and obesity via ERa [134-136]. Additionally, the type
and origin of oil have been shown to result in varied responses[139]. Williams, et al.,
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studied the estrogenic effects of MC252-derived CWAF and estrogen receptor sequences
of the American Alligator (Alligator mississippiensis) and similarly found that the ERb
isoform to be more sensitive than ERa [191]. Although we did not interrogate the antiestrogenic activity in MC252 oil and Corexit, others have identified this response in
WAFs prepared from other oil types [138].
We also observed low but significant estrogenic activity in Corexit, which was
not observed by others [140]. Thesis research by McNabb et al. (College of Charleston)
studied the estrogenic activity of Corexit in the American Alligator and found no
functional estrogenic effect as measured by male to female sex reversal after treatment
during development and analysis of gene expression markers indicative of estrogen
exposure indicated the observed weak estrogenic activity of Corexit may not be
biological relevant [192] . Estrogenic activity was also observed in an alternative, foodgrade dispersant (composed of lecithin and Tween 80). This is consistent with others who
have tested lecithin for its estrogenic activity, given that it is a common food additive,
and found it to be strongly estrogenic [193].
To my knowledge this is the first investigation into the progestin and antiprogestin effects of oil and dispersants. Here we identify potential anti-progestin effects
of DOSS, a component of Corexit, but also a common stool softener taken by pregnant
women. Given that anti-progestins, such as RU486, are pharmaceuticals used to
terminate pregnancies [194], it may be of critical importance to further study the effects
of DOSS on pregnancy and progesterone receptor signaling at the doses and frequencies
taken. Initial studies of women taking DOSS during pregnancy have not report increased
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rates of preterm births, although these studies primarily focused on identifying risk for
birth defects and malformations associated with DOSS use [151, 152].
RXRa forms a heterodimeric complex with PPARg and many other nuclear
hormone receptors to regulate gene expression [195]. Therefore, identifying compounds
that activate RXRa might be important in several pathways. The PPARg pathway in
particular is of interest as a master regulator of adipogenesis and fat metabolism [196].
Environmental chemicals that interact with the RXRa and PPARg receptors have been
labeled as environmental ‘obesogens’ since they can lead to increases in adipogenesis, fat
accumulation and overall metabolic disruption in vivo [92]. TBT is a well-studied
obesogen that activates both RXRa and PPARg [94, 197]. Here we demonstrated both
RXRa and PPARg transactivation activity by Corexit dispersants, suggesting Corexit
exposure may lead to obesogenic effects by multiple pathways. Although we tested
mammalian receptors in this study, there is high conservation among the nuclear
hormone receptor super family among vertebrates and invertebrates, as well [198, 199]. It
has been shown that environmental obesogens can alter lipid homeostasis in Daphnia
[200] and piscine hepatocytes [201]. These results indicate the relevance and unintended
yet widespread potential consequences of oil spill clean-up efforts, including marine
organisms and humans exposed to Corexit during the DWH spill. Therefore, identifying
specific compounds in Corexit that activate RXRa and PPARg is a worthwhile endeavor
to pursue.
To help narrow the search in silico modeling was used to assist with prediction of
compounds in Corexit that exhibit potential RXRa and PPARg binding. In silico
modeling revealed Span 80, Tween 80 and DOSS as potential PPARg ligands. Given that
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DOSS and Tween 80 were detected in the 50:50 water:ethanol fraction of CWAF, these
data are consistent with the concept that one of these two compounds (or both) may bind
PPARg. The fatty acid moiety of Tween 80 is oleic acid. While fatty acids are
endogenous ligands of PPARg, oleic acid shows weak affinity for PPARg and the large
hydrophobic head of Tween 80 would likely interfere with binding [104]. On the other
hand, DOSS contains a methyl branched hydrocarbon chain similar to that observed in
the chemical structure of MEHP and MiNP, the metabolites of the phthalate esters DEHP
and DiNP respectively, both of which are EDCs known to activate PPARg [202]. This
suggests DOSS is the more likely PPARg agonist.
The ability of Corexit components to interact with the PPARg receptor, in silico
modeling prediction of DOSS as a PPARg ligand and the presence of DOSS in fractions
of CWAF that activate PPARg, all indicate that additional studies to validate the
hypothesis that DOSS is a PPARg ligand and obesogen are requisite. More focused
aspects of this hypothesis are therefore explored in the subsequent two chapters.
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CHAPTER 3: VALIDATION OF DOSS, A COMPONENT OF THE DISPERSANT
COREXIT 9500A, AS A PROBABLE OBESOGEN IN VITRO
3.1 Introduction
The past three decades have witnessed a remarkable increase in the prevalence of
obesity, a condition which contributes to the development of several chronic medical
problems including type II diabetes, hypertension, cardiovascular and neurological
diseases and several cancers [203-205]. While an imbalance in caloric intake and
expenditure is the root cause of obesity, body weight regulation is a complex process
involving interactions between genetics, behavior, diet and other environmental factors
[206]. Increased industrial production of chemicals and increased consumption of
processed foods containing food additives have coincided with increases in obesity rates
[66, 207]. In addition, emulsifiers that are widely used in processed foods have been
shown to induce inflammation, obesity and metabolic syndrome in mice [208].
Interestingly, domesticated animals living within proximity to humans and industrialized
areas also demonstrate increased weight gain over the last several decades [70].
Mounting evidence suggests that endocrine disrupting chemicals (EDCs) termed
"obesogens" may contribute to the development of obesity by driving fat cell
differentiation from multipotent progenitors (adipogenesis), reducing metabolism or
increasing appetite [206, 209]. PPARγ, along with members of the C/EBP family of
transcription factors are master transcriptional regulators of adipogenesis [103]. PPARγ
functions as a heterodimer with RXRα in this process [98, 210]. Bone-marrow derived
stem cells and adipose derived stem cells are the progenitor cell types for fully
differentiated adipocytes in vitro and in vivo [211-213]. PPARg is a member of the
nuclear receptor super family, a ligand activated transcription factor which binds to
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PPAR response elements (PPRE) regulating insulin sensitization, energy homeostasis and
metabolic disease [108]. Endogenous ligands for PPARg, and RXRa, have been
identified and include fatty acids (e.g., arachidonic acid [104]) and arachidonic acidderived eicosanoids (e.g., 9-hydrocyoctadecadienoic acid and 15-deoxy-delta 12, 14prostaglandin J2 [180, 214]).
Obesogens also can function as ligands of this pathway, activating PPARγ or
RXRα or both. The extensively well characterized obesogen, tributyltin (TBT), is an
organotin compound that was used as a biocide in anti-fouling marine paint prior to being
banned in all sites other than those known as “convenient ports of call” [92]. TBT acts as
an agonist for the nuclear receptors PPARγ and RXRα and increases adipocyte
differentiation [94, 197, 215]. Other PPARg agonists that have been investigated as
obesogens include phthalate metabolite monoesters [202, 216], perfluorinated chemicals
[217], some pesticides [159], and flame retardants [218]. Two anionic sulfonyl
surfactants, SDS and SDBS have also been identified as PPARg ligands and to increase
adipogenesis in preadipocyte cell lines [219].
In Chapter 2, the endocrine disrupting and obesogenic potential of DWH oil and
Corexit 9500A dispersant was investigated using nuclear receptor transactivation assays.
Through that investigation and analysis, it was determined that Corexit is likely to
contain obesogenic compounds, as PPARg and RXRa activity was observed in mixtures
containing Corexit. DOSS is hypothesized to be the most likely component to activate
PPARg based on in silico and LC MS/MS analysis of CWAF and fractionated CWAF.
The primary objective of this current study was to test this hypothesis by validating
DOSS as a PPARg activator and describing the functional role of DOSS as an obesogen
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in vitro. Additionally, RXRa ligands present in Corexit were investigated to determine
the obesogenic potential of Corexit as a whole. Lastly, oleic acid was investigated for
PPARg and RXRa activity since it is a dietary fatty acid that shares structural similarity
with the Corexit components Span80 and Tween80.
3.2. Materials and Methods
3.2.1 Cell viability assays
AlamarBlue® cell viability reagent was used for the viability assay. The cell’s
ability to reduce resazurin (active ingredient in AlamarBlue®) was measured as
fluorescence with excitation wavelength at 530 nm and emission wavelength at 590 nm
using a TYPHOON scanner or BioTek Luminometer. Cells were treated with indicated
test compounds for 18 hours and data was normalized to the non-treated control (NTC)
representing 100% viability. Wells with no cells were used as a background control.
Renilla luciferase expression was also used as a viability marker. Cells were transfected
with the Renilla PRL (constitutive expression) plasmid in a solution using
Lipofectamine® 2000 (Invitrogen) according to the manufacturer’s guidelines and
described in Section 2.2.1. The day after transfection cells were exposed to various
dilutions of DOSS for 18hrs in serum free conditions. Luciferase was quantified using the
Promega Dual Luciferase kit (Promega), and BioTek Luminometer. Data were
normalized to the NTC as 100% and compared to results obtained from Alamar Blue
assay (Figure 1A).
3.2.2. Receptor transactivation and ligand-induced activation assays
PPARg and RXRa GAL4/UAS ligand-induced activation assays were performed
as described in Chapter 2. For transactivation assays employing native RXRa, a vector
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encoding full-length human RXRα and a vector employing the RXRα binding element
from the ApoA1 gene driving firefly luciferase expression were used with pRL in a ratio
of 1:5:0.1, respectively [214]. These vectors were kindly provided by B. Blumberg; UC
Irvine. Additionally, GAL4/UAS ligand-induced activation assays using human PPARg,
PPARa and PPARb/d LBD-GAL4 fusion receptors were also performed as described in
section 2.2 using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. These additional plasmids were kindly donated by Dr. Barbara Abbott, EPA
as described in Bility et al 2004 [202]. Interrogated ligands included Corexit components
petroleum distillates (ICP; CAS 64742-47-8), propylene glycol (PG), dioctyl sodium
sulfosuccinate (DOSS), Span80 and Tween80 (Sigma Aldrich), the PPARg agonist
Rosiglitazone (Rosi), the PPARg inhibitor T007907, and Wy14643 the PPARa agonist
(Cayman Chemical).
3.2.3. TR-FRET RXRa and PPARg binding Assays
For time-resolved fluorescence resonance energy transfer (TR-FRET) based
assays, SelectScreen® Biochemical Nuclear Receptor profiling was employed (Life
Technologies). Specifically, the LanthaScreen® TR-FRET coactivator protocol was used
for RXRα. Briefly, a GST-tagged ligand binding domain (LBD) of RXRα was incubated
with terbium labeled anti-GST antibody (excitation/emission 340/495 nm), test ligands,
and a fluorescein labeled coactivator peptide (excitation/emission 495/520). A TR-FRET
ratio of 520:495 was calculated to determine percent ligand binding and coactivator
recruitment since energy transfer from the terbium labeled LBD to the fluorescein
coactivator can occur when the two are in close proximity to one another. The
LanthaScreen® TR-FRET competitive binding assay was used for PPARγ. Briefly, a
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terbium labeled GST-tagged PPARγ LBD domain (excitation/emission 340/495 nm) was
incubated with test ligands and a fluorescein labeled tracer ligand (excitation/emission
495/520). Loss of FRET signal between the antibody and tracer indicates displacement of
high affinity labeled ligand by the test ligands since the complex is no longer intact and
energy transfer cannot occur.
3.2.4. 3T3 L1 adipocyte differentiation assays
For triacylglycerol staining assays to quantify adipogenic differentiation 3T3 L1
preadipocyte cells (Zenbio; Research Triangle Park, NC) were plated in 48-well plates at
a density of 10,000 cells per well in Preadipocyte Growth Medium (PGM); DMEM
(Gibco by Life Technologies) supplemented with 10% Hyclone Defined fetal bovine
serum (ThermoScientific), 2mM glutamax, 100 µM nonessential amino acids and
antibiotic/antimycotic (all from Invitrogen) and grown until confluence. Two days postconfluence the media was changed to differentiation media (minimal induction media,
MIM) with test ligands or 1 µM Rosiglitazone (positive control). MIM was determined to
be 0.25X PDM (preadipocyte differentiation media) from serial dilutions with 1X PDM;
PGM supplemented with 0.25 µM dexamethasone, 0.5 mM IBMX and 1 µg/mL insulin,
1X. After 72 hrs of induction, the media was switched to PGM containing 1 µg/mL
insulin. Cells were differentiated for four more days (7 days total) and fixed with 4%
PFA. Triacylglycerol staining with AdipoRed (Lonza) and nuclear counter-staining with
NucBlue (Hoechst; Invitrogen) was conducted according to the manufacturers’
recommendations. Relative adipogenesis is expressed as fold change of MIM. Data are
represented from mean fluorescence of 42 fields per well with five replicates used for
each treatment. Fluorescence was quantified using a HERMES high content screening
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scanner (WiScan, IDEA Bio-Medical Ltd., Rehovot, Israel). Hoechst fluorescence was
quantified using excitation 390/18nm, emission 440/40nm (light intensity: 50%,
exposure: 30ms, gain: 30%) and AdipoRed was quantified using excitation
485/20nm, emission 525/30nm (light intensity: 90%, exposure 58 ms, gain: 30%).
3.2.5. Mouse and human bone marrow derived mesenchymal stem cell adipogenesis
assay
Murine (C57BL/6) BM-MSCs were obtained from Dr. Phinney’s lab at The
Scripps Research Institute (Jupiter, FL) in line with the NIH policy on resource sharing.
Human BM-MSCs were obtained from Texas A&M University Institute of Regenerative
Medicine. Both types of BM-MSCs were maintained in complete culture medium
(CCM), alpha-MEM (Gibco by Life Technoliges), supplemented with 16% Hyclone
Defined FBS (ThermoScientific), 2mM glutamax and antibiotic/antimycotic (all from
Invitrogen). Murine MSCs and human MSCs were plated at a cell density of 2 x 104
cells/well in CCM and grown until 90% confluence. Media was then changed 0.5X PDM
(determined to be optimal based on serial dilutions) differentiation media (described in
3.2.3) alone, or with different concentrations of DOSS or 1uM Rosiglitazone as a positive
control. Media was changed every three days for 14 days (mouse MSCs) or 18 days
(human MSCs) at which point cells were fixed with PFA, stained with AdipoRed and
NucBlue and quantified as described in 3.2.3. The settings on the Hermes were optimized
at each run.
3.2.6. mRNA gene expression by qPCR
3T3-L1 preadipocytes, human BM-MSCs, and mouse BM-MSCs were exposed
or not to differentiation media or differentiation media supplemented with test ligands as
described in 3.2.3 and 3.2.4. Three wells of cells from each treatment group were pooled
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from each of two experiments for mRNA expression analyses. RNA was isolated using
the RNeasy Kit (Qiagen) or Trizol with the PureLink RNA Minikit (Invtrogen) following
the manufacturer’s instructions with addition of DNaseI. RNA quality was assessed using
Nanodrop absorbance ratios 260/280 (2.0-2.2) and 260/230 (>1.5). Two types of gene
expression analysis were used. For 3T3 L1 cells gene expression was assessed in
triplicate using 25 ng of RNA per qPCR reaction and the iTaq Universal SYBR Green
One-Step Kit following the manufacturer’s instructions (BioRad). For mouse and human
BM-MSCs, 250ng to 1µg RNA was reverse transcribed to cDNA using SuperScriptIII
(Invitrogen) following the manufacturer’s instructions. cDNA was then diluted
appropriately so that ~10-20 ng of cDNA was used per qPCR reaction with Roche
FastStart Essential DNA Green Master mix (Roche). The same touchdown PCR cycle
program was used for all primer pairs: 95ºC 10 sec, 66ºC-56ºC 20 sec dropping a degree
each cycle for 10 cycles, then remaining 35 cycles at 56ºC, 72ºC 20 sec for a total of 45
cycles. Results were normalized to the reference gene Hprt using the DDCt method. Hprt
was used at the reference gene, however Gapdh and 18S rRNA were also analyzed and
determined to be more variable with treatment (stdev Ct value, 0.44, 0.85 and 0.94
respectively). Calibration curves were prepared to ensure equal PCR efficiencies between
test and reference genes (+/- st. dev. <1.01%). Data are expressed as a fold change
compared with the MIM/PDM-only control. Queried genes and primer sequences are
listed in Table1.
Table 1. Genes and corresponding primers used for qRT-PCR analysis.
Gene
Hprt

Species
Mouse

Forward Primer
AGGCCAGACTTTGTTGGATTTG

Reverse Primer
TTCAACTTGCGCTCATCTTAGG

Dlk1/
Pref1
AdipoQ

Mouse

CCTGGCTGTGTCAATGGAGT

CAAGTTCCATTGTTGGCGCA

Mouse

GTTCCTCTTAATCCTGCCCA

GTTCCTCTTAATCCTGCCCA
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Fabp4
HPRT
ADIPOQ
FABP4
EZH2

Mouse
Human
Human
Human
Human

ATGTGTGATGCCTTTGTGGGA
TGACACTGGCAAAACAATGCA
GCTGGGAGCTGTTCTACTGC
TCACTGCAGATGACAGGAAAGT
AATCAGAGTACATGCGACTGAGA

GATGATCATGTTGGGCTTGGC
GGTCCTTTTCACCAGCAAGCT
CGATGTCTCCCTTAGGACCA
GTGACGCCTTTCATGACGCA
GCTGTATCCTTCGCTGTTTCC

3.2.7. Statistical analysis
All data analyses were performed using GraphPad Prism software (GraphPad
Software Inc.). Prior to statistical analysis, data represented as fold change or percentages
that did not meet Gaussian distribution and equivalency of variance conditions for
ANOVA analysis were log transformed. Normality and equal variance was assessed via
graphical display and confirmed using the Shairo-Wilk or Kolmogorov-Smirnov test and
Brown-Forsythe test respectively. P-values < 0.05 were deemed significantly different
using one-way ANOVA with Dunnett’s, Tukey or Sidak’s multiple comparisons post-hoc
tests. Two-way ANOVA was used for multiple comparison analysis with Sidak’s test and
significant p-value < 0.05. GraphPad Prism software was used to calculate EC50 data
using sigmoidal, 4PL curves. Similarly, LC50 was calculated using log (inhibitor) vs.
normalized response – variable slope.
3.3. Results
3.3.1. DOSS activates PPARg
The results from Section 2.3 implicated a Corexit component(s) in the PPARg
transactivation observed in the CWAF prepared from MC252 oil. Mass spectrometry
indicated that Tween 80 and DOSS are present in the 50:50 water:ethanol fraction of
CWAF, which exhibits activity in the GAL4-UAS assay system, and molecular modeling
predicts that Span 80, Tween 80 and DOSS can bind to the PPARg ligand binding
domain (Section 2.3). Therefore, these compounds were tested for PPARg activity. We

66

used assay conditions optimized in Chapter 2 to test Corexit components for PPARg
activity. Prior to testing, we obtained LC50 values for test compounds using AlamarBlue
cell viability assay as a marker for metabolic activity which also validated Renilla
luciferase values as a proxy for cytotoxicity to monitor assay to assay (Figure 1A). The
LC50 for DOSS was determined to be 10 ppm in HEK 293 cells under serum free
conditions (Figure 1A and B). We determined the LC50 value for Span 80 and Tween 80
to be approximately 500 µM (about 200 ppm) and 150 µM (about 200 ppm), respectively
(Figure 1E and F). It should be noted that DOSS is more cytotoxic than Span 80, with the
same cytotoxicity at approximately 10-fold lower concentration than that of Span 80.
We observed that Span 80 and Tween 80 both demonstrate weak PPARg
activation, even at the highest concentrations tested, reaching only about 10% of maximal
induction (based on 100nM Rosi) at 128 µM (Figure 2A and B) for both compounds. We
observed no activities for these compounds at the concentrations used in Corexit.
Furthermore, a mixture of petroleum distillate (ICP) and propylene glycol (PG), other
major components of Corexit, does not demonstrate PPARg activation (Figure 3C). We
next tested DOSS for PPARg activation. Unlike Span 80 and Tween 80, DOSS alone
elicits a dose-dependent increase in PPARg activity in the low ppm range (Figure 3A, B
and C). Significant activation was observed at 2, 4 and 8 ppm, reaching approximately
50% maximal induction compared to Rosi (Figure 3A). When using water or DMSO as
DOSS solvents, we observed comparable activities, with DOSS dissolved in water being
slightly more efficacious (Figure 3B). Under control conditions, when cells were
transfected with the reporter plasmids but no receptor plasmid and treated with DOSS, no
response was observed (Figure 3B), indicating DOSS specificity. As described above,
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ICP:PG mixtures do not activate PPARg, however, when this mixture is supplemented
with increasing concentrations of DOSS, robust PPARg activity is now observed (Figure
3C). Thus, DOSS has PPARg ligand induced activity in this assay whereas Span 80,
Tween 80, ICP, and PG do not. Since Corexit 9500 is approximately 10-30% DOSS
[162], it is likely that the PPARg agonist activity observed following treatment with
CWAF, CMWAF or Corexit (Section 2.3) is largely due to DOSS.
Curiously, only slight reductions in PPARg activation were observed when cells
were treated with 75ppm DOSS and 1µM of the PPARg inhibitor T007907, using serum
containing conditions (Figure 3D). Conversely, activity observed with 100 nM Rosi was
reduced ten fold in the presence of 1 µM T007907 inhibitor. Interestingly, when
preadipocyte differentiation media (PDM) containing DOSS was tested for PPARg
activation with and without inhibitor, the activity was decreased by about half in the
presence of the inhibitor (Figure 3E). However, the greatest reduction was always
observed in the Rosi with inhibitor treatments suggesting that DOSS and Rosi may not
interact with the ligand binding and/or other domains of PPARg in the same way.
DOSS interaction with the ligand-binding domain of PPARg was validated using
a TR-FRET competitive binding assay. Using this assay, DOSS was able to displace a
high-affinity ligand bound to the LBD of PPARg with an EC50 of 1.38 µM, similar to
that of the endogenous PPARg ligand arachidonic acid (Figure 3E). In the same assay,
EC50 values for Span 80 and Tween 80 were much higher, at 315 µM and 45.14 µM,
respectively (Figure 5C and D). This is consistent with the concept that DOSS is largely
responsible for PPARg activation observed in CWAF and Corexit.
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Given the structural similarity of the PPAR isoforms with each other as well as
between species, we tested human PPARg, PPARb/d and PPARa for DOSS ligand
induced activity as well using the GAL4/UAS system (Figure 6). DOSS was able to
activate human PPARg in a dose-dependent manner, although this assay was not as
sensitive as for mouse PPARg, with 100nM Rosi producing only a 4-fold response and
4ppm DOSS producing a 3-fold response using the human PPARγ LBD-GAL4 assay
(Figure 6A). We observed approximately a 1.2-fold induction of PPARa activity by
DOSS, but no trend relating to dose was observed, suggesting that DOSS has extremely
low if any affinity for PPARa (Figure 6B). Interestingly, and worth further investigation,
we observed a strong dose response in PPARb/d activity by DOSS, with 7-fold induction
at 4ppm DOSS (Figure 6C). While PPARb/d is a widely-expressed isoform, it is also
arguably the least studied PPAR isoform, but has been implicated as an essential
mediator of COX-2/PGE2-driven inflammation in colorectal carcinogenesis [220].
3.3.2 Span 80 exhibits RXRa activity
Since Corexit was able to activate both PPARg and RXRa (section 2.3), several
Corexit components were interrogated specifically for RXRa ligand induced activity
including DOSS, Span 80 and Tween 80 using the GAL4/UAS system. While we
observed weak PPARg activation by Span 80 and Tween 80, these compounds had
stronger RXRa activity, particularly Span 80 (Figure 2A and B).
Corexit components DOSS (Figure 4A), petroleum distillates and propylene
glycol mixed 50/50 (ICP/PG; Figure 4B) demonstrated no significant RXRα activity.
Conversely, Tween 80 modestly (Figure 2B), and Span 80 markedly (Figure 2A)
activated RXRα, reaching 20% maximal induction (relative to TBT) at 64 µM (~30 ppm)
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and 40% maximal induction at 128 µM (~60 ppm), respectively. Collectively, these
results suggested that the RXRα activity present in CWAF and Corexit (section 2.3)
derives primarily from Span 80, with a lesser contribution from Tween 80. To further
confirm Span 80 in a true RXRα transactivation assay (requiring ligand binding and
DNA binding domain transactivation), HEK 293T cells were transfected with a fulllength human RXRα expression vector and with a reporter vector containing the
validated RXRα binding element of the ApoA1 gene driving luciferase reporter
expression [214]. As shown in Figure 5D, Span 80 exhibited robust, dose-dependent
RXRα transactivation in these assays, which was very similar to that observed with the
RXRα ligand-binding domain – Gal4-DNA binding domain UAS luciferase system
(Figure 5C).
Lastly, to verify that Span 80 can displace a high-affinity ligand for RXRα, the
TR-FRET coactivator assays for Span 80 and Tween 80 was used. EC50s for Span 80
and Tween 80 in this assay were in the low micromolar range, 6.65 and 2.84 µM
respectively. However, it should be noted that Tween 80 only reached a maximum
percent activation of roughly 45% in this assay, supporting the concept that Span 80 is a
higher affinity activator of RXRa than Tween 80.
3.3.3. Oleic acid has stronger activity for RXRa than PPARg
Oleic acid (C18:1 cis-9), is a fatty acid component of both Span 80 (a sorbitan
monoester) and Tween 80 (an ethoxylated sorbitan ester) and represents a naturally
occurring dietary fatty acid. As Span 80 and Tween 80 showed greater activation of
RXRα than PPARg (Figure 2A and B), we sought to directly compare Span 80, Tween 80
and their fatty acid component oleic acid in the ligand induced (GAL4/UAS) activity
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assays. As with all other dosing experiments, treatments were in the sub lethal range;
LC50 values for HEK 293 cells were 319 µM for oleic acid; Figure1). As shown in
Figure 7A, oleic acid was more potent than either Span 80 or Tween 80 with significant
RXRα activity at 16 µM versus 64 µM for Span 80 and Tween 80. From these data,
EC50s for oleic acid, Span 80 and Tween 80 were 33 µM, 33 µM and 70 µM,
respectively. Oleic acid was also more efficacious, eliciting approximately 60% of
maximal activation at 128 µM compared to approximately 45% activation for Span 80
and approximately 20% for Tween 80 (100% activation is that achieved with 10 nM
TBT).
For PPARg, all three compounds behaved similarly, eliciting only 12-15%
maximal activation at 128 µM (Figure 7B). When these compounds were assessed using
the TR-FRET assays for both receptors, similar results were obtained. As described
above, EC50s for Span 80 and Tween 80 were in the low micromolar range for RXRa
but an order of magnitude higher for PPARg (Figure 7C, D). As predicted by
transactivation assays, oleic acid elicited the lowest EC50 for RXRa at 1.6 µM (Figure
7C) and was roughly 50 times greater for PPARg at 90 µM (Figure 7D). In sum, oleic
acid and Span 80 are more potent and efficacious agonists for RXRa than PPARg with
oleic acid eliciting the strongest response, suggesting that the sorbitan group of Span 80
and ethoxylated sorbitan group on Tween 80 may interact with the RXRa ligand binding
domain to dysregulate signaling.
3.3.4. DOSS increases adipogenesis in preadipocytes and BM-MSCs
To functionally test the obesogenic potential of DOSS, murine 3T3-L1
preadipocytes, murine BM-MSCs and human BM-MSCs were exposed to low-level
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adipocyte differentiation inducers with and without a dosage series of DOSS and then
adipogenesis was quantified by measuring triacylglycerol content (Figure 8). To ensure
test concentrations of DOSS were in the sublethal range, viability tests were performed
(as above). The LC50 of DOSS in 3T3 L1 cells was determined to be approximately 90
ppm, which was well above the highest doses applied in adipogenesis experiments
(Figure 1C). Cells were treated with minimal induction media (MIM) and DOSS, or 1
µM Rosi as a positive control. Triacylglycerol accumulation was quantified and
visualized using AdipoRed staining (Lonza; green) and normalized to cell number
(Hoechst nuclear counter-staining). MIM with and without DOSS was tested for PPARg
activity to coordinately demonstrate increases in PPARg activation with increases in
triglyceride accumulation (Figure 3E). A dose-dependent increase in adipogenesis was
observed with increasing concentrations of DOSS (Figures 8 and 9). Significant increases
in adipogenesis in 3T3 L1 cells were observed at 20, 25 and 50 ppm DOSS exposure
compared to MIM alone (Figure 8A). Additionally, murine BM-MSCs were exposed to
MIM alone or MIM with increasing concentrations of DOSS (and Rosi as a positive
control) to see if DOSS increased adipogenesis in undifferentiated progenitor primary
cells. Significant induction was observed in 50 ppm DOSS and 1 µM Rosi treated cells
only with 3 fold and 40 fold induction over MIM respectively (Figure 8B), suggesting
that mouse primary BM-MSCs are responsive to DOSS treatment, but less so than the
3T3 L1 cell line.
Human primary BM-MSCs were also used to assess the ability of DOSS to
increase adipogenesis in an undifferentiated progenitor cell type, and to validate DOSS as
an agonist for not only mouse PPARg but human PPARg as well. For human BM-MSCs,
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similar results were observed (Figure 8C). Adipogenesis was quantified using the same
methods as described for 3T3 L1 cells. Human BM-MSCs were treated with MIM alone,
increasing concentrations of DOSS or 1µM rosiglitazone as a positive control for 18
days. Significant increases in adipogenesis relative to the MIM alone control were
observed at 30, 40 and 60 ppm DOSS (Figure 8C), further supporting a role for DOSS as
a driver of adipogenesis in vitro not only for the murine preadipocyte cell line and
primary cell progenitors but also for the human primary cell progenitors as well.
Lastly, because results indicated that Span 80 is capable of activating RXRα and
weakly activating PPARγ, and that these receptors are known to regulate adipogenesis
through dimerization, the potential of Span 80 to promote adipocyte differentiation in
vitro was tested using the 3T3 L1 preadipocyte differentiation assay. Span 80 addition at
250, 500 or 1000 ppm to minimal induction media (MIM) caused a dose-dependent
increase in adipocyte differentiation over basal levels; at 500 ppm Span 80 there was an
approximately 2-fold and at 1000 ppm an approximately 3-fold increase in
triacylglycerol levels (Figure 9A and B). Comparable to results described above,
treatment with 12.5, 25, or 50 ppm DOSS in the presence of MIM also resulted in a dosedependent increase in adipocyte differentiation (Figure 8A and Figure 9B; Ref. [13]).
These results are also consistent with the concept that DOSS is more potent than Span 80,
increasing adipogenic differentiation at concentrations over an order of magnitude lower
than that of Span 80.
3.3.5. DOSS increases expression of adipogenic genes
To extend triglyceride data and validate that adipogenesis was occurring in
differentiation assays, changes in gene expression of adipogenic genes resulting from
DOSS treatment was investigated. For analysis in 3T3 L1 cells qPCR mRNA analysis
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was performed on day three of differentiation. Significant dose dependent increases in
gene expression was observed for two adipogenic gene markers, AdipoQ and Fabp4
(Figure 10A and B). Decreases in the preadipocyte marker, Pref-1/Dlk-1 (preadipocyte
factor 1/delta like kinase 1) mRNA levels are an accurate and precise measure of
adipocyte differentiation by preadipocytes [221]. Consistent with this, a significant dosedependent decrease in Pref-1/Dlk-1 in DOSS and Rosi treated 3T3 L1 cells was observed
(Figure 10C). These data further support the conclusion that DOSS increases
adipogenesis (and not merely triglyceride levels) in 3T3 L1 preadipocytes. Similarly, for
mouse primary BM-MSC progenitors increases in AdipoQ and Fabp4 expression were
also observed (Figure 10D and E). However, similar to the results observed in the
differentiation assays, these changes were only significant at the highest concentration of
DOSS tests (50ppm), suggesting that primary progenitor cells are not as responsive as a
mouse preadipocyte cell line.
The same adipogenic markers were also investigated in human BM-MSCs at day
16 of adipogenesis. Similarly, dose-dependent increases in gene expression for both
ADIPOQ and FABP4 were observed (Figure 11A and B). Notably, Rosi increased
expression of these genes 100 fold more than the highest concentration of DOSS tested,
suggesting that the adipocytes produced by DOSS may be different than adipocytes
derived from Rosi treatment even though their triglyceride accumulation is comparable
(Figure 8C). In MSCs, the histone methyltransferase gene, EZH2, is an early adipogenic
marker as its methyl marks are documented to repress genes involved in osteogenesis,
another lineage fate of BM MSCs [222]. Indeed, significantly decreased EZH2
expression was observed in terminally differentiated DOSS and Rosi treated cells relative
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to MIM (Figure 11C), suggesting that DOSS differentiated populations have fewer noncommitted cells and more terminally differentiated adipocytes.
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Figure 1. Cytotoxicty of DOSS, Span 80 and Tween 80 in HEK 293 T17 Cells and
3T3 L1 murine preadipocytes.
Percent viability of HEK293 T17 cells and 3T3 L1 preadipocytes was calculated for test
compounds used in transactivation and adipogenesis assays. Cells were treated with test
compounds in triplicate for 18hrs, AlamarBlue reagent was added and mitochondrial
activity was measured based on the colorimetric assay. A) Comparison of percent
viability of HEK 293 cells exposed to 1, 2, 4, 8, 16 and 32 ppm DOSS in serum free
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Figure 2. Comparison of Span 80, and Tween 80 potency and efficiency for RXRa
and PPARg using receptor transactivation assays.
HEK293T/17 cells were transfected with RXRa and PPARg GAL4-LBD, UASluciferase and renilla luciferase reporter plasmids. Dilutions of mixtures were prepared
and cells were exposed in triplicate for 18 h, luciferase activities were measured and
firefly to renilla luciferase ratios were calculated. Data are expressed as percent activation
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Figure 3. DOSS activates PPARγ.
HEK293T/17 cells were transfected with PPARγ GAL4-LBD, UAS-luciferase and renilla
luciferase reporter plasmids. Dilutions of mixtures were prepared and cells were exposed
in triplicate for 18 h, luciferase activities were measured and firefly to Renilla luciferase
ratios were calculated. Data are expressed as percent activation relative to 100%
activation by 100nM Rosiglitazone for PPARγ or as fold change over the non treated
control (NTC). A) DOSS activation of PPARγ. B) Comparison of PPARγ activation by
DOSS in water or DMSO. C) PPARγ activation by DOSS, ICP:PG and ICP:PG
supplemented with DOSS. D) Effect of the PPARγ inhibitor T007907 on the ability of
DOSS to activate PPARγ. E) Validation of PDM media with DOSS to activate PPARγ
with and without inhibitor F) Competitive binding of DOSS to PPARγ measured by
percent displacement in TR-FRET assay.
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79

A

B
RXRα ICP:PG

70

70

65

65

0

5

0

50

25

12

5

.5

62

.6

.2

10

DOSS (ppm)

31

4

8

2

7.

1

15

NTC 10nM TBT

60
5
4
3
2
1
0
N
nM TC
TB
T
3.
9

60
5
4
3
2
1
0

Fold Induction

Fold Induction

RXRα DOSS

C

D

Treatment (ppm)

*

Fold Change

75
70
65
60
55
30
25
20
15

*
*

.2
5
62
.5
12
5
25
0
50
0

VC

31

8
7.

.6

*
15

N

10

*

*

6
4
2
0
nM TC
TB
T
3.
9

Fold Induction

RXRα Span80

50

100

200

400

Span 80 (ppm)

Treatment (ppm)

10

100

RA (nM)
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Figure 6. Potential activation of other PPAR isoforms by DOSS.
HEK293T/17 cells were transfected with each of three human PPAR isoform GAL4LBD, UAS-luciferase and Renilla luciferase reporter plasmids. Dilutions of mixtures
were prepared and cells were exposed in triplicate for 18 h, luciferase activities were
measured and firefly to renilla luciferase ratios were calculated. Data are expressed as
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Figure 7. Oleic acid has stronger transactivation activity for RXRα than PPARγ.
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Figure 8. DOSS increases adipogenesis in preadipocytes and bone marrow derived
mesenchymal stem cells.
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Figure 10. DOSS increase expression of adipogenic genes murine cell lines.
3T3-L1 cells and mouse BM MSCs were cultured as described in methods. Cells were
either maintained in PGM or treated with MIM (Minimal Induction Media) alone or
supplemented with increasing concentrations of DOSS or 1uM Rosiglitazone. RNA was
isolated on day3 of adipogenesis for 3T3L1 cells or day15 from mouse BM-MSCs. Gene
expression was measured using qRT-PCR and the ΔΔCt method normalized to the
housekeeping gene Hprt. Data are represented as fold change over MIM alone for A)
AdipoQ, B) Fabp4, and C) Pref1/Dlk in 3t3L1 cells and D) AdipoQ and E) Fabp4 in
mouse BM-MSCs.
n= 3-6 replicates. *P<0.05 One-Way ANOVA compared to MIM.
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Figure 11. DOSS increase expression of adipogenic genes in human BM-MSCs.
Human BM MSCs were cultured as described in methods. Cells were either maintained
in PGM or treated with MIM (Minimal Induction Media) alone or supplemented with
increasing concentrations of DOSS or 1uM Rosiglitazone. RNA was isolated on day 16
of adipogenesis. Gene expression was measured using qRT-PCR and the ΔΔCt method
normalized to the housekeeping gene HPRT. Data are represented as fold change over
MIM alone for A) ADIPOQ, B) FABP4, and C) EZH2.
n= 3 replicates. *P<0.05 One-Way ANOVA compared to MIM.
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3.4 Discussion
PPARg is often referred to as the gate keeper or master regulator of adipogenesis.
Once PPARg is activated via ligand binding, it translocates to the nucleus and regulates
gene expression to promote adipogenic differentiation, lipid uptake and even
autoactivation or induced expression of itself. Thus, PPARg ligand-binding and
transactivation assays serve as convenient in vitro surrogates to identify potential in vivo
obesogen. Since 2006, investigators have been exploring the obesogen hypothesis,
investigating the role of exogenous compounds to promote obesity in wildlife and
humans. Naturally, identification of PPARg ligands is an extremely active area of
investigation, given the role of this receptor in promotion of obesity through adipogenesis
[92]. Of note, the use of pharmaceutical PPARg agonists in the clinic to treat diabetes
have been shown to cause weight gain and bone loss [223, 224]. PPARg has been used as
a tool to identify obesogens, including the antifouling agent tributyltin, perflourinated
compounds and several flame retardants [111, 206].
Here evidence is provided in support of the hypothesis that DOSS, an anionic
surfactant widely used as a food-additive and stool softener taken by pregnant women, is
a probable obesogen in vitro via activation of PPARg in GAL4/UAS transactivation
assays and increases in adipogenic differentiation of a murine preadipocyte cell line and
murine/human primary stem cells. Additionally, we identified Span 80 and oleic acid as
RXRa activators and showed that high concentrations of Span 80 can also promote
adipogenic differentiation.
Other investigators have shown that surfactants with similar structures as DOSS,
including SDS and SDBS can also act as ligands of PPARg, using receptor
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transactivation assays and adipogenic differentiation assays like the ones describe herein
[219]. It is hypothesized that the hydrocarbon chains of these anionic surfactants
resemble the endogenous PPARg ligands (fatty acids and eicosanoids). Additionally, the
extremely polar sulfonyl group of these compounds is likely to have interaction
capabilities with residues in the ligand binding domain of PPARg. In the case of SDS and
SDBS, they most closely resemble lauric acid, which has been shown to activate PPARg
[104]. The hydrocarbon chain of DOSS is a branched fatty acid, a class of molecules
which are also produced by bacteria in the gut, and which have also been shown to
activate PPARg [225].
In this Chapter a fatty acid moiety of Span 80, oleic acid, was shown to act as an
RXRa activator and weak PPARg activator, further supporting the idea these types of
compounds can interact with PPARg and RXRa via their hydrocarbon chains. Our data
agrees with studies suggesting that oleic acid can bind to and activate both RXRα and
PPARγ with low micromolar affinity, as demonstrated using in vitro transactivation
assays. While Fan and coworkers report very modest RXRα activation by oleic acid,
using a GAL-4-UAS in vitro system [226], Lengqvist and coworkers report results of
oleic acid RXRa activation very similar to those described herein, and the authors noted
that reported EC50s may be conservative estimates as reagent dilution in plastic tubes
may affect apparent ligand concentration [214].
Currently, human exposure to and the metabolism and circulating/intracellular
levels of Span 80 and DOSS in vivo are unknown. Toxicity data for Span 80 is presented
here and by others [227, 228], however the work presented is its first evaluation of either
compound as a potential endocrine disruptor. Circulating levels of oleic acid in healthy
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adults range between 179 µM and 3.2 µM [229], and liver levels are between 100 µM
and 500 µM [230, 231]. These levels are much greater than our reported EC50s for oleic
acid activation of RXRa, while intracellular levels of free fatty acids may be impacted by
the expression of fatty acid binding proteins, which are expressed at millimolar levels,
they can bind to free fatty acids only in the low nanomolar range [232]. Thus,
intracellular concentrations of oleic acid may be in the low micromolar range, and
capable of activating RXRa. Additionally, given that RXRa and PPARg are ubiquitously
expressed throughout the human gastrointestinal tract, dietary consumption of Span 80
may alter endogenous fatty acid absorption and signaling [233].
Comparable levels of triglyceride accumulation was observed in 50ppm DOSS
treated 3T3 L1 cells and human BM-MSCs when compared to Rosi treated cells,
suggesting that DOSS might function as a PPARg agonist in vitro and facilitate
adipogenesis. This is supported by our observation of increases in proadipogenic genes
and decreases in antiadipogenic genes, however their expression levels, particularly in
the MSCs, were orders of magnitude lower than their rosiglitazone counterparts. These
data might suggest that DOSS may produce a functionally distinct adipocyte when
compared to Rosi, as has been shown with the obesogen TBT, or may be more potent as
an inhibitor of osteogenesis. While TBT increases adipogenesis, it has been shown that
the resulting adipocyte produces less adiponectin and has altered glucose uptake when
compared to equivalently differentiated adipocytes from Rosi treatment [234]. These may
have deleterious effects in vivo resulting in systemic metabolic disruption. Similarly,
adipocytes differentiated in the presence of DOSS seem to produce less adiponectin
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mRNA and could potentially be less sensitive to insulin stimulated glucose uptake than
their Rosi counter parts.
Contrary to the anticipated mode of action, DOSS activation of PPARg in ligand
induced activation assays was not inhibited by the PPARg competitive inhibitor
T007907. Gene expression data suggests that DOSS is acting through a PPARg
dependent mechanism to increase adipocyte differentiation and promote gene expression
changes in PPARg target genes (Figures 7, 8, 9 and 10). However, and in support of the
receptor activation assay results, there is a new body of research that support the concept
of alternate binding sites in the PPARg ligand binding domain. Like DOSS, ligands for
this alternate binding site are not inhibited by T007097 in transactivation assays but still
result in conformational changes leading to DNA binding and downstream gene
transcription [235]. Determining how DOSS interacts with the ligand binding domain of
PPARg warrants future investigation.
Human exposure to DOSS is likely to be wide-spread given its ubiquitous use
[236]. Apart from its use as a crude oil dispersant, DOSS is approved by the FDA as a
food additive and is used in certain types of food at up to 1% total weight [148, 237].
Additionally, 38% of pregnant women suffer from constipation, and DOSS is approved
for use as a stool-softener to treat such symptoms [238, 239]. Studies on the
pharmacokinetics of DOSS suggest that some of it is excreted through the GI tract but
also absorbed into the blood stream and excreted via biliary metabolism, suggesting that
DOSS enters circulation and reaches multiple target organs. However, there are gaps in
knowledge and insufficient information concerning DOSS metabolism and/or impacts of
DOSS exposure on infant and adult health. To the best of our knowledge, DOSS

91

detection in breast milk has not been investigated. However, a study on women taking
DOSS while breast feeding did not detect increase bowel movements in the exposed
infants [154]. Given the ability of DOSS to activate PPARg, increase adipogenic
differentiation in multiple cell types, its wide use in consumer products, as a food
additive, and use as a stool softener by pregnant women, the evaluation of DOSS as an
obesogen in vivo is essential to fully evaluate the safety of its use, as pursued in Chapter
4.
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CHAPTER 4: CHARACTERIZATION OF DOSS AS AN OBESOGEN AND
METABOLIC DISRUPTOR IN VIVO
4.1 Introduction
Obesity and diabetes are chronic diseases effecting human populations
worldwide. In the last 30-50 years, rates of occurrence of these metabolic disorders have
increased to unprecedented levels. In the United States, 37.7% of adults are obese and
7.7% are extremely obese, based on the most recent data from 2013-2014 [1]. This
epidemic effects children and adolescents as well with 17% of children ages 2-19 obese
and 5.8% extremely obese [2]. Rates of diabetes and metabolic syndrome have also
increased and are often coupled with the presence of obesity [4, 240]. Additionally,
despite increased efforts in nutrition and fitness education, rates of obesity and diabetes
have not subsided or declined and are expected to continue to increase with an estimated
51% of the population obese by 2030 [241]. Genetics and heritability are important
factors in obesity cases accounting for roughly 50-90% of disease based on studies from
obesity discordant twins and 20-80% based on familial heritability studies [242, 243].
However, while genome-wide association studies have identified several polymorphisms
as contributors to obesity rather than single deleterious mutations, these SNPs only
account for roughly 2% of the variance associated with BMI [244]. Even when genetic
loci are analyzed in an additive manner via complex trait analysis only 30-37% of
variance is explained [245]. This indicates that the remaining cases or “missing
heritability” can likely be attributed to environmental/epigenetic factors and gene by
environment interactions, the most accepted being lifestyle choices influencing caloric
intake and expenditure [246, 247].
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In recent years, research has focused increasingly more on understanding how the
environment may play a role in the development of obesity and metabolic syndrome
[248]. In particular, the environment in which an individual is exposed to during
development and how it relates to later life health trajectories has been investigated and
broadly classified as the exposome [249] and historically classified as the
fetal/developmental origins of adult disease due to the more long lasting epigenetic
impacts [250, 251]. Environmental exposures can include stress, diet, exposure to
pollutants, as well as exogenous pharmaceuticals and chemicals used during pregnancy,
all of which interact with the systemic chemical environment to elicit a biological
response [252]. For example, children of women who experienced severe malnutrition
during pregnancy as a direct result of the Dutch famine, have higher BMIs and display
glucose intolerance [73]. Additionally, recent epidemiological studies have identified
positive correlations with several chemicals measured during pregnancy, such as
phthalates and persistent organic pollutants, and obesity in the children [253-255].
Exogenous chemicals that can promote the development of obesity and metabolic
syndrome have been deemed environmental obesogens, a class of endocrine and
metabolic disruptors [66, 256].
There are multiple mechanisms of action by which obesogens could act to drive
obesity including nuclear hormone receptor interaction, neuroendocrinology effects on
hunger and satiety signaling, interference with coactivator and corepressor recruitment,
membrane receptor signaling, cell membrane and organelle lipid bilayer destabilization
(e.g. mitochondrial membrane potential), epigenetic programming and commitment of
stem cells towards adipogenic lineages. The most well studied mechanism of action is via
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compounds that act as agonists for the nuclear receptor PPARg [92, 166, 257]. Primarily,
these obesogenic activities have been identified and evaluated in vitro using methods
described in Chapter 2 and Chapter 3 such as transactivation assays and adipogenic
differentiation assays, respectively. Published work described in these chapters identified
DOSS as a probable obesogen using molecular modeling, receptor transactivation assays
and adipogenic differentiation of murine preadipocytes and human bone marrow derived
mesenchymal stem cells [258]. Using similar assays, other groups have identified similar
molecules, the anionic surfactants SDS and SDBS, as PPARg agonists as well, suggesting
a previously unidentified and unexplored mechanism of action for this class of molecules
[219]. The hydrocarbon chains of many anionic surfactants resemble hydrocarbon chains
of fatty acids (such as arachidonic acid and oleic acid), one class of endogenous ligands
for PPAR receptors.
However, to the best of our knowledge, these molecules have not been evaluated
for their obesogenic effects in vivo, especially using and considering in utero
development as vulnerable and a critical window for exposure. Studies of obesogen
exposure in vivo have primarily evaluated the obesogenic effects in the offspring of
exposed dams and mothers using markers of adiposity and metabolic syndrome such as a
combination of morphometrics, glucose tolerance, body composition, circulating
adipokines and cytokines, tissue gene expression and epigenetic marks like DNA
methylation. Obesogens that act as ligands to activate PPARg and have currently been
evaluated in vivo include MEHP [158], tributyltin [93], PFOA[156], and triflumazole
[159].
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Approximately 11- 38% of pregnant women experience constipation during
pregnancy due to physiological and anatomical changes directly impacting the
gastrointestinal tract including increased progesterone levels, water absorption, and
increased blood volume associated with anemia [238]. Common practice to treat
pregnancy related constipation is via prescription of stool softeners, specifically
Colace/docusate sodium, comprised of DOSS and iron-supplemented vitamins containing
DOSS [153]. Given the widespread use of docusate sodium stool softeners during
pregnancy at up to 500mg a day during gestation as well as postpartum, human exposure
to DOSS is evident especially during vulnerable times of development. While levels and
duration of Colace use vary among women, the highest levels and longest duration are
associated with African Americans and underserved populations (personal comm. DDS).
Therefore, it is essential to fully understand the use and safety of DOSS during
pregnancy.
The aim of this study was to use a mouse model to evaluate DOSS as an obesogen
in vivo with a dose and exposure scenario relevant to pregnant women. The offspring of
exposed dams were analyzed for multiple established obesogenic endpoints to test the
hypothesis that developmental DOSS exposure promotes adult onset of obesity
associated symptoms (metabolic syndrome).
4.2. Materials and Methods
4.2.1. Animal husbandry and treatment
C57BL/6J mice were housed in the MUSC DLAR facilities in accordance with
IACUC standards. This strain of mice (and especially males of this strain) are susceptible
to diet and environmental induced obesity and metabolic syndrome [259-261]. Animals
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were fed a standard chow diet of Envigo/Teklad 2918 containing 18.6% crude protein,
6.2% fat, and 44.2% carbohydrates. Sterile corncob bedding was used in cages, except
when mice were fasted (see 4.2.2). Room temperature was maintained between 68-740F
and relative humidity between 30-70%. Light was controlled to 12hr:12 hr light:dark
cycle. Two females and one male were placed in a cage together to initiate breeding at
D0. At D7, females were weighed to determine if they were pregnant based on weight
gain. It was determined that a 5.5g weight gain correlated with E11.5, at which point
females were housed individually with water bottles containing water and either vehicle
control or DOSS. The automatic watering system was inactivated by either disconnecting
the water supply hose or by removal of Lixit sipper tubes.
Pregnant dams (n=3-4 per group [159]) were exposed to either vehicle control
(0.5% carboxymethylcellulose; CMC) or 31.25 µg/mL DOSS from E11.5 through
weaning. The dose we chose to use is representative of a dose received by a pregnant
woman (88.5 kg) taking 500mg of DOSS in the form of Colace stool softener daily
(5.6mg/kg) given that a mouse drinks about 4mL per day and weighs around 25g. The
timing of exposure was based on the incidence of constipation in women rising up
through mid-gestation [262]. CMC was used to increase palatability of the DOSS
solution and had been used as a vehicle control in other studies on obesogens [94]. Stock
bottles of each solution were prepared as needed (usually weekly). A 1% CMC solution
in autoclaved water and a 62.5µg/mL solution of DOSS in autoclaved water were
prepared and then mixed together in a ratio of 1:1 to achieve the final desired
concentration for treatment. Autoclaved water was used to dilute the 1% CMC solution
1:1 to achieve the desired concentration of 0.5% CMC for the vehicle control.
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Only litters with 5-7 pups were used for analysis to control for nutrient
availability in utero. Due to this criterion, some litters had to be eliminated resulting in
decreased sample size for certain groups. Therefore, the first “Cohort A” experiment was
repeated in a second cohort approximately five to six months later. In figures and
discussion of results, data from this second group of animals is referred to as Cohort B
and are represented by open black circles (controls) and open blue squares (DOSS
treated). Solid black circles (controls) and solid blue squares (DOSS treated) are used for
animals of Cohort A.
4.2.2. Oral glucose tolerance test
At 12 weeks of age, animals were assessed for glucose tolerance using an oral
glucose tolerance test (oGTT). Animals were fasted for 5-6 hours before administering
the test by changing animals to cages containing alphadri bedding with no food but
access to water. At T0 animals were weighed and a baseline blood glucose measurement
was taken by making a 0.5-1mm cut at the base of the tale with a razor blade. A glucose
bolus (2mg/g body weight) was administered via oral gavage followed with blood
glucose measurements at 15, 30, 60, 90 and 120 minutes. TRUEBalance glucose meter
and strips were used for all measurements. If a “HI” error was obtained, the value was
assigned as 600 (mg/dL), the maximum output of the detector. If other errors occurred,
the measurement was taken again using a new test strip.
4.2.3. Body composition assessment
Dual-Energy X-Ray Absorptiometry (DXA) was used to assess body composition
at 12 weeks of age. Mice were anesthetized using isoflurane, placed into the DEXA
instrument and scanned individually, ventral down. Data were collected for bone mineral
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density (BMD; g/cm2), bone mineral content (BMC; grams), bone area (cm2), lean mass
(grams), fat mass (grams) total mass (grams) and percent fat. BMD is defined as the ratio
of BMC to bone area and is primarily used for assessment and prediction of osteoporotic
associated fractures. The amount of BMC present in the bone will influence the amount
of energy absorbed. Denser bones absorb more energy and a relative energy/pixel can be
calculated as a density [263] . BMD and BMC are tightly correlated with one another
while BMD and bone area correlations are weaker possibly due to variations in bone size
in different regions [264]. Both BMD and bone area are associated with stronger bones
although some studies suggest bone size and not density is a better measure for stiffness
[265]. DXA data was only collected on the first cohort of mice due to instrument
availability. At 16 weeks of age, mice were sacrificed and the reproductive fat pads
(epididymal or EWAT; and ovarian or OWAT) and inguinal fat pads (IWAT) were
dissected and weighed. Percent fat was calculated as total fat pad weight relative to total
body mass at time of sacrifice.
4.2.4. Animal sacrifice and tissue collection
Animals were sacrificed and exsanguinated at 16 weeks of age after being
anesthetized (freshly prepared tribromoethanol solution; 125 mg/Kg; 15 µL of 2.5%
Avertin per gram of body weight, i.p.) and cervically dislocated. Reproductive fat pads
(EWAT and OWAT), inguinal fat pads (IWAT) and liver were dissected, weighed, and a
200mg piece was homogenized in 1mL Trizol for subsequent nucleic acid isolation.
Remaining fat pads were fixed over night at 40C in 4% PFA in PBS. The following day,
fixed tissues were washed 2X with PBS then stored in 70% ethanol until further analysis.
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4.2.5. Circulating adipokine and cytokine levels
At time of sacrifice (16 wks), plasma was collected from each mouse. Blood was
collected via cardiac puncture into EDTA coated tubes and incubated at room
temperature for at least 15 minutes. Blood was then transferred to Eppendorf tubes and
centrifuged at 2,000 x g for 10 minutes at 40C. Plasma was collected (about 500uL),
aliquoted and stored at -80°C until analysis.
Adiponectin, leptin, insulin, IL-6 and TNF-alpha were measured using
commercially available kits from Meso Scale Discovery (MSD) following the
manufacture’s protocol and MESO QuickPlex SQ 120 instrument. Specifically, the
Mouse Adiponectin Kit (K152BXC-1), the Mouse Metabolic (leptin and insulin) Kit
(K15124C-1) and mouse Proinflammatory Panel (IL-6 and TNF-alpha) V-PLEX Kit
(K15048D) were used. This method is similar to standard sandwich ELIZA immunoassay
protocols in that it utilizes a capture antibody pre-coated onto a plate, followed by
addition of the sample in which the target of interest binds to the capture antibody. A
detection antibody is then added, binds to the analyte and emits a measurable and
detectable signal. These MSD assays utilize detection antibodies labeled with
electroactive (rhenium-based) compounds that emit light in the presence of a redoxsensitive compound when voltage is applied to the plate. This allows for more sensitivity,
a broader dynamic range, less signal to noise background, the ability to multiplex
samples and fewer washing steps than standard ELISA methods. Specific protocols differ
slightly for each metabolite. Plates were pre-coated with capture antibodies and provided
by the manufacturer. An eight-point standard curve was prepared with provided
calibrators and buffers each time the assays were run. Plasma samples were then diluted
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as suggested by MSD with supplied diluent before measurement. Calibrator or diluted
sample were added to the plate in duplicate and incubated at room temperature with
shaking for two hours. The 96-well plate was then washed three times with 150µL of
wash buffer (0.5% Tween20 in PBS) per well. Supplied detection antibody was added to
each well and incubated at room temperature with shaking for two hours. The plate was
then again washed three times with wash buffer, 150µL of 2X Read buffer was added per
well and the plate was read on the MSD SECTOR instrument. Discovery Workbench 4.0
Software (Meso Scale Discovery) was used to determine analyte measurements using
standard curves.
4.2.6. Gene expression
At time of sacrifice, approximately 200mg of tissue was homogenized in Trizol
reagent and stored at -80oC. RNA was isolated using Trizol Reagent following the
manufacturer’s protocol. For adipose tissue extractions, an additional chloroform wash
step was performed to minimalize phenol contamination typically associated with lipid
rich tissues. RNA concentration and quality was assessed using Nanodrop ND 1000
(Thermo Fisher Scientific) absorbance ratios 260/280 (2.0-2.2) and 260/230 (>1.5). One
µg of RNA was reverse transcribed to cDNA using Superscript III First-Strand Synthesis
Super Mix (Invitrogen) following the manufacturer’s instructions. qPCR was performed
using the FastStart Essential DNA Green Master Kit (Roche). All primers were designed
to be intron spanning to ensure no DNA contamination could be amplified. The same
touchdown PCR cycle program was used for all primer pairs: 95°C 10 sec, 66°C-56°C 20
sec dropping a degree each cycle for 10 cycles, then remaining 35 cycles at 56°C, 72°C
20 sec for a total of 45 cycles on the LightCycler 96 system (Roche). Results were
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normalized to the reference gene Hprt using the DDCt method as it showed minimal
variation between samples across treatment (Ct +/- 0.34 SD). Calibration curves were
prepared to ensure equal and high PCR efficiencies (90-110%) between test and
reference genes. Data are expressed as a fold change in treated animals compared with
control animals. Primers used are listed in Table1.
Table 1. Genes and corresponding primers used for qRT - PCR analysis
Gene
Hprt

Forward Primer

Reverse Primer

AGGCCAGACTTTGTTGGATTTG

TTCAACTTGCGCTCATCTTAGG

AdipoQ

GTTCCTCTTAATCCTGCCCA

CTCCTGTCATTCCAACATCTC

Leptin

CCTGTGTCGGTTCCTGTG

CCTGTTGATAGACTGCCAGAG

IL-6

AGCCAGAGTCCTTCAGAGAGAT

GAGAGCATTGGAAATTGGGGT

Cox2

TTCAACACACTCTATCACTGGC

AGAAGCGTTTGCGGTACTCAT

Nox4

CCTTTTACCTATGTGCCGGAC

CATGTGATGTGTAGAGTCTTGCT

4.2.7 DNA Methylation Analysis via Targeted Bisulfite Sequencing
DNA Isolation
After RNA was isolated from samples, residual interphase and organic material
was stored at 4oC (Section 4.2.6) until DNA isolation was performed. Samples were
centrifuged at 15,000 x g at 4oC for 15 minutes. Any remaining aqueous phase containing
RNA was removed. An equal volume (about 600µL) of Back Extraction Buffer (4 M
guanidine thiocyanate, 50 mM sodium citrate and 1 M Tris) was added to interphaseorganic phase mixture. The sample was vigorously mixed by inversion an incubated at
room temperature for 10 minutes. Samples were centrifuged at 15,000 x g at 4oC for 15
minutes and 420uL of the aqueous phase was transferred to a separate tube. At this point
samples were processed following a modified protocol for Qiagen Blood and Tissue
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DNeasy Kit. Briefly, 200uL of ethanol was added to the sample, mixed well and pipetted
onto a provided spin column, centrifuged and flow through discarded. The column was
washed 1x with 500uL Buffer AW1, then 1X with 500uL Buffer AW2. Care was taken to
ensure the column was completely free of ethanol before eluting DNA with 75uL Buffer
AE. DNA concentrations were quantified using Nanodrop ND 1000 (ThermoFisher
Scientific).
Bisulfite Conversion and PCR Amplification
Genomic DNA (500ng) from IWAT of 16 week-old mice was bisulfite converted
for methylation analysis using the Methylamp DNA Modification Kit (Epigentek)
following the manufacturer’s protocol. Eight control samples (4 from Cohort A and 4
from Cohort B) and all 12 treated samples were used. Target genes for PCR were
selected based on previous studies that identified methylation or expression changes in
these genes as a result of obesity, glucose intolerance and diabetes, or obesogen exposure
(referenced in Table 2). Studies from both human and mice were utilized. For targets
where primers were listed in publications, these primers were used with conditions
optimized in house. For new targets, primers were designed using MethPrimer in
promoter regions of genes flanking CpG islands. For PCR amplification, 12.5 ng of
converted DNA was used with EpiMark HotStart Taq DNA polymerase following the
manufacturer’s recommendations. Primer sequences, PCR conditions and references are
listed in Table 2. Amplification of single products was validated using gel
electrophoresis. PCR products were purified using GenCatch PCR Clean Up Kit (Epoch)
and quantified using Nandrop equipment (Thermo Fisher Scientific). All products from a
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single individual were then pooled using equal nanomoles using volumes adjusted based
on nM concentration (based on lowest concentration) for sequencing.
Illumina Library Prep, Next Generation Sequencing and Analysis
The MUSC Cancer Genomics core was used for next generation sequencing of
products. The sequencing library was prepared using the TruSeq Kit, following the
manufacturer’s protocol beginning at “End Repair”. Adapters were ligated so each
individual was barcoded. Samples were then paired end sequenced on an Illumina MiSeq.
All data analysis was performed in BaseSpace. Raw sequences were trimmed using
Trimmomatic [266]. Methylation analysis was performed in Methyl Seq v1.0 (Illumina,
Inc.). Methyl Seq aligns generated sequences to a bisulfite converted genome using
Bowtie 2 [267]. Sequences were aligned to Mouse mm9 using a targeted manifest
specifically for targeted amplicons based on chromosomal locations for start and end
sires. CpG methylation status was obtained for each CpG in an amplicon using BisMark
[268]. If a sample didn’t have at least 12 reads per CpG site it was dropped from analysis.
No correlation was observed between read count and methylation status (data not
shown).
4.2.8 Plasma lipidomic profiling
Lipids were extracted from blood plasma samples using Bligh-dyer extraction
[269]. Thirty microliters of plasma were spiked with lipid internal standards (36µL), and
4mL of 1:1 chloroform:methanol, followed by the addition of 1.8mL water. Samples
were then incubated on ice for 30 minutes, vortexed for 20 seconds and centrifuged at
2000 rpm for 10 min to separate organic and aqueous layers. The organic layer was
collected and the aqueous layer was re-extracted with 1mL 1:1 chloroform:methanol. The
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organic layers were combined, transferred to a new tube then dried down under nitrogen
and reconstituted in 50uL isopropanol.
All lipid extracts were analyzed by ultra-high performance liquid chromatography
coupled to high-resolution mass spectrometry (UHPLC-HRMS). Samples were deidentified and individuals performing extractions and running samples were blinded to
sample conditions. Mass spectra were acquired on a Thermo Scientific Orbitrap Fusion
Lumos Tribrid mass spectrometer equipped with a heated electrospray ionization (HESI
II) probe in positive and negative ion mode. HESI and mass spectrometric parameters for
lipid extracts were as follows in positive/negative ion mode, respectively: spray voltage:
3.5/2.5 kV, sheath gas: 40/35 AU; auxiliary nitrogen pressure: 15 AU; sweep gas: 1/0
AU; ion transfer tube and vaporizer temperatures: 325 and 300/275 °C, respectfully; and
RF lens level: 30. Full scan, data-dependent MS/MS (top10-ddMS2), and dataindependent acquisition mode data were collected at m/z 150-2000, corresponding to the
mass range of most expected cellular lipids. External calibration was applied before each
run to allow for LC-HRMS analysis at 120,000 resolution (at m/z=200).
A Thermo Scientific Vanquish UHPLC system (Thermo Scientific, San Jose, CA)
was coupled to the Orbitrap Fusion Lumos Tribrid for the chromatographic separation of
lipids. The autosampler temperature was maintained at 4 °C for all experiments. Solvent
extraction blanks and quality control samples were jointly analyzed over the course of a
batch (10-15 samples). A Waters Acquity™ C18 BEH column (2.1 × 100 mm, 1.7 µm
particle size, Waters, Milford, MA) maintained at 60 °C was used for all lipidomic
studies. The injection volume was 5 µL in positive and negative ion mode with a mobile
phase flow rate of 450 µL/min. The gradient program consisted of mobile phase C [60:40
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v/v acetonitrile/water] and mobile phase D [90:8:2 v/v/v isopropanol/ acetonitrile/water],
each containing 10 mM ammonium formate and 0.1% formic acid. The gradient included
32% D at 0 min, 40% D at 1 min, a hold at 40% D until 1.5 min, 45% D at 4 min, 50% D
at 5 min, 60% D at 8 min, 70% D at 11 min, 80% D at 14 min, 100% D at 16 min, and a
hold at 100% D until 17 min. The total run time was 22 min, including a 5 min
equilibration
Full scan raw data files acquired from Xcalibur™ (Thermo Fisher Scientific),
centroided and converted to a useable format (mzXML) using MSConvert. Data
processing and peak area integration was performed using MZmine, resulting in a feature
intensity table. The resulting feature table was filtered using extraction blank samples in
FRAMe (Feature Reduction Assistant for Metabolomics v1.0). Only features with a
signal/noise ratio greater than 10 times that of the blank were included. LipidSearch™
(Thermo Scientific) and LipidMatch were used to identify features [270]. Peak areas
were normalized to plasma weight for each sample.
4.2.9 Statistical analysis
For oGTT data, area under the curve (AUC) was calculated for each individual in
GraphPad Prism. Means for AUC from treated and control groups were then compared
using unpaired student’s t-test. Additionally, means for blood glucose were compared at
each time point between treated and control groups using two-way ANOVA.
Since data were collected from two different cohorts and grouped together for
graphical display, significant differences were tested between controls from each group
and treated animals using students t-test and reported in the text. Normality and equal
variances was assessed by Shapiro-Wilks test and Brown-Forsythe or F test respectively,
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before proceeding with mean comparisons. If data did not pass the assumptions, data
were log transformed to increase normality or Welch’s correction was used to account for
differences in variance. Results are discussed in each section and statistical tests are
specified in Figure legends. Two-way ANOVA was also used to assess differences
between treatment and cohorts and is described in text. For DNA methylation analysis,
average methylation results are presented for each CpG site in an amplicon. Two-way
ANOVA was used to assess overall treatment effect and differences observed at specific
CpG sites.
4.3 Results
4.3.1 DOSS treatment induces glucose intolerance in male mice
Glucose tolerance tests are used to assess metabolic function clinically in humans
at risk for diabetes and can be used in mouse models of diabetes and obesity, as well. To
determine if DOSS treatment during development altered glucose tolerance in F1 mice,
oral glucose tolerance tests were performed at 12 weeks of age on control and animals
treated with DOSS in utero. Male, but not female animals exposed to DOSS during
development display marked glucose intolerance compared to animals receiving vehicle
control (Figures 1 and 2). Data are represented with cohorts grouped together as well as
for each Cohort separately. When grouped and analyzed together all male data indicates
DOSS induces impaired glucose tolerance via significantly higher blood glucose levels at
15 min, 30 min, and 60 min when compared to control males using a repeated measures
ANOVA (Figure 1A). Similarly, treated animals show a significantly increased area
under the curve, indicative of glucose tolerance impairment (Figure 1B p=0.0012). For
animals in Cohort A only, significant increase in blood glucose was observed at 15 and
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30 min only (Figure 1C). Significant increases in area under the curve were also observed
in treated animals from this cohort (Figure 1D p=0.0004). For cohort B, higher levels of
blood glucose were observed at all time points, although this trend did not reach
significance (Figure 1E). Similarly, DOSS treated animals in Cohort B displayed
increased area under the curve, although these values did not achieve significance (Figure
1F p=0.0898).
For female animals, the data indicate DOSS did not significantly alter normal
glucose homeostasis (Figure 2). For Cohort A, increases in blood glucose, although not
significant, were observed at T15 and T30 only, however basal levels were reached by
T60 in both control and treated animals (Figure 2C). No differences between control and
treated females were observed in the second group on animals (Figure 2E and F).
Of note, in the second cohort, male and female control animals had higher levels
of blood glucose compared to cohort A. This is likely attributed to the test being
performed by different individuals and successful and accurate delivery of the glucose
bolus, since animals do not show significant differences in basal glucose levels.
4.3.2. DOSS treatment increases body mass, fat grams, fat percentage and reduces bone
area in male mice
By definition, bona fide obesogens have been shown to increase overall body
weight as well as fat percentage in treated animals [256]. At 12 and 16 weeks of age, F1
males from treated dams weighed significantly more than females (Figure 3A and B
p<0.0001). No significant cohort differences in males were observed between controls at
12 and 16 week (p=0.1480 and p=0.2044) and 12 and 16 week treated animals (p=0.2012
and p=0.1510 ) from each cohort so they were grouped together for analysis (unpaired ttest with Welch’s correction for unequal SD).
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F1 males from treated dams were slightly but significantly heavier than control
males at 12 (p=0.015) and 16 weeks (p=0.0181) of age with mean/median values of
27.44/27.14 g and 29.42/28.25 g for treated animals and 26.28/25.9 g and 28.27/28.00 g
for control animals respectively (Figure 3A; two-tailed Mann Whitney non-parametric
test was used because a non-Gaussian distribution was observed). No significant
differences were observed between control and treated females at either 12 or 16 weeks
of age (Figure 3B).
For a subset of animals (Cohort A), DXA scans were used to assess body
composition including percent body fat, fat mass, lean mass, bone area, bone mineral
density and bone mineral content at 12 weeks of age (Figure 2). In male mice, DOSS
treatment increased total body fat percentage analyzed by DXA with mean fat
percentages of 14.5% and 16.6% for control and treated males, respectively (Figure 2A,
p=0.0476). There was also a significant increase in fat grams for male mice with mean fat
mass values of 3.2g and 3.9g for control and treated male mice respectively (Figure 2B,
p=0.0200). Importantly, there were no differences observed in lean mass (Figure 2C),
indicating that overall body weight gain was due to increase in fat mass. Additionally, a
significant reduction in male bone area, 8.30 and 8.83 cm2 for treated and control animals
respectively, and a decrease, although not significant in bone mineral density and bone
mineral content were observed (Figure 2D p=0.0014 and E). No significant differences
were observed in female mice. Based on the nature of the equation to calculate BMD
(BMD = BMC/BoneArea), a reduction in bone area would not influence a reduction in
BMD given constant BMC. Bone Area as measured by DXA is calculated based on a 2D
planar image and is not a complete representation of total bone volume. Bone area can
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also be influenced by different regions of the body, suggesting BMC and BMD are better
indicators of bone strength although some studies in human suggest bone size is a better
determinant for stiffness than density [264, 265].
At 16 weeks of age, all animals (Cohort A and B) were sacrificed and gross tissue
weight for liver, inguinal (IWAT) and reproductive white adipose tissue (male EWAT
and female OWAT) was recorded. Fat percentage was calculated for each fat pad
individually and combined for a representative total fat percentage ((Total WAT
weight/16wk body mass) X 100). When all animals were analyzed together, F1 males
from treated dams showed significant increases in grams adipose tissue for IWAT
(p=0.0099), EWAT (p=0.0205) and total WAT (p=0.0101) (Figure 4C). Graphically
display of these data, suggest this result may be driven by Cohort differences with F1
males from treated dams in Cohort B exhibiting more adiposity than those from Cohort
A. In fact, F1 males from treated dams in cohort B, but not Cohort A, showed a
significant increase in grams adipose tissue for IWAT (p=0.0001), EWAT (p=0.0008)
and total WAT (p<0.0001) relative to grouped controls. No significant differences were
observed between control animals in different cohorts and were therefore grouped
together for statistical analyses. Body fat percentage as well as fat pad specific fat
percentage also significantly increased in treated animals (Figure 4E), primarily driven
by Cohort B DOSS-treated animals. No significant differences were observed in female
mice for adipose tissue weight or percent (Figure 3D and F). Similarly, no differences
were observed between treated and control animals for liver weight in both males and
females (data not shown).
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Bone density measurements were not performed on the second group of animals.
Although an increase in percent body fat measured by tissue weight at 16 weeks was not
observed in Cohort A, the DXA scans of Cohort A at 12 weeks did provide a
comprehensive indication of increased body fat percentage due to DOSS treatment. This
could indicate that overall body adiposity measured by DXA is more likely to detect
significant differences than IWAT/EWAT weight measurements alone, which represent
only a portion of overall adiposity. This could also indicate that differences in adiposity
decrease from 12 week to 16 weeks of age. That said, Cohort B did result in a larger
increase in body fat observed in tissue weight suggesting that IWAT/EWAT weight
measurements alone can suffice and that the effects of DOSS treatment on body
composition can be variable and in this case were more pronounced in the second group.
These data demonstrate variability in cohort or individual susceptible to the effects
induced by DOSS exposure during development.
4.3.3. DOSS treatment alters circulating adipokine levels
In both human and mouse studies, obesity and metabolic disorders are often
associated with differences in multiple circulating adipokines and cytokines that are
either increased or decreased based on their given disease state. For example, a decrease
in adipose tissue-derived circulating adiponectin and an increase in circulating leptin are
hallmarks of obesity and metabolic syndrome [271]. Also, obesity can be characterized as
a chronic low-grade inflammatory disease [51]. Thus, to further characterize the level and
type of metabolic disruption observed in animals treated with DOSS, adipokine
(adiponectin and leptin), proinflammatory cytokine (IL-6 and TNF-alpha) and insulin
levels were chosen for analysis in plasma. Multiple diet-induced obesity studies focus on
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male C57BL/6 mice [272] [273]. Also, due to limited resources and since male C57BL/6
animals displayed a significant phenotype while females did not, adipokine and cytokine
levels were measured in control and DOSS males only.
Adiponectin is a signaling molecule exclusively produced by adipose tissue and
plays a role in insulin sensitization and glucose homeostasis [274]. In both cohorts, there
were significant differences in adiponectin levels in treated animals compared to controls
(Figure 5). To account for increases in adiposity in treated animals (Figure 3),
adiponectin levels were normalized to gram weight of adipose tissue (IWAT + EWAT)
for all individuals, a method that has been previously utilized [115]. After correcting for
adiposity, no differences were observed between controls or treated animals between
cohorts and therefore both cohorts were grouped together for each controls and treatment
groups (data represented as µg adiponectin/mL plasma*gram adipose tissue). Relative
(normalized per gram fat) circulating adiponectin levels were significantly lower in F1
males from treated dams than in control males with means of 9.51 µg/mL*g and 13.30
µg/mL*g respectively (Figure 5A p=0.0029). Primarily glucose intolerance and
adiponectin, but also obesity and adiponectin have previously been described to have an
inverse relationship [275], although positive correlations between circulating adiponectin
and adipose fat mass have been observed [276, 277]. In fact, in our animals adiponectin
is positively correlated with adipose tissue weight in both control and treated mice
(Figure 5B). However, in cohort A treated animals displayed lower mean circulating
levels of adiponectin (12.7 µg/mL) compared to controls (15.17 µg/mL), while in cohort
B, treated animals displayed higher circulating levels of adiponectin (20.66 µg/mL)
compared to controls (17.43 µg/mL). This observation might be expected given that
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treated animals from Cohort A exhibit more severe glucose intolerance than those from
Cohort B (Figure 1). The increase in adiponectin in treated animals from Cohort B (open
blue squares) is likely driven by increases in body fat percentage even though these
animals also display mild glucose intolerance.
The significant reduction in normalized adiponectin levels observed in treated
animals could be due to significant changes in white adipose tissue gene expression,
specifically of the inguinal adipose depots (IWAT), since AdipoQ, the gene encoding
adiponectin, is down regulated in treated versus control animals in IWAT (Figure 5C
p=0.0153) regardless of cohort. Although not significant, a trend for lower AdipoQ
expression was observed in female animals (data not shown). Similarly, decreased gene
expression of AdipoQ, although not significant, was observed in the gonadal (EWAT)
adipose tissue as well (data not shown). These data further support the hypothesis that
prenatal DOSS treatment can result in decreased adiponectin in C57BL/6J male mice
relative to control males.
Leptin is an adipokine that regulates satiety and control of appetite and positively
correlated with adiposity and obesity [278]. When animals from both cohorts were group
together significant increases in leptin were observed (Figure 5D, p=0.0332 Mann
Whitney). As expected, leptin levels were positively correlated with fat grams in our
animals (Figure 5E), as a positive relationship between leptin and adiposity markers is
well documented in both humans and mice [279, 280] . Circulating mean leptin levels for
Cohort A control and treated animals were 2.91 ng/mL and 2.91 ng/mL, respectively and
for Cohort B were 4.50 and 11.28 ng/mL, respectively. Thus, no significant difference in
leptin was observed between control and treated animals in Cohort A (p=0.99 or between
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controls from either group (p=0.2275) even though there was an increased trend.
However, treated animals from Cohort B showed increase circulating levels of leptin
compared to combined controls (p=0.0002 Mann Whitney). Notably, the cohort effects
for circulating leptin levels were much more pronounced than for adiponectin (Fig. 5B,
E) as expected due to the increase in fat mass in Cohort B treated animals. While some
individuals from Cohort B displayed high leptin expression relative to controls, no
significant differences were observed between control and treated animals (Figure 5F).
Other fat depots may produce and secrete more leptin than IWAT which was investigated
here.
While we also measured circulating insulin levels to determine if the glucose
intolerance observed in our treated animals was due to insulin desensitization marked by
hyperinsulinemia, we observed no significant differences between any of the groups
(Figure 5G, p = 0.8507). However, the data for insulin were not taken after fasting, which
would be more indicative of insulin desensitization. In future experiments plasma for
insulin measurements should be collected after fasting and prior to gavage in oGTT tests.
4.3.4. DOSS treatment is associated with a persistent inflammatory state
IL-6 is a proinflammatory cytokine secreted by immune cells. Obesity and type 2
diabetes (T2D) are often accompanied by an inflammatory state driven by infiltration of
adipose tissue with macrophages [281]. To determine if DOSS treated animals showed
indication of a proinflammatory state, we analyzed circulating IL-6 levels. We observed
increased circulating levels of IL-6 in treated animals compared to controls without
cohort differences and therefore cohorts were grouped together for analysis. The mean
levels of IL-6 were 13.70 pg/mL and 48.12 pg/mL for control and treated animals
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respectively, where treated animals had significantly higher levels of IL-6 than controls
(Figure 6A, p=0.0112). However, unlike adiponectin and leptin, we did not observe a
correlation between body fat percentage and circulating IL-6 levels in either treated or
control animals (Figure 6B).
TNFa is another inflammatory cytokine secreted by immune cells positively
correlated with obesity and T2D in some cases. We analyzed mouse plasma for levels of
TNFa. In cohort B we observed non-detectable levels in four samples. These values
were removed from the analysis and attributed to assay error given that the values were
below the LOD for TNFa in this assay. Although mean circulating TNFa was higher in
DOSS animals (8.44 pg/mL) compared to control animals (7.54pg/mL), it was not
significant (Figure 6D). However, we did observe a cohort effect for TNFa levels. There
was a slight but significant increase in circulating TNFa levels in DOSS treated animals
for Cohort A only (p=0.0277). This was a notable result, as most other significant
differences occurred in Cohort B, but not Cohort A.
We also investigated gene expression changes in adipose tissue associated with
inflammation. Although a few individuals had elevated expression of IL-6, we observed
no significant differences in IL-6 gene expression in IWAT tissue, despite increase
circulating levels of IL-6 in treated animals (Figure 6C). However other fat depots could
be contributing to overall circulating IL-6 levels. And within adipose tissue, the stromal
vascular fraction accounts for 90% of the IL-6 expression in adipose tissue although it
represents a small percentage of adipose tissue cells [52] . Other genes we investigated
were cyclooxygenase 2 (Cox2) and NADPH oxidase (Nox4). Elevation in expression for
both Cox2 and Nox4 are associated with the presence of reactive oxygen species and
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systemic chronic inflammation [282, 283]. We observed significantly increased
expression of both Cox2 and Nox4 expression in IWAT from DOSS exposed male mice
(Fig. 6E, F). Interestingly, Cox2 expression was primarily significant in Cohort B (Figure
6E), while Nox4 (Figure 6F) expression was more significant in Cohort A.
4.3.5 DOSS treatment altered DNA promoter methylation of IL-6 and Cox2
Since we observed persistent changes in gene expression and circulating levels of
adipokines and cytokines in 16 week-old F1 males of DOSS treated dams, we
hypothesized that promoter methylation may be altered at these loci in IWAT. We
investigated promoter methylation at several genes identified to be significant to DOSS
exposure (adiponectin, IL-6 and Cox-2) and/or previously identified to be regulated by
DNA methylation in response to high fat diet, obesity or T2D (Leptin, Pparg, Glut4,
Fasn, Irs1, Hmox1, Fabp4). A complete list of loci interrogated, bisulfite primers used
and references can be found in Table 2. Highlighted here are the most significant results.
We observed decreased levels of circulating adiponectin as well as decreased
levels of gene expression in IWAT tissue, suggesting the adiponectin promoter may be
hypermethylated, repressing gene expression. We performed targeted bisulfite sequences
for 6 CpG sites in the adiponectin promoter, four sites which have been associated with
gene expression in response to high fat diet (deemed adiponectin region 2) and two sites
nearby which were not associated with gene expression (deemed adiponectin region 1)
(Figure 7A). Unexpectedly, at region 1 significant hypomethlation was observed,
particularly at CpG site 1 (Figure 7B) in tissue from treated animals. There was no
significant difference in average region 2 promoter methylation between treated and
control animals, although on average treated animals had slightly higher mean overall
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methylation and at each CpG site in R2 (Figure 7C). Particularly interesting results were
observed at CpG site 3 in which 58.33% of treated animals had over 80% methylation
compared to 28.57% for controls. When CpG 3 methylation was correlated with gene
expression, no significant positive or negative correlations were observed (Figure 7D).
Although changes in Il-6 gene expression was not observed, there were
significant increases in circulating levels of IL-6 in response to prenatal DOSS exposure.
Therefore the promoter region of Il-6 was investigated for changes in DNA methylation.
Five CpG sites roughly 300bp upstream of the IL-6 transcription start site that were
previously identified as possible regulatory CpGs were evaluated for methylation status
[284] (Figure 7E). DOSS treatment significantly reduced overall promoter methylation
(Figure 7F p=0.0042 Two way ANOVA) and especially at CpG site 2 (Figure 7F
p=0.045). As with adiponectin, no significant correlation between gene expression and
DNA methylation was observed at this loci (Figure 7G). However, there was a significant
inverse correlation between IL-6 methylation and circulating IL-6 levels (Figure 7H p =
0.011).
Since there were changes in Cox2 expression relative to treatment and Cox2
promoter hypermethylation has been linked to gene expression in other studies [285], 14
CpG sites about 500bp upstream of the Cox2 transcription start site were evaluated for
methylation status (Figure 7I). While treatment did not affect the overall Cox2 promoter
methylation for the region (Figure 7J p=0.1277), average DNA methylation at CpG site 1
was significantly reduced in treated animals (Figure 7K p=0.0052 outlier removed).
While increased Cox2 gene expression for IWAT was observed there were no significant
correlations between CpG site 1 methylation and Cox2 expression (Figure 7L).
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No significant differences in promoter methylation were observed for Leptin,
Fasn, Pparg, Glut4, Irs1, Fabp4, or Hmox1. Specific average methylation results for all
loci are displayed in Table 3.
4.3.6 DOSS treated animals have elevated circulating phospholipids associated with high
fat diet induced obesity and diabetes
Due to advances in mass spectrometry and ultra high performance liquid
chromatography, untargeted lipidomics has been employed to survey for changes in
circulating lipids associated with obesity and diabetes [270, 286, 287]. Targets identified
may potentially be used as diagnostic biomarkers as well as to elucidate cellular
mechanisms associated with disease states. We used an untargeted lipidomics approach
to identify significant changes in circulating lipids associated with DOSS exposure. We
were able to identify 664 features in positive mode and 171 features in negative mode.
One treated individual was excluded from analysis due to outlier behavior as identified
by random forest test. Multiple lipids were significantly increased in 16 week-old F1
male offspring of dams exposed to DOSS, including several phosphatidyl choline
species, two phosphatidylethanolamine species, one cholesterol ester and one oxidized
phosphatidyl choline species. We observed significant or near significant increases in
relative peak area for PC(34:3) (p=0.0433), PC(36:1) (p=0.0053), PC(18:0_20:1)
(p=0.0179), PC(18:0_20:3) (p=0.0383), PC(38:4) (p=0.0125), PE(18:0_20:1) (p=0.0149),
PE(18:0_20:3) (p=0.0444), CE(20:3) (p=0.0583), and OxPC(24:1) (p=0.0224) as shown
in Figure 8A-I. Visual inspection of the data suggests that for PC(34:3), PC(18:0_20:1),
PC(38:4), and PE(18:0_20:3) the relative increase in F1 males prenatally exposed to
DOSS is driven by animals from Cohort B. Several lipid species identified here have also
been identified as associated with high fat diet induced obesity in C57BL/6J mice
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including PC(36:1), PC(38:3), PC(38:4) and CE(20:3) [288]. Similarly, although not
significant, we did observed reductions in several LPC species including 15:0, 17:0, 19:0,
20:0, 22:0, 22:1 and 24:1. These specific LPCs have not been described before but in
general, LPCs are reduced in response to high fat diet, obesity and diabetes [289]. These
results indicate that developmental exposure to DOSS promotes a persistent dyslipidemia
akin to long-term high fat diet induced obesity in adult mice.
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Figure 1. Developmental DOSS treatment promotes glucose intolerance in male F1
mice.
Pregnant C57BL/6J dams were treated with either vehicle control CMC or 31.25 µg/mL
DOSS from E11.5 through weaning. F1 pups were assed for indications of metabolic
syndrome at 12 weeks using oral glucose tolerance testing. Mice were fasted for 6 hours
and basal glucose measurements were taken. Mice were then administered at 2mg/g
bolus of glucose and blood glucose was measured at 15, 30, 60 and 120 minutes. Blood
glucose measurements for all control and treated male mice are shown in A) with
corresponding area under the curve values in B). Blood glucose values from male mice in
Cohort A and area under the curve values are shown in C) and D). Blood glucose values
and area under the curve values from male mice in Cohort B are shown in E) and F)
respectively.
Two-Way Anova was used to determine significant difference in blood glucose at
different time points (*p<0.05 for a given time point). Area under the curve values were
calculated for each individual mouse, pooled and students t-test was used to determine
significance (**p<0.01, ***p<0.0001).

121

B

All Female oGTT

500

Control

400

DOSS

40000

300
200
100
0

0

15

30

60

90

All Female oGTT AUC
Area Under the Curve

Blood Glucose (mg/dL)

A

30000
20000
10000
0

120

Control

DOSS

Time (minutes)

D

Cohort A Female oGTT

400

30000

Control
DOSS

300
200
100
0

0

15

30

60

90

Cohort A Female oGTT
Area Under the Curve

Blood Glucose (mg/dL)

C

20000

10000

0

120

Control

DOSS

Time (minutes)

Cohort B Female oGTT

800

50000

Control
DOSS

600
400
200
0

0

15

30

60

90

Cohort B Female oGTT

F
Area Under the Curve

Blood Glucose (mg/dL)

E

40000
30000
20000
10000
0

120

Time (minutes)

122

Control

DOSS

Figure 2. Developmental DOSS treatment does not promote glucose intolerance in
female F1 mice.
Pregnant C57BL/6J dams were treated with either vehicle control CMC or 31.25 µg/mL
DOSS from E11.5 through weaning. F1 pups were assed for indications of metabolic
syndrome at 12 weeks using oral glucose tolerance testing. Mice were fasted for 6 hours
and basal glucose measurements were taken. Mice were then administered at 2mg/g
bolus of glucose and blood glucose was measured at 15, 30, 60 and 120 minutes. Blood
glucose measurements for all control and treated female mice are shown in A) with
corresponding area under the curve values in B). Blood glucose values from female mice
in Cohort A and area under the curve values are shown in C) and D). Blood glucose
values and area under the curve values from female mice in Cohort B are shown in E)
and F) respectively.
Two-Way Anova was used to determine significant difference in blood glucose at
different time points (*p<0.05 for a given time point). Area under the curve values were
calculated for each individual mouse, pooled and students t-test was used to determine
significance (**p<0.01, ***p<0.0001).
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Figure 3. Body composition at 12 weeks of age in F1 male and female mice from
dams treated with DOSS or vehicle control.
At 12 weeks of age, DXA scans were used to asses body composition in male and female
mice from Cohort A. Measurements were obtained for A) percent fat, B) fat grams, C)
lean grams, D) bone area, E) bone mineral density, and F) bone mineral content.
Male and Female mice were analyzed separately using unpaired t-test (*p<0.05).
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Figure 4. Effects of DOSS treatment on body mass, adipose tissue weight and
percent adipose tissue and male and female F1 mice.
Body mass was measured at 12 and 16 weeks of age. At 16 weeks of age, F1 males and
females were sacrificed and inguinal and gonadal adipose tissue was weighed and
collected. Adipose tissue percent was calculated as grams adipose tissue/total body mass.
A) Male body mass, B) female body mass, C) male adipose tissue weight, D) female
adipose tissue weight, E) male adipose tissue percent, F) female adipose tissue percent.
Data are represented as mean +/- SD and pooled from both cohorts with animals from
Cohort A as closed shapes and animals from Cohort B as open shapes. Unpaired students
t-test with Welch’s correction for unequal variance was used for male mice (*p<0.05).
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Figure 5. Developmental DOSS treatment alters expression and circulating levels of
adipokines in male F1 mice.
At time of sacrifice (16 wks), plasma and adipose tissue was collected. Circulating levels
of adiponectin and leptin were determined using MSD assays. Gene expression was
determined via RNA isolation, cDNA conversion and qPCR using the deltadelta Ct
method with Hprt as the housekeeping gene. A) normalized circulating levels of
adiponectin, B) raw diponectin correlated with fat grams, C) AdipoQ gene expression in
IWAT, D) circulating levels of leptin, E) leptin correlated with fat grams, F) leptin gene
expression in IWAT and G) circulating insulin levels. Linear regression was used to
determine correlations between adiponectin and leptin and fat grams. *p<0.05 Unpaired
t-test
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Figure 6. Developmental DOSS treatment promotes a proinflammatory state in
male F1 mice.
At time of sacrifice (16 wks), plasma and adipose tissue was collected. Circulating levels
of IL-6 and TNF-α were determined using MSD assays. Gene expression was determined
via RNA isolation, cDNA conversion and qPCR using the deltadelta Ct method with
Hprt as the housekeeping gene. A) circulating levels of IL-6 in plasma, B) plasma IL-6
correlated with fat grams, C) IL-6 gene expression in IWAT tissue, D) circulating levels
of TNF-α in plasma, E) Cox2 gene expression ion IWAT tissue, F) Nox4 gene expression
in IWAT tissue.
*p<0.05 Unpaired ttest.
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Figure 7. DOSS promotes changes in DNA methylation in promoter regions of
inflammatory genes in IWAT.
Targeted bisulfite sequencing was used to assess promoter methylation in IWAT tissue
for genes in which changes in gene expression and circulating protein levels associated
with DOSS treatment were observed including adiponectin (A-D), IL-6 (E-H) and Cox-2
(I-L). A) Chromosomal location of promoter adiponectin regions investigated for CpG
methylation. Average methylation for individual CpGs in B) region 1 and C) region two
of the adiponectin promoter. D) Correlation between adiponectin region 2 CpG3
methylation and AdipoQ expression. E) Chromosomal location of the IL-6 promoter
region investigated for CpG methylation. F) Average methylation for individual CpG
sites in the IL-6 promoter. G) Correlation between CpG2 methylation and Il-6
expression. H) Correlation between CpG2 methylation and circulating adiponectin levels.
I) Chromosomal location of the Cox-2 promoter region investigated for CpG
methylation. J) Average methylation for individual CpG sites in the Cox-2 promoter. K)
Average percent methylation for CpG1 in the Cox-2 promoter. L) Correlation between
CpG1 methylation and Cox2 expression.
Two Way Anova was used to assess significant changes in DNA methylation based on
treatment across the whole promoter region with Sidak’s post-hoc test for individual CpG
sites differences.
*p<0.05 treated vs. control Two-Way Anova. Individual sites were then also compared
using Sidak’s post-hoc test (#p<0.05).
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Figure 8. DOSS treatment promotes changes in circulating phospholipids.
At time of sacrifice plasma was collected from F1 animals. Untargeted lipidomics was used to
determine the presence of circulating lipids. An in-house software called LipidMatch and
LipidSearch™ was used to identify lipid species based on unique m/z ratios and retention times.
Feature processing and peak area integration was performed using mzMine. The resulting peak
area table was filtered using FRAMe. Relative peak areas between DOSS treated and vehicle
control F1 males are shown for A) PC(34:3) (unpaired ttest equal SD, p=0.0433), B) PC(36:1
(unpaired ttest equal SD, p=0.0053), C) PC(18:0_20:1) (unpaired ttest equal SD, p =0.0179), D)
PC(18:0_20:3) (unpaired ttest equal SD, p=0.0373), E) PC(38:4) (log transformed unpaired ttest
equal SD, p=0.0125), F) PE(18:0_20:1) (unpaired ttest equal SD, p=0.0149), G) E(18:0_20:3)
(unpaired ttest equal SD, p=0.0444), H) CE (20:3) (unpaired ttest equal SD p = 0.0583) and I)
OxPC(16:0_8:1) (unpaired ttest equal SD, p=0.0224) *p<0.05, **p<0.01
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4.4. Discussion
From results of experiments delineated in this Chapter, evidence is presented in
support of the hypothesis that DOSS has the potential to act as an obesogen in vivo via
metabolic disruption indicated by impaired glucose tolerance, increases in adiposity (e.g.
fat grams and fat percentage), and changes in gene expression and circulating levels of
adipokines, cytokines and phospholipids consistent with obese, diabetic, and metabolic
syndrome phenotypes. This phenotype was observed in C57BL/6J male mice, but not
females. Sexually dimorphic metabolic and obesogenic effects have been observed in this
strain of mice and others before. For instance, although female and male mice both gain
weight when fed a high fat diet for 14 weeks, females are protected from metabolic
syndrome [114, 290]. In a prenatal exposure model for MEHP in C57BL/6J mice,
markers of obesity were observed in male offspring but not female offspring [158].With
regard to obesogen exposure, in studies by Blumberg et al., on TBT exposed C57BL/6
mice during development, the obesogenic phenotype is observed in both the female and
male offspring. This phenotype persisted transgenerationally for TBT, supporting the
concept that the obesogenic phenotype observed in offspring of DOSS-exposed dams
could persist transgenerational as well although additional experiments would be needed
to evaluate this hypothesis [93]. Similarly, triflumazole, another PPARg agonist induces
obesogenic effects including MSC fate commitment in male mice, although this was
tested in the CD1 mice not C57BL/6J background [159]. The recently identified
metabolic disruptor, tolyfluanid, although not a PPARg agonist, similarly exerts its
metabolic disrupting effects in adult male C57BL/6J mice, while the phenotype is not
observed in females.
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Results indicate that DOSS induces glucose intolerance and increases fat
percentage, coupled with a reduction in adiponectin gene expression and circulating
levels. This inverse relationship is well documented in the literature as a marker of
metabolic syndrome in humans and mice [291]. Adiponectin signaling is involved in
insulin sensitization and the observed reduction in adiponectin in treated animals may be
a reason for the observed glucose intolerance. For instance, when T2D patients are
treated with adiponectin their hyperglycemia symptoms are ameliorated and in
adiponectin knockout mice the effects induced by a high fat diet are accentuated [292].
In general, human cohort studies have identified lower circulating levels of adiponectin
in individuals with T2D compared to controls. In one study, a positive correlation
between BMI and serum adiponectin was observed in a human cohort of obese and nonobese T2D described in a 2016 study by Chand and Silambanan [293]. Although all T2D
individuals in this study had lower adiponectin levels than the control group. Given that
we observed decreases in normalized adiponectin in all treated mice relative to controls,
where as we only observed increases in leptin for mice with the threshold level of greater
than 2 grams adipose tissue (Cohort B; Fig. 5A), adiponectin may serve as a better
marker for understanding the phenotype associated with developmental DOSS exposure
and mild metabolic syndrome.
Similarly, from one perspective, our two treatment cohorts may represent two
classes of type two diabetics (T2D), that is, obese (Cohort B) and non-obese T2D (Cohort
A) individuals since Cohort B treated animals displayed increased circulating leptin
levels relative to controls and treated animals from Cohort A. Similarly, while non-obese
T2D patients have reduced circulating adiponectin, data suggests they do not have

135

increased leptin as is the case with obese T2D patients [294]. As shown in Figure 5A, the
2 grams threshold could be used to distinguish these two cohorts, at least on the level of
adiposity and circulating adiponectin and leptin levels with further characterization
necessary to fully establish those populations.
Counter to our hypothesis, no significant increases in DNA promoter methylation
for adiponectin were observed given the observation of decreased gene expression in
treated animals, however not all control animals were analyzed for promoter methylation
and only select promoter regions were interrogated. Others also have shown that a high
fat diet induces adiponectin promoter hypermethylation and correlated with decreased
adiponectin gene expression in region 2 of the adiponectin promoter [46]. Future studies
should investigate other adiponectin promoter regions for regulatory CpG sites. For
instance, 500bp upstream of the region investigated in this study, there is an Ebf1
transcription factor binding site and Ebf1 binding has been shown to be reduced at
methylated sites [295]. In this study, there was significant hypomethylation in region 1 of
the adiponectin promoter. It would be interesting to determine if CpG methylation in this
region promotes recruitment of transcription factors as this mechanism has recently been
described for other genomic loci [38].
Notably, no significant differences in insulin levels between F1 males from DOSS
treated or control dams was observed. Hyperinsulinemia is commonly associated with
impaired glucose tolerance, increased adiposity and reduced adiponectin levels, all of
which are indicators of metabolic syndrome and were observed in treated animals from
this study [296]. In this study, insulin was measured at time of sacrifice, not at time of
oGTT and the values were not obtained from fasted animals. Future studies should
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measure fasting insulin as well as insulin after glucose challenge (glucose stimulated
insulin secretion) to get a more comprehensive view of insulin signaling in DOSS treated
animals. Alternatively, the observed impaired glucose tolerance and elevated blood
glucose could be a result of malfunctioning glucose transporters like Glut4 in skeletal
muscle tissue, the tissue that first responds to insulin stimulation[297, 298].
Both cohorts of treated mice had higher circulating levels of IL-6 a cytokine
commonly found to be positively correlated with diabetes and obesity [56]. Here, an
increase in IL-6 gene expression in IWAT was not observed, although there were
decreases in promoter methylation which negatively correlated with circulating IL-6
levels suggesting a function role for DNA methylation in the IL-6 promoter. Given that a
hallmark of obesity is adipose tissue inflammation and adipose tissue is comprised of
multiple cell types including adipocytes, mesenchymal stem cells, immune macrophage
and lymphocytes, it is possible that the heterogeneity of the tissue is confounding the
results, especially given that cells predominantly expressing IL-6 such as macrophage
and preadipocytes are likely a small proportion of the total cell population. Future studies
should separate the stromal vascular fraction from adipoctytes and perform gene
expression and DNA methylation in both cell fractions to gain a more comprehensive
understanding of IL-6 regulation. Additionally, not all control adipose tissue samples
were included in the methylation analysis and two samples were excluded from analysis
due to low coverage. It is possible that some highly representative samples were missed
in this analysis. IL-6 promoter methylation in adipose tissue has not been investigated
with regards to obesity, but in humans IL-6 promoter methylation has been investigated
in circulating white blood cells with differing results. In circulating white blood cells
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Kirchner et al observed hypomethylation of IL-6 promoter with no correlation to
circulating levels [299] while Kyung Na et al (2015) observed hypermethylation of the
IL-6 promoter [300] without having determined circulating levels. Determining if white
blood cell IL-6 methylation correlates with adipose tissue IL-6 methylation would
strengthen the results observed human studies.
Increases in expression of two other genes commonly associated with a systemic
inflammatory state and obesity, Cox2 and Nox4, were observed in IWAT tissues in F1
males from DOSS treated dams [282, 283]. Cox2 has been shown to be an essential
mediator in obesity-induced adipose tissue inflammation and insulin resistance [301].
DOSS treatment of induced pluripotent stem cells (iPSCs) has been shown to increase
Cox2 enzyme activity and gene expression (correspondence with Theresa Cantu),
suggesting increased arachidonic metabolism to proinflammatory eicosanoids and a
common role for DOSS promoted inflammatory response. Eicosanoid profiling focusing
on products of Cox2 mediated reactions in adipose tissue or plasma from males
prenatally exposed to DOSS would further elucidate the role of DOSS induced
inflammation in vivo. Others have identified increased Cox2 expression in IWAT in
response to maternal obesogen exposure, specifically PAHs [136]. In F1 males from
DOSS treated dams from this study, upregulated transcription of Cox2 and
hypomethylation of one CpG site in the promoter region of Cox2 in IWAT was observed.
This site was the most upstream site interrogated and was more methylated than the other
sites examined (Fig. 7I-L; sites 2-14). It is possible that the regulatory region associated
with DOSS-mediated upregulation of Cox2 in adipose tissue may be located further
upstream given the trend observed at CpG site 1. While Cox2 methylation has been
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investigated in other tissue types and plays a role in progression of some cancers [301], to
the best of my knowledge this is the first investigation into adipose tissue Cox2
methylation as it relates to obesity and diabetes. Given that indicators of low-grade
inflammation were observed at the epigenetic (IL-6 and Cox2 hypomethylation), gene
expression (Cox2 and Nox4) and protein levels, (circulating IL-6) inflammation is likely
a key mechanism by which developmental DOSS exposure can promote adult onset
metabolic syndrome.
Cox2 activity is associated with a specific category of lipid mediators in
inflammation. The broader field of lipidomics has emerged as a useful tool in identifying
pathological pathways of diseases like diabetes and obesity as well as to serve in
identifying biomarkers of disease states [302]. Using untargeted lipidomics analysis on
plasma samples from F1 male offspring of DOSS exposed and unexposed dams
significant differences in multiple circulating phospholipids was observed (Fig. 8).
Difference were observed primarily in phosphatidylcholine species. There have been a
few studies that independently performed untargeted lipidomics on blood samples from
C57BL/6 male mice fed a high fat diet to determine lipid biomarkers of obesity while
others have explored the associations in human cases of obesity and diabetes. Van
Ginneken et al. identified CE(20:3) and PC(36:1) to be increased in animals fed a high fat
diet, both of which were significantly increased in our DOSS treatment animals [303].
PC(36:1) has also been identified as a biomarker for T2D in a large human cohort study
[304]. Of note, it will be important to determine the specific composition of this
phosphatidylcholine species, since treatment of db/db mice with PC(18:0_18:1) improves
glucose tolerance obesity and T2D. Similarly, Eisinger et al. also observed increases in
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CE(20:3) along with PC(38:3) and PC(38:4), both of which were also significantly
increased in our DOSS treatment animals [288]. Similarly, PC(38:3) was associated with
an increased risk in diabetes in a human cohort [304]. While Barber et al. observed
increases in PE(38:0), PE(36:1) and PE(38:4), DOSS treatment animals displayed
increases in related, but different phosphatidylethanolamine species, PE(18:0_20:1) and
PE(18:0_20:3). Importantly, the method used in this study was able to identify specific
tale composition while Barber et al. did not [289]. Although not significant, a decrease in
several LPC species in DOSS treated males was observed, which have been negatively
correlated with diet induced obesity and T2D in mice and humans [288, 289, 305].
Although no significant differences were observed for sphingomyelin and ceramide
species, these lipid classes have also been associated with obesity and T2D. Together
these data suggest that DOSS treatment induces phospholipid changes similar to diet
induced obesity models but that some distinct differences are still evident and
identifiable.
A limitation of this study is low sample size. Due to criteria necessary for
consistent litter numbers, several experimental and control litters had to be dropped from
analysis, reducing sample size and power. There were also some observable differences
in the effects of DOSS treatment in our two cohorts of animals (performed to increase
sample size) with animals from Cohort B showing a more exaggerated effect with regard
to fat accumulation and variables that correlate with adiposity including circulating
leptin. This could be a result of natural individual variance, differences in maternal water
consumption and therefore effective dose of DOSS, differences in food consumption and
physical activity of pups, or seasonality of birth of offspring. Future experimentation
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would be needed to determine the source of variation. Monitoring food, water
consumption and activity would be good measures to take in future studies. Since
treatment conditions did not vary between cohorts and even though mice are maintained
in relatively controlled conditions, winter (Cohort A) versus summer (Cohort B) seasonal
differences often remains a factor [306]. Siberian hamsters are an extreme example of
rodent’s changing adiposity based on season [307]. Thus, the season in which the dosing
was administered may mask the ability to detect differences in adiposity in treated and
control groups.
DOSS may elicit features in the syndrome of its obesogenic effects (glucose and
lipid metabolism, inflammation and adiposity) through alternative mechanisms not
explored here. While DOSS has been shown to act as a ligand activator of PPARg,
(described in previous publications by our group [258] and Chapter 2/3), DOSS is also
likely to alter fundamental properties of lipid bilayers associated with cell membranes
and organelles given it’s molecular structure and function [308]. Additionally, DOSS
may alter the microbiome of pregnant dams, thereby influencing maternal nutrition and
transfer to pups, which could also explain some of the variation observed in treated
animals. In humans, it has been documented that the composition of the maternal
microbiome, as well maternal nutrition, can impact the onset of obesity and diabetes in
offspring [309]. Furthermore, other food additives and emulsifiers like DOSS have been
evaluated for their impact on the microbiome and subsequent adverse health effects
including obesity and inflammatory bowel disease were observed [208, 310]. In cows,
DOSS exposure was shown to alter microbial communities, increased circulating blood
glucose and changed the fatty acid composition of their milk [311]. Given that many
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EDCs have multiple mechanisms of action, it is likely that DOSS can simultaneously act
as a PPARg agonist and through other mechanisms that we have yet to explore.
Given the observed indication of metabolic disruption in male offspring from
dams treated with DOSS compared to controls, the use, safety and prescription of
docusate (Colace) stool softener during pregnancy should undergo further study.
Interestingly, several studies have evaluated the effectiveness of DOSS to treat
constipation with similar results suggesting it is not very effective and that there are
missed opportunities to reduce prescription or use this medication [312, 313]. This
indicates that Colace use perhaps presents unintended risks that could easily be
ameliorated through changes in standard of care practices. A standard protocol for
measuring DOSS in biological samples like blood and breast milk is currently
nonexistent. While protocols for DOSS exist for seawater and fish tissue, they are not
directly transferable to human biological samples due to differences in matrix
composition and their high limits of detection [185, 314]. Development of such protocols
in conjunction with data provided herein may significantly aid in understanding how the
use of docusate (Colace) during pregnancy may impact child metabolism, obesity and
overall health later in life.
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Table 2. Bisulfite sequencing primer sequences, chromosomal location, product size, CpG number and references.
Gene
Loci

Forward

Reverse

Chromosome
location mm9

Size(bp) CpG

Ref

#

143

AdipoQ
R1

AGGTAAGTGTTTTGTGATATTGGGT

ACACCCACAATAATTCCATAAAATC

chr16:23145842+23146117

276

2

[46]

AdipoQ
R2

TGGAGGAAGTAGATGTTTGGTTAGT

CAAAACAATACCTTAAAAACCTCTC

chr16:23145441+23145636

196

4

[46]

IL-6

TGTTTAGGTTGGGTGTTG

ACCCTAAAAAACATAAACACTCTTC

chr5:30339113+30339453

341

5

[284]

Cox-2

AGATGTGGATTTTGATAGAGGATATT

CTACCCTTAACTACCCCAAATAATAC

chr1:151946703+151947035

333

14

[315]

Leptin

GAGTAGTTAGGTTAGGTATGTAAAGAG

TAATAACTACCCCAATACCACTTAC

chr6:29009816+29010194

379

19

[48]

Fabp4

AGGAATTGTTTTTTTTGAAAAGTAG

AATAAAACACCTCCAAACACTATACC

chr3:10202723+10202992

270

5

[94]

Glut4

TGGGTTATATGTATTTGTTAGGGTA

TATTAATCCCTTAAATCATCTCCTC

chr11:69761972+69762232

261

13

[316]

Fasn

TAGTAGGTAGGATAGGGAATATTGA

CAACCTCTCTAAACACTCAAAAAAC

chr11:120686159+120686445

286

17

[317]

Irs-1

GTAGTGGGTTTAGGGTGAGTGTAGT

CCCCTACCCAAAAATATTTAATTTAC

chr1:82287290+82287526

237

15

[318]

Hmox1

GGGTTGGATGTTGTAATAGTAG

CATTCCCAAACAAAATAAAAAACAC

chr8:77617422+77617730

308

24

[319]

Pparg2

GATGTGTGATTAGGAGTTTTAATTAAAG

CAAACCTAAATTAACTAACACTATCCTAAC

chr6:115371595+115371953

259

4

[320]

Table 3. Average percent methylation of interrogated genes in IWAT tissue of F1 males from control and DOSS treated
dams.
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Gene
Loci

Percent Methylation
Control (Mean +/- SD)

Percent Methylation
DOSS (Mean +/- SD)

P value - 2Way ANOVA
Treatment/Post-Hoc CpG

Coverage
(Mean +/- SE)

AdipoQ
R1
AdipoQ
R2
IL-6

88.93 +/- 4.8

83.13 +/- 6.6

0.008/0.032

121.5 +/- 45.3

67.88 +/- 5.7

69.21 +/- 6.2

0.431/NA

155.6 +/- 44.3

41.10 +/- 7.4

34.29+/-9.3

0.004/0.041

41.5 +/- 15.5

Cox-2

3.46 +/- 0.5

3.30 +/- 0.3

0.349/0.005

280.6 +/- 69.7

Leptin

64.08 +/- 4.8

65.06 +/- 6.4

0.240/NA

141.4 +/- 56.3

Fabp4

78.01 +/- 5.8

77.46 +/- 11.9

0.789/NA

128.6 +/-32.3

Glut4

3.01 +/- 0.5

3.02+/- 0.9

0.996/NA

136.0 +/- 41.5

Fasn

2.66 +/- 0.3

2.73 +/- 0.7

0.752/NA

113.2 +/-41.6

Irs-1

3.37 +/- 0.5

2.28 +/- 0.5

0.631/NA

237.9 +/-41.6

Hmox1

1.66 +/- 0.2

1.59 +/- 0.4

0.535/NA

211.4 +/- 38.7

Pparg2

63.83 +/- 6.7

61.69 +/- 12.4

0.412/NA

127.5 +/- 36.9

CHAPTER 5: CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS
The work presented here describes a logical workflow designed to identify,
validate and characterize metabolic disrupting compounds using several screening assays,
functional in vitro validation assays and ultimately an in vivo exposure model to
characterize phenotypic changes associated with metabolic syndrome as a result of
exposure. In a time when industrial chemical production and usage is at its highest points
and our environment and bodies are burdened with multiple exposures, this work helps
identify a potentially unanticipated outcome of a commonly used chemical, dioctyl
sodium sulfosuccinate (DOSS).
As presented and reported in a publication derived from the work of Chapter 2
and Chapter 3, receptor transactivation assays for multiple nuclear receptors were used to
identify potential endocrine disrupting chemicals present in the Deepwater Horizon oil
(MC252 Louisiana sweet crude) and/or Corexit 9500 dispersant used in the spill
remediation process. Major research efforts have focused on understanding the role of
exogenous compounds in the development of obesity, diabetes and metabolic syndrome
given the alarming prevalence of these diseases [256]. Therefore, particular interest was
put on identifying novel obesogens or metabolic disruptors, leveraging as a tool for
identification, compounds capable of activating the PPARg/RXR signaling pathway. This
search identified a compound present in Corexit 9500, likely dioctyl sodium
sulfosuccinate (DOSS), as a PPARg agonist which was then validated in vitro and in vivo
in subsequent aims and chapters (Figure 1).
This first required the generation and testing of a variety of oil and dispersant
mixtures that led to an elegant set of experiments based on nuclear hormone receptor
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activation helping to identify the component within the mixture that exhibited potential
obesogenic activity. Since oil and dispersant are both complex mixtures in and of
themselves, this was a critical and necessary step to efficiently and effectively evaluate
transactivation assay results.
While responses of several nuclear hormone receptors were investigated,
including PPARγ, PPARa, PPARb/d, RXRa, PRb, ERa and ERb it was not an
exhaustive list. From this investigation DOSS activated mouse and human PPARγ,
human PPARb/d, weakly activated PPARa, had no observed activity for RXRa or the
estrogen receptors and possibly antagonized PRb. Other receptors of interest that were
not investigated due to time and experimental limitations are thyroid hormone receptor,
androgen receptor and glucocorticoid receptor. Glucocorticoid receptor would be
particularly relevant for identification of other potential obesogens based on the work of
Sargis et al., which concluded that activation of glucocorticoid receptor by exogenous
chemicals induced adipogenesis in 3T3L1 cells [113].
Iida et al., investigated SDS and SDBS, molecules that are similar in structure and
function to DOSS, and identified these compounds as PPARg agonists, but did not find
activity for 19 other receptors tested, suggesting possible PPARg specificity for similar
compounds like DOSS [219]. The Environmental Protection Agency has an assay
screening program under the names of Toxcast and Tox21 that includes hundreds of
assays (receptor transactivation assays, radio ligand binding assays, transcription assays)
to help identify EDCs and other chemicals of concern[321]. Based on analysis of
ToxCast reported data from one set of assays, NovaScreen radioligand binding assays for
human nuclear receptors [322], DOSS elicited the highest response for PPARg, with
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some affinity for glucocorticoid receptor (GR) and progesterone receptor (PR) (Figure 2).
Extremely weak or no activity was observed in these assays for androgen (AR) and
estrogen receptor (ERa) as well as PPARa (Figure 1). Together with data presented in
Chapter 2, this suggests the primary mechanism of action regarding DOSS and nuclear
receptors would be through the PPARγ pathway, further demonstrated in Chapters 3.
However, it should be noted that the reliability of ToxCast assays for identifying
obesogens in particular may not be highly reliable. Results from similar assays do not
overlap very well and such data should be interpreted with caution and careful validation
is required [112]. Similarly, the presence of pan assay interference compounds (PAINS)
can confound results [323]. Others have suggested DOSS may be a PAIN since it
delivers several positive hits in the ToxCast dashboard [112]. However, in the assays
presented here DOSS does not behave as a PAIN showing specificity for PPAR receptors
(PPARγ and PPARb/d,) with no activity on RXRa, or estrogen receptors, and
furthermore increases adipogenesis, indicative of PPARγ activation.
In Chapter 3 evidence was provided in support of DOSS as a PPARg agonist and
its ability to act as an obesogen in vitro primarily using adipogenic differentiation assays
in three cell types. DOSS significantly increases the adipogenic differentiation of mouse
3T3L1 preadipocytes and human bone marrow derived mesenchymal stem cells and to a
lesser extent mouse BM-MSCs. Importantly, this suggests that DOSS has affinity for
both the mouse and human PPARg receptor.
While adipogenic differentiation was investigated, a process highly regulated by
PPARg, the effects of DOSS on osteogenic or chondrogenic differentiation were not
investigate beyond DXA scan measurements of bone area and density in mice. MSCs can
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differentiate into multiple lineages including fat, bone, cartilage and others. Lineage
commitment to either fat or bone have been shown to be a delicate, highly regulated
process that can be influenced by environmental factors [211]. Furthermore, commitment
to one of these lineages often occurs at the expense of the other. The obesogen and
PPARg agonist tributyltin predisposes MSCs to an adipogenic lineage and reduces the
ability of this cell type to differentiate into the bone lineage. Similarly, when MSCs are
treated with the pharmaceutical PPARg agonist rosiglitazone, their ability for
osteogenesis is reduced, while adipogenesis is greatly increased [324]. Given that DOSS
activates PPARg and increases adipogenesis it is reasonable to propose the hypothesis
that DOSS treatment in conjunction with osteogenic differentiation inducers, would
similarly lead to a reduction or inhibition of osteogenic differentiation in MSCs. The
Chapter 4 DXA scan results showing increased adiposity and decreased bone area
provide some support for this hypothesis.
Similarly, this investigation did not test function in adipocytes that were produced
by cells treated with DOSS and how this may differ from that of a rosiglitazone derived
adipocyte. This is a relevant question given that pharmaceutical drug development has
recently started developing selective PPARg modulators (SPPARgMs) [325]. These
compounds are designed to activate PPARg but only initiate gene transcription and
signaling of specific pathways. For example, a compound that activates PPARg eliciting
insulin-sensitizing effects without the adipogenic effects (weight gain symptoms) would
be more desirable than the currently available thiazolidinedione drugs, which have these
and many other adverse side effects. However, it will not be a trivial task developing
SPPARMs, not only with PPARg specificity, but also with selective transactivation

148

activities considering population variants in these pathways (e.g. coactivators,
corepressors, etc.).
Industrial chemicals, such as the phthalate monoester, MEHP, have also been
identified as adipogenic SPPARMs [86]. MEHP promotes adipogenesis but does not
reach the maximum effect elicited from rosiglitazone, a result which we also observed for
DOSS in our BM-MSC experiments (Chapter 3). MEHP is also involved in the
recruitment of different coactivators and corepressors than rosiglitazone and, although
many of the same genes are up or downregulated by MEHP and rosiglitazone, there is a
unique set of genes that are regulated by each agonist as well. Unpublished work from
our group studying the transcriptome of iPSCs exposed to either DOSS or rosiglitazone
also identified a group of genes consistent with both exposures but also a set of genes
unique to each exposure (correspondence with Demetri Spyropoulos; Theresa Cantu,
PhD Thesis, MUSC 2017). TBT, another well studied environmental obesogen, may also
be considered a SPPARM. It has been documented that TBT promotes a phenotypically
distinct adipocyte compared to the troglitazone derived adipocyte but with equal potency
(eliciting equal PPARg induction) [234]. TBT adipocytes secrete less adiponectin and
have higher basal rates of glucose uptake but lower rates of insulin stimulated glucose
uptake compared to troglitazone derived adipocytes. Evaluating the DOSS adipocyte for
basal and insulin stimulated glucose uptake is a logical and important next step to further
characterize DOSS as an obesogen.
DOSS, as the pharmaceutical docusate sodium, is often prescribed as a stool
softener to pregnant women who suffer from pregnancy-induced constipation. Thus,
pregnant women, and potentially their fetuses, are exposed to DOSS during a very
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sensitive window of fetal development. In Chapter 4, multiple experiments for the
phenotypic evaluation and characterization of DOSS as a metabolic disruptor were
performed in vivo using a standard inbred mouse strain with dosing scenarios relevant to
those experienced by pregnant women taking DOSS. We investigated the F1 adults for
markers of obesity, diabetes and metabolic syndrome. Results indicate that DOSS
promotes a phenotype indicative of metabolic syndrome in male mice, but not female
mice. Most notably, male F1 adults of treated dams displayed marked glucose intolerance
coupled with an increase in adiposity, a reduction in adiponectin, an increase in markers
of inflammation particularly circulating levels of the proinflammatory cytokine IL-6,
hypomethylation of the IL-6 promoter in IWAT and altered circulating phospholipids.
Together, these data suggest that DOSS can act as an obesogen in vitro and in vivo and
more research should be focused on further characterizing the metabolic disrupting
effects of DOSS. In this study, C57BL/6 mice were used, a strain of mouse known to be
susceptible to environmentally induced metabolic changes especially in males [326]. This
is a limitation of this study, given that several strains of mice exist with the majority of
metabolic disruptors research split between C57BL/6 and CD-1 strains (Table 1).
Determining which strains of mice are susceptible to DOSS induced metabolic effects,
and which ones are not, will provide better understanding for how these results can be
translated to human exposure. This could be done using Collaborative Cross mice, which
are an array of mice resulting from crosses between 8 commonly used inbred strains of
mice and arguably more representative of the human population than any one inbred
strain of mouse [327]. SNP analysis of each affected and unaffected mouse could yield
genetic elements important in the obesity phenotypes observed with DOSS.
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Additionally, in this study, two cohorts of F1 mice were used in order to increase
our sample size. While control F1 mice from both groups appeared to have no significant
differences for the majority of variables measured, there were differences observed
between the two F1 ‘treatment’ cohorts (offspring of DOSS-treated dams). Particularly
noticeable was the larger increase in adiposity observed in the second cohort of treated
mice. To account for this, determined variables that were correlated with fat percentage
were determined, such as circulating adiponectin levels, and normalized values based on
total white adipose tissue for a given mouse. There are several factors that could
influence this increased variance observed in treatment cohorts. Many features of the
treated dams could contribute to this variance. For instance, in this experiment water
consumption by the pregnant dams or effective concentrations of DOSS in adipose, liver
and placental target tissues was not measured due to the lack of an established analytical
method. It is possible that dams could drink different amounts of DOSS-containing water
therefore altering the effective dose, increasing response variability in the offspring.
Similarly, food consumption, lipid absorption and metabolism or energy output were not
measured in the pregnant dams or offspring, all of which would have impacts on
metabolic function. While littermates are genetically identical and the same mothers,
natural behavioral dominance (i.e. alpha males) would contribute to altered feeding and
activity levels among littermates that likely contribute to variable phenotypes. In fact,
outlayers in multiple studies tend to be the same individuals. Due to experimental
procedures, mice in one cohort (Cohort A) were transferred to USC Medical Center for
oGTT and DXA measurements, while Cohort B was housed in MUSC CRI the entire
time. It is possible that the transfer or different housing conditions could also affect these
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mice physiologically. Lastly, pups from Cohort A and pups from Cohort B were born
roughly six months apart and perhaps seasonal differences could have an effect on
obesogen susceptibility. This would be a particularly interesting question to address.
To identify phenotypes that supersede the variability observed in the treatment
cohorts, we performed multiple linear regression analysis to track individuals through
multiple end point analyses. Significant correlations between adiposity and circulating
adiponectin and leptin levels, but not IL-6 levels were observed. This was also observed
for circulating levels of leptin and adiponectin compared with IWAT tissue gene
expression, but not EWAT tissue gene expression. Additionally, a significant positive
correlation between adiposity and glucose intolerance, as well as a significant negative
correlation between circulating adiponectin and glucose intolerance were observed.
Similarly, several phospholipid species were directly correlated with each other as well
as adiposity. This is notable because some phospholipid species identified in adult F1
male offspring of DOSS-treated dams are also observed in the same strain of adult male
mice after long-term high fat diet exposure [288, 303]. Correlations between gene
expression and DNA methylation changes were not observed, although there was a
significant inverse correlation between IL-6 gene CpG 2 methylation and circulating IL-6
levels. CpG methylation in IWAT could be acting as a proxy for overall IL-6 methylation
levels. So, although we did not see correlation with expression in IWAT, expression from
another tissue could be contributing to overall circulating levels that has similar
methylation patterns to those observed in IWAT. Additionally, although promoter
methylation is typically associated with decreased gene expression, there are other
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functions for DNA methylation as well as several different CpG sites within a promoter
that could be regulatory[37, 328].
In these experiments, maternal DOSS exposure was either a) acting directly on
the F1 offspring via placental transfer; b) acting indirectly on the F1 offspring by eliciting
one or more responses in the dams that altered fetal programming; or c) both a and b. The
ability to measure DOSS in the placenta and fetus would greatly aid in assessing these
possibilities, especially scenario A. DOSS is thought to be minimally absorbed when
taken orally (<5%); however, Dujovne and Shoeman showed that DOSS taken orally can
be measured in human bile at concentrations ranging from 40-90uM (20-40 ppm),
indicative that DOSS is absorbed through the GI tract into the blood stream, followed by
biliary excretion back into the GI track and enterohepatic circulation [329]. Metabolism
and excretion studies in rat, rabbit and dog using radiolabeled DOSS suggest that a
percentage of DOSS is metabolized to 2-ethylhexanol cleavage product within 96 hours
of administration, and primarily excreted in the urine and feces; it can be detected in the
blood up to 8 hours after administration with trace detection in tissues [330]. This
indicates that DOSS may be able to enter the blood stream and potentially be present in
cord blood. Follow-up pharmacokinetics studies should be repeated, in this case with
pregnant dams, using current high resolution analytical techniques. Results of the studies
presented herein also warrant studies that analyze maternal blood of pregnant women
(who took DOSS containing or DOSS free laxative) and associated cord blood samples in
order to help address this question.
Intriguingly, work from Sigurdsson et al. indicates that maternal bile acids can act
as chemical chaperones and influence fetal hematopoietic stem cell expansion in the fetal
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liver [331]. This may provide a unique mechanism of action, by which fetal DOSS
exposure (via maternal bile) could influence fetal stem cell expansion and programming.
To investigate this, fetal HSC number, lineage commitment and bile acid composition
could be assessed in fetuses (E15.5) from pregnant dams exposed to DOSS (E10-15).
Quantitative methods for DOSS using high performance liquid chromatography
and tandem mass spectrometry (HPLC-MS/MS) exist for sea water and fish tissues [162,
314, 332]. Both of these methods were developed quickly with the specific intention of
quantifying contamination due to the use of Corexit 9500 in the remediation of the
Deepwater Horizon oil spill in 2010. Unpublished, preliminary data from our group
suggests that these methods are not suitable for biological samples given the extreme
differences in matrix composition, lipid over aqueous partitioning of DOSS and the high
limits of detection. Blood and breast milk are biological matrices important in
understanding the body burden of DOSS, potential exposure to offspring and to test the
hypotheses that a) DOSS can be detected in circulating blood and deposited to other
tissues and b) Colace users have greater levels of DOSS in blood and breast milk
compared to non-Colace users. Research projects to address this would likely involve
optimization of efficient extraction from blood and breast milk as well as modifying
current LC-MS/MS protocols to effectively quantify DOSS in these biological samples.
With regard to scenario B (above), it is certainly possible for DOSS to have
indirect effects that were not measured in this study. Several EDCs can have multiple
mechanisms of action which are often identified at different points in time with new
mechanisms of action under investigation [257]. One such example is diethylstilbestrol
(DES), a potent estrogen that also has metabolic disrupting effects that are independent of

154

estrogen signaling [160]. Similarly, phthalates are often classified as anti androgenic
chemicals, of which there are multiple mechanisms, but can also act as metabolic
disruptors. A likely mechanism whereby DOSS could indirectly effect obesity and
metabolic syndrome is low grade chronic inflammation. In fact, changes to inflammatory
cytokines were observed at the epigenetic, expression, and protein level, indicating the
role of DOSS in mediating inflammation may be a major mechanism of action by which
it can elicit metabolic disrupting effects. The non-ionic detergent 4-nonylphenol (4-NP)
may be most similar to DOSS as an inflammatory inducer (COX-2 and PGE2 production)
and an obesogen [333, 334].
While data in this work indicate that DOSS is primarily acting through a PPARg
dependent mechanism, another logical indirect effect of DOSS exposure could be
through alterations to the gut microbiota. Understanding the role of the gut microbiome
in relation to diabetes and obesity is an extremely exciting area of research. Studies have
shown that there are significant differences in species composition and diversity between
lean and obese individuals, in both rodents and humans [335]. In fact, DOSS is used in
agriculture to effectively remove gut fauna from livestock, suggesting DOSS could also
alter the microbiome in humans or mice [311]. Although a low sample size, ruminal
dosing of cows with DOSS had altered fatty acid composition in their milk compared to
cows with no DOSS induced defaunation [311]. Furthermore, when gut fauna are
transferred from an obese mouse to a germ free lean mouse, the previously lean mouse
gains weight despite no changes in food consumption and vice versa [336]. Transplant of
human obese and lean associated gut microbiota to mice yields similar results with regard
to obese and lean phenotype development [337]. Studies have also shown that the
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maternal microbiome can have an impact on obesity and diabetes development in
offspring particularly as it relates to maternal obesity [309].
Several emulsifiers and surfactants similar to and including DOSS are used as
common food additives at up to 1% of the food content. Research has begun to assess
biological effects of these emulsifiers as it relates to human health. Chassaing et al. found
that mice exposed to two common food emulsifiers (Carboxymethylcellulose and Tween
80) at environmentally relevant concentrations (1% w/v or v/v) altered gut microbiota
composition to that of a population that promoted inflammatory bowel disease and
obesity [208]. Additionally, Lecomte et al. found that in combination with a high fat diet,
different types of emulsifiers (polar lipids from milk and soybean) can exaggerate the
effects of the diet through impacts on intestinal absorption further promoting metabolic
syndrome [310]. In order to test the hypothesis that DOSS alters the maternal
microbiome of exposed dams thereby influencing metabolic syndrome development in
the pups, meta genomic sequencing of fecal samples from dams, as well as weaning
pups, should be performed as part of the studies produced by this work.
The aforementioned work brings up another relevant area of research that is
combinatorial exposures and multiple stressors. While several metabolic disruptors elicit
their effects through treatment with the compound of interest only, researchers have
begun to assess how exposure effects metabolic outcomes when combined with high
fight diet, or other contributors to obesity. For instance, Wei et al. (2011) demonstrated
that animals prenatally exposed to BPA developed markers of metabolic syndrome and
that these results were exacerbated in conjunction with a high fat diet [338]. Interestingly,
these results were only observed at a relevant low dose of BPA exposure, but not a high
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dose. Investigating DOSS exposure in the context of a high fat diet or a high carb diet
reflective of a typical Western diet is interesting and relevant.
In summary, the work presented in this Dissertation lead to the identification and
preliminary characterization of a novel probable metabolic disruptor, DOSS, which has
important implications for human health and likely will significantly impact the field.
Despite the fact that this investigation initiated with oil originating from the DWH oil
spill as an exposure source and held the hypothesis that PAHs in the oil would be the
predominating obesogenic/EDC compounds, to the results of these studies identified the
Corexit component DOSS as the primary obesogenic compound, a finding that may have
far-reaching impacts on human health due to its use in a wide array of pharmaceuticals,
foods, flavoring/coloring agents, as well as industrial and household cleaners. Therefore,
human exposure to DOSS is likely to be widespread over the lifetime of individuals and
perhaps predominantly occurs during sensitive and vulnerable times of fetal and
childhood development. Although DOSS may be rapidly metabolized with minimal
absorption, due to its pervasive use, DOSS may be considered a “pseudo-persistent”
chemical, as is the case with phthalate esters. Further work into the pharmacokinetics of
DOSS, as well as longitudinal epidemiological studies following growth and metabolic
outcomes of children of mothers prescribed and taking DOSS during pregnancy and
nursing, will help address these major questions associated with DOSS.
While this work generates several questions surrounding DOSS exposure, its
ability to act as a metabolic disruptor, and its relevance towards human health, this work
was foundational in beginning to answer those questions and shape this body of research.
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Figure 1. Summary of results presented in Chapters 2, 3 and 4.
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Figure 2. EPA ToxCast data for docusate sodium activation of several nuclear
receptors using the NovaScreen radioligand binding assay.
The EPA iCSS ToxCast Dashboard was used to compile data available for human
nuclear receptor radioligand assay binding. The action of docusate sodium on ligand
binding is compared for PPARg, GR, PR, ER, PPARa and AR.
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